21 January 2022  
Gates MRI -RSM01 -101 Protocol v4.0  
Bill & Melinda Gates Medical Research Institute 1 
CONFIDENTIAL  Title Page  
Protocol Title:  A Phase 1 Randomized, Double -blind, Placebo -Controlled Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of Single Ascending Doses of RSM01, a Monoclonal Antibody 
Targeting Respiratory Syncytial Virus, in Healthy Adults  
Protocol Number: Gates MRI -RSM01 -101, Version (v)4.0  
Short Title: Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in 
Healthy Adults  
Compound Number:  RSM01  
Study Phase:  1 
Sponsor Name: Bill & Melinda Gates Medical Research Institute (Gates MRI)  
Lega l Registered Address:  
One Kendall Square  
Building 600, Suite 6 -301 
Cambridge, MA 02139  
Medical Monitor and other important study personnel information will be provided in a separate 
document.  
v4.0; Approval Date:  21 January 2022  
                                                   Study ID: [REMOVED]
This NCT number has been applied to the document for purposes of posting on Clinicaltrials.gov
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   2 
CONFIDENTIAL     
  
Document History  
 
Document  Date  
v4.0 21 January 2022  
v3.0 10 December 2021  
v2.0 20 July 2021  
Original Protocol v1.1  09 June 2021  
 
Refer to Sec tion 12 for the r ationale for v4.0 and a complete list of changes.  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   3 
CONFIDENTIAL    Sponsor Signature Page  
Version 3.0  
 
See appended electronic signature page  
 
 
 
___________________________________   ____________________  
Sponsor Signatory      Date  
MD, PhD, MPH  
Clinical Development Leader  
Bill & Me linda Gates Medical Research Institute  
 
 

21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   4 
CONFIDENTIAL    Table of Contents  
Table of Contents  ................................ ................................ ................................ ........................... 4 
List of Tables  ................................ ................................ ................................ ................................ ..7 
List of Figures  ................................ ................................ ................................ ................................ .7 
1. Protocol Summary  ................................ ................................ ................................ ........ 10 
1.1. Synopsis  ................................ ................................ ................................ .......................... 10 
1.2. Schema  ................................ ................................ ................................ ............................ 16 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 17 
2. Introduction  ................................ ................................ ................................ ................... 20 
2.1. RSV and Burden of Disease  ................................ ................................ ........................... 20 
2.2. RSV Prevention - Monoclonal Antibodies  ................................ ................................ ......21 
2.3. RSM01 mAb Candidate  ................................ ................................ ................................ ..22 
2.3.1.  Non-Clinical Development of RSM01  ................................ ................................ ........... 22 
2.4. Study Rationale  ................................ ................................ ................................ ............... 23 
2.5. Justification for Dose  ................................ ................................ ................................ ......23 
2.5.1.  Doses for Escalation Phase Cohorts  ................................ ................................ ............... 23 
2.5.2.  Dose for Expansion Phase Cohort  ................................ ................................ .................. 24 
2.6. Benefit/Risk Assessment  ................................ ................................ ................................ 25 
3. Objectives and Endpoints  ................................ ................................ ............................ 27 
4. Study Design  ................................ ................................ ................................ .................. 28 
4.1. Design Overvi ew ................................ ................................ ................................ ............ 28 
4.2. End of Study Definition  ................................ ................................ ................................ ..30 
5. Study Population  ................................ ................................ ................................ ........... 30 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ............ 31 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 32 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .33 
5.4. Screen Failures  ................................ ................................ ................................ ................ 34 
6. Study Intervention  ................................ ................................ ................................ ........ 35 
6.1. RSM01 Drug Product  ................................ ................................ ................................ .....35 
6.2. Place bo Drug Product  ................................ ................................ ................................ .....36 
6.3. Study Intervention Preparation and Administration  ................................ ....................... 36 
6.3.1.  IM Injection  ................................ ................................ ................................ .................... 36 
6.3.2.  IV Infu sion ................................ ................................ ................................ ...................... 37 
6.4. Handling/Storage/Accountability  ................................ ................................ ................... 37 
6.5. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 38 
6.5.1.  Randomization  ................................ ................................ ................................ ................ 38 
6.5.2.  Maski ng................................ ................................ ................................ ........................... 39 
6.5.3.  Blind Break  ................................ ................................ ................................ ..................... 40 
6.6. Study Intervention Compliance  ................................ ................................ ...................... 40 
6.7. Concomitant Therapy  ................................ ................................ ................................ .....40 
6.8. Dose Modification  ................................ ................................ ................................ .......... 40 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   5 
CONFIDENTIAL    7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 40 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 40 
7.1.1.  Pausing Rules  ................................ ................................ ................................ .................. 41 
7.2. Participant Discontinuation or Withdrawal from the Study  ................................ ........... 41 
7.3. Lost to Follow -up................................ ................................ ................................ ............ 43 
7.4. COVID -19 Contingency Plans  ................................ ................................ ....................... 43 
8. Study Assessments and Procedures ................................ ................................ ............. 44 
8.1. Safety Assessments  ................................ ................................ ................................ ......... 44 
8.1.1.  Confinement Period and Sentinel Participants  ................................ ............................... 45 
8.1.2.  Full Physical Examination and Medical History  ................................ ............................ 45 
8.1.3.  Focused Physical Examination and Medications/Vaccinations  ................................ ......46 
8.1.4.  Pregnancy Status Assessment  ................................ ................................ ......................... 46 
8.1.5.  HIV Antibody Assessment  ................................ ................................ ............................. 47 
8.1.6.  Electrocardiogram, Hepatitis Screening and Urine Drug 
Screening ................................ ................................ ................................ ......................... 47 
8.1.7.  Clinical Safety Laboratory Assessments  ................................ ................................ ........ 47 
8.1.8.  Pre- and Post -Study Intervention Safety Monitoring ................................ ...................... 48 
8.1.9.  Diary Card, Memory Aid and Daily Monitoring  ................................ ............................ 49 
8.1.10.  Participant Follow -Up ................................ ................................ ................................ .....49 
8.2. Adverse Events and Serious Adverse Events  ................................ ................................ .50 
8.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ................................ ..................... 51 
8.2.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 51 
8.2.3.  Follow -up of AEs  ................................ ................................ ................................ ............ 51 
8.2.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 52 
8.2.5.  Death Events  ................................ ................................ ................................ ................... 52 
8.2.6.  Safety Review Team  ................................ ................................ ................................ .......53 
8.2.7.  Independent Data Monitoring Committee  ................................ ................................ ......53 
8.3. Treatment of Overdose  ................................ ................................ ................................ ...53 
8.4. Blood Sampling  ................................ ................................ ................................ .............. 53 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 54 
8.6. Pharmacodynamics  ................................ ................................ ................................ ......... 54 
8.7. Genetic s ................................ ................................ ................................ .......................... 55 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 55 
8.9. Immunogenicity  ................................ ................................ ................................ .............. 55 
9. Statistical Considerations  ................................ ................................ ............................. 55 
9.1. Sample Size Determination  ................................ ................................ ............................ 55 
9.2. Populations for Analyses  ................................ ................................ ................................ 56 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 56 
9.3.1.  Safety Primary Endpoints  ................................ ................................ ............................... 58 
9.3.2.  Safety Secondary Laboratory Assessments  ................................ ................................ ....58 
9.3.3.  Other Safety Measures  ................................ ................................ ................................ ....59 
9.3.4.  Pharmacokinetics  ................................ ................................ ................................ ............ 59 
9.4. Serum  and Capillary Blood Immunogenicity  ................................ ................................ .59 
9.5. Serum and Capillary Blood RSV Neutralizing Antibody  ................................ ............... 59 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   6 
CONFIDENTIAL    9.6. Demographic and Compliance Analyses  ................................ ................................ ........ 59 
9.7. Interim Analyses  ................................ ................................ ................................ ............. 60 
9.8. National Regulatory Authority  ................................ ................................ ....................... 60 
10. Supporting Documentation and Operational Considerations  ................................ ..61 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 61 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 61 
10.1.2.  Study Oversight  ................................ ................................ ................................ .............. 61 
10.1.3.  Financial Disclosure ................................ ................................ ................................ ........ 62 
10.1.4.  Informed Consent Process  ................................ ................................ .............................. 62 
10.1.5.  Data Protection ................................ ................................ ................................ ................ 63 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 63 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..64 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 64 
10.1.9.  Record Retention  ................................ ................................ ................................ ............ 65 
10.1.10.  Study and Site Closure  ................................ ................................ ................................ ....65 
10.1.11.  Publication Policy  ................................ ................................ ................................ ........... 65 
10.2.  Appendix 2: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and R eporting  ................................ ......................... 66 
10.2.1.  Definition of AE  ................................ ................................ ................................ ............. 66 
10.2.2.  Definition of SAE  ................................ ................................ ................................ ........... 67 
10.2.3.  Definition of Serious Adverse Drug Reaction (Serious ADR)  ................................ .......68 
10.2.4.  Definition of AESI  ................................ ................................ ................................ .......... 68 
10.2.5.  Recording and Follow -Up of AE, SAE, AESI  ................................ ............................... 68 
10.2.6.  SAEs, AESIs, and Serious ADR Reporting  ................................ ................................ ....72 
10.3.  Appendix 3: Contraceptive Guidance and Collection of 
Pregnancy Information  ................................ ................................ ................................ ...73 
10.4.  Appendix 4: Toxicity Tables  ................................ ................................ .......................... 75 
11. References  ................................ ................................ ................................ ...................... 80 
12. Protocol Version History  ................................ ................................ .............................. 82 
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   7 
CONFIDENTIAL    List of Tables  
 
Table 1: Objectives and Endpoints  ................................ ................................ ...............................  11 
Table 2: Schedule of Activities for the Dose Escalation Phase (Cohorts 1 -4) .............................  17 
Table 3: Schedule of Activities for the Expansion Phase (Cohort 5)  ................................ ...........  19 
Table 4: Objectives and Endpoints  ................................ ................................ ...............................  27 
Table 5: Study Interventions  ................................ ................................ ................................ .........  35 
Table 6: Populations for Analyses  ................................ ................................ ................................  56 
Table 7: Summary of Primary and Secondary Endpoints and Analyses  ................................ ...... 57 
Table 8: FDA Toxicity Grading Scale - Clinical Abnormalities  ................................ ...................  75 
Table 9: FDA Toxicity Grading Scale - Laboratory Abnormalities  ................................ ..............  77 
Table 10: FDA Toxicity Grading Scale - Urine  ................................ ................................ .............  79 
 
List of Figures  
Figure 1: Outline of Study Dosing Procedures  ................................ ................................ .............  16 
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   8 
CONFIDENTIAL    List of Abbreviations  
ADA  Anti-drug antibody  
ADR  Adverse drug reaction  
AE Adverse event  
AESI  Adverse event of special interest  
AUC  Area under the (time) curve (e.g., capillary blood -concentration time curve 
for RSM01)  
CD91 Day 91 capillary blood -concentration of RSM01  
CD151 Day 151 capillary blood -concentration of RSM01  
Cmax Maximum capillary blood -concentration of RSM01  
Cmin Minimum capillary blood -concentration of RSM01  
CFR  Code of Federal Regulations  
CL Systemic clearance  
CRF  Case report form  
CSR  Clinical study report  
EC 90 Effective concentration that leads to 90% maximal response (or the logarithm 
of the EC9 0) 
ECG  Electrocardiogram  
EDC  Electronic data capture  
ELISA  Enzyme -linked immunosorbent assay  
GCP  Good clinical practices  
Gates MRI  Bill & Melinda Gates Medical Research Institute  
GGT  Gamma glutamyl transferase  
HIV Human immunodeficiency virus  
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
IM Intramuscular  
IRB Institutional Review Board  
IUD Intrauterine device  
IV Intravenous  
IXRS  Interactive voice/web response system  
LTRI  Lower respiratory tract infection  
mAb  Monoclonal antibody  
Mg Milligram  
mL Milliliter  
mITT  Modified intention to treat  
NA Not applicable  
NCA  Noncompartmental analysis  
NCT  National (U.S.) Clinical Trial Identifier  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per protocol  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   9 
CONFIDENTIAL    Pre-F Prefusion conformation of the Respiratory Syncytial Virus F glycoprotein  
RSM01  Monoclonal antibody targeting Respiratory Syncytial Virus, Drug Product for 
use in the clinical trial  
RSV  Respiratory Syncytial Virus  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SoA Schedule of activities  
SRT Safety Review Team  
t1/2 Apparent terminal half -life  
Tmax Time to maximum capillary blood -concentration of RSM01  
ULN  Upper limit of normal  
U.S. United States  
VAMS  Volumetric absorptive microsampling  
Vz Volume of distribution  
WBC  White blood cell count  
WHO  World Health Organization  
YTE  Triple amino acid substitutions  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   10 
CONFIDENTIAL    1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  A Phase 1, Randomized, Double -blind, Placebo -controlled Study to Evaluate the 
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of RSM01, a Monoclonal 
Antibody Targeting Respiratory Syncytial Virus, in Healthy Adults  
Shor t Title:  Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 
in Healthy Adults  
Rationale: The high and continued burden of Respiratory Syncytial Virus (RSV) infection, 
especially among infants and young children, underscores the nee d for safe and effective 
prevention against RSV disease that is affordable in low- and middle -income countries ( LMICs).  
This study will evaluate the safety, tolerability, and pharmacokinetics in adults of an RSV 
monoclonal antibody (mAb) candidate engineer ed to be highly neutralizing and long acting, and 
to determine an appropriate dose with acceptable safety profile in adults, prior to administration 
to infants in a future clinical study.  
Proof of concept for passive immunization of infants with a mAb has been demonstrated for 
palivizumab, a commercial mAb product indicated to prevent RSV disease in premature infants. 
Palivizumab, however, must be administered monthly during the RSV season and is very costly.  
Two (2) next generation RSV mAb candidates are i n clinical development: Merck’s MK -1654 
and AstraZeneca’s MEDI8897 (nirsevimab).  In completed trials, nirsevimab shows promise in 
reducing the incidence of medically -attended lower respiratory tract infection (LRTI) and 
hospitalizations caused by RSV, in h ealthy preterm infants. Both of these 2 mAb candidates 
were well -tolerated. Regardless, the cost of these candidates when commercialized may not 
allow for global access to the product.  
RSM01 is a fully human IgG1 mAb that targets glycoprotein F of RSV and binds to the antigenic 
site Ø of the prefusion conformation of the F protein (a region considered to be highly sensitive 
to neutralization). The major mode of action for RSM01 is virus neutralization. RSM01 has the 
same half -life extension, triple amino ac id substitutions (YTE) M252Y/S254T/T256E (European 
Union numbering), mutation in its crystallizable fragment (Fc) domain, as do the MK -1654 and 
nirsevimab RSV mAb candidates.  
In this study, healthy adults will receive either intravenous (IV) or intramuscul ar (IM) doses of 
RSM01, which will enable assessment of the safety profiles together with estimation of human 
bioavailability following IM injection, which is the intended route of administration in infants.  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   11 
CONFIDENTIAL    Table 1: Objectives and  Endpoints  
Objectives  Endpoints (Endpoints apply to all cohorts unless noted)  
Primary  
To characterize the safety and 
tolerability of a single dose of 
RSM01  • Unsolicited adverse events (AEs) through Day 151  
• All serious adverse events (SAEs) and AE of special 
interest (AESIs) through Day 151  
• Solicited systemic AEs for 7 days after dose 
administration  
• Solicited local AEs for injection site reactions for 7 days 
after dose administration (only applies to IM doses)  
Secondary  
To characterize safety 
laboratory parameters following 
RSM01 administration  • Safety laboratory parameters Grade 1 and above through 
Day 151  
To characterize the 
pharmacokinetics (PK) 
following RSM01 
administration  PK parameters including:  
• Area under the capillary blood -concentration time curve 
from zero to infinity (AUC 0-∞) 
• Day 91 capillary blood -concentration and area under the 
capillary blood -concentration time curve (C D91 and AUC 0-
D91) 
• Day 151 capillary blood -concentration and area under the 
capillary blood -conc entration time curve  (CD151 and 
AUC 0-D151) 
• Maximum capillary blood -concentration (C max following 
IM administration and C 0 following IV) administration), 
minimum concentration (C min) 
• Time to maximum capillary blood -concentration (T max) 
apparent terminal hal f-life (t1/2)  
• Systemic clearance (CL)  
• Volume of distribution (Vz) of RSM01 through Day 151  
To characterize the formation of 
anti-drug antibodies (ADAs) 
following RSM01 
administration  • Incidence  of ADAs to RSM01 through Day 151  
Exploratory  
 To characterize RSV 
neutralizing antibody activity 
following RSM01 
administration  • Capillary blood RSV neutralizing antibody levels through 
Day 151 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   12 
CONFIDENTIAL    Overall Design  
Disclosure statement:  This is a First -in-Human (FiH) trial of RSM01, administered to adults. It 
is a randomized, double -blind, placebo -controlled study of RSM01.  
Study Population and Number of Participants: Adult participants between 18 and 49 years of 
age (inclusive) of both sexes who are capable of and willing to provide informed consent may be 
eligible for the study.  
Candidates will be screened to enroll at least 56 eligible participants.  
Assuming that all cohorts are allowed to undergo treatment, approximately 48 participan ts will 
be exposed to RSM01 and approximately 8 participants will receive Placebo.  
Interventional model : The study will be conducted in 2 parts: A Dose Escalation Phase (N=28) 
with 4 dosing cohorts, followed by an Expansion Phase (N=28) with a single cohor t. 
Dose Escalation Phase:  
The Dose Escalation Phase will include 28 participants.  
The first participant in each Dose Escalation Phase cohort will not be randomized and will 
receive the RSM01 dose level appropriate to the assigned cohort to serve as a senti nel exposure 
participant.  
The remaining 6 participants in each of Cohorts 1, 2, 3, and 4 will be randomized 5:1 to receive 
either RSM01 or Placebo. The overall ratio of RSM01 to Placebo will be 6:1 in each cohort.  
The Dose Escalation Phase will  occur seque ntially in 2 escalation steps.  
• Cohort 1:  7 participants will receive RSM01  300mg IV (n=6 total including sentinel 
participant) or Placebo IV (n=1)  
First escalation step : from Cohort 1 to Cohorts 2 and 3, conducted in parallel  
• Cohort 2: 7 participants will receive RSM01 300mg IM (n=6 total including sentinel 
participant) or Placebo IM (n=1)  
• Cohort 3 : 7 participants to receive RSM01  1000mg IV (n=6 total including sentinel 
participant) or Placebo IV (n=1)  
Second escalation step : from Cohorts 2 and 3 to Cohort 4 
• Cohort 4: 7 participants will receive RSM01 3000mg IV (n=6 total including sentinel 
participant) or Placebo IV (n=1).  
For the Dose Escalation Phase cohorts, all participants will be confined at the study site from 
Day -1 (i.e., the day before dosing) to after completion of the Day 3 assessments (a total of 3 
nights).  
After the sentinel participant in each cohort receives RSM01, the next participant can be dosed 
24 hours later, if there is no safety concern. After the 24 -hour post -dose period for the senti nel 
participant in each cohort, participants in the Dose Escalation Phase cohorts should be dosed at 
least 2 hours apart regardless of route of administration (IM or IV). The ≥2-hour interval 
between administering IV infusions is to begin at the end of the  previous infusion. For 
participants receiving the IM dose of study drug in Cohort 2, the ≥2-hour interval between 
administering IM injections to successive participants is to begin at the time of the previous 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   13 
CONFIDENTIAL    participant’s IM injection. If RSM01 is admini stered using 2 injections, the ≥2-hour interval 
begins at the time of the second injection.  
Each dose escalation step will proceed after all participants in the prior cohort have completed 
Day 15, and the Safety Review Team (SRT) has reviewed the data and determined that a pausing 
rule has not been met.  
Dose Expansion Phase : 
Enrollment in the Dose Expansion Phase cohort (Cohort 5) will begin after Day 15 for all 
participants in Cohort 4, and after the SRT has reviewed the data and determined that a pausing 
rule has not been met. Cohort 5  will include  28 participants randomized 6:1.  
• Cohort 5: participants will receive RSM01 IM (n=24) or Placebo IM (n=4).  
For Cohort 5, participants will be asked to present to the clinic within 24 hours of the Day 1 visit 
for D ay -1 (Pre -V1) confinement.  
On Day 1 after dosing, participants will be observed for at least 4 hours post -dose at the study 
site for safety monitoring. Based on investigator’s decision, a participant may be asked to remain 
at the study site, for an additi onal overnight stay on the night of Day 1.  
Final selection of the dose of RSM01 to be administered to Cohort 5 will be made by the sponsor 
and informed by available RSM01 PK data from the Dose Escalation Phase.  
The tentatively determined dose to be evaluat ed in the Expansion Phase cohort is ≥300 mg to 
≤600 mg IM. This determination is based on predictions of RSM01 human PK exposures made  
using extrapolation from the RSM01 non -human primate PK and on published data from the 
other RSV mAbs nirsevimab and MK -1654 administered to healthy adults [ Griffin  2017, 
Aliprantis  2020]. The predictions suggest that the concentration of RSM01 wi ll be above the 
efficacy threshold (EC90) on Day 151 following a RSM01dose of 300 or 600 mg IM.  
Pausing Rules  
Pausing rules (reasons for pausing the study) are in effect during the active enrollment and 
dosing period. Any one of the following will prompt a  study pause:  
• death in any participant in whom the event causing death is judged to be related to the 
study drug by the investigator.  
• any occurrence in any participant of a SAE judged to be related by the investigator.  
• any occurrence in any participant of an AESI (anaphylaxis, hypersensitivity reaction, 
and/or infusion reaction resulting in permanent discontinuation of study drug infusion 
during IV administration).  
• any occurrence of Grade 3 or higher toxicity assessed to be related to the study drug by 
the investigator.  
• any occurrence of a clinically significant Grade 3 or higher laboratory abnormality 
assessed to be related to the study drug by the investigator.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   14 
CONFIDENTIAL    If any of the pausing criteria are met, enrollment/patient accrual as well as dosing of enrolled  
participants will be suspended pending IDMC’s review of all available safety data and the U.S. 
Food and Drug administration (FDA) will be notified in an expedited manner.  
IDMC:  The IDMC will review safety data if a pausing rule is met and make a recommend ation 
on how to proceed (See Section 8.2.7.). The IDMC will be provided unblinded data by an 
independent statistician.  
Safety Review Team: A SRT will be established as the team responsible for recommending 
dose escalation or dose expansion to the sponsor’s  Chief Medical Officer. Meetings of the SRT 
to provide a recommendation on dose escalation or dose expansion will occur during the Dose 
Escalation Phase when all participants in the currently dosed cohort have completed Day 15. The 
SRT will also meet appro ximately every 8 weeks during the Dose Expansion Phase (See Section 
8.2.6). The SRT will review blinded data only.  
Visits:  After the Screening Visit, and the Day -1 Visit, there will be a total of 11 visits over 151 
days for the Dose Escalation Phase and a  total of 5 visits over 151 days for the Dose Expansion 
Phase.  
Note that when participants arrive for the Day -1 clinic visit, they will stay overnight at the 
clinic. Participants in the Dose Escalation Phase cohorts will remain at the clinic for Visits 1,  2, 
and 3, on Day 1, Day 2, and Day 3, respectively.  
The participants in the Dose Expansion Phase cohort will remain at the clinic for at l east 4 hours 
after dosing on Day 1, and possibly for the night of Day 1, based on investigator’s de cision.  
The study Schema is shown in Figure 1 and the Schedule of Activities (SoA) is shown in Ta ble 
2, and Table 3 for Dose Escalation Phase and Dose Expansion Phase, respectively.  
Blood Sampling: Dose Escalation Phase cohorts: On Day 1, PK blood draw will occ ur pre-
dosing 1 hour (+/ - 30 minutes) before administration of IM injection or beginning of IV 
infusion , at 5 minutes ( ± 1 minute) after end of infusion for IV dosing only, and at 8 -hours (±0.5 
hour) and 24 -hours (±1 hour) after end of infusion for IV doses and at 8 -hours (±0.5 hour)  and 
24-hours (±1 hour) after IM dose. ADA and RSV neutralizing a ntibody activity sampl es will be 
obtained pre -dose only 1 hour (+/ - 30 minutes) before administration of IM injection or  
beginning of IV infusion.  
Dose Expansion Phase cohort: On Day 1, the blood collection for PK, ADA and RSV 
neutralizing antibody activit y will occur pre -dosing only 1 hour (+/ - 30 minutes) befor e 
administration of IM injection.  
Serum will be collected as shown in the SoA (Section 1.3), for screening and safety labor atories. 
Venous serum and capillary volumetric absorptive microsampling (VAMS) will be c ollected as 
shown in the SoA ( Table 2 and Table 3) for PK, ADA testing and RSV neutralizing a ntibody 
testing.  
A maximum of approximately 200 mL of whole blood will be collected from each pa rticipant 
during the entire study period, assuming all planned samples are collected, according to the SoA.  
Masking : The study is double -blind. Participants and all study personnel will be blinded to the 
randomization, with one exception: the first sentinel participant in each Dose Escalation Phas e 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   15 
CONFIDENTIAL    cohort will be single -blinded (participant -blinded) and will receive the respective dose of 
RSM01. Authorized study site personnel will administer doses.  
Analysis : An interim analysis will occur after all participants in the Dose Escalation Phase 
cohorts  (Cohorts 1 through 4), have reached Day 91. The primary analysis will occur after all 
participants in all 5 cohorts complete Day 151.  
Total duration of study participation : The study duration for each participant is 151 days, in 
addition to a maximum of 3 0 days for screening and Day -1. 
Study site/s : The study will be conducted at 1 site in the United States (U.S.).  
 
 
1.2. Schema 
Figure 1: Outline of Study Dosing Procedure s 
Cohort 1: 300 mg IV 
N=7 {6:1) RSM:placebo dose • 1 0 15 
SRT review 
Cohort 2: 300 mg IM 
N=7 {6:1) dose • 01 
SRT review 
Cohort 4: 3000 mg IV 
N=7 {6:1) 
Coho rt 5: dose 
ti 
SRT review 
Between 300 mg and 600 mg IM (6:1) 
Bill & Melinda Gates Medi cal Resear ch Institute 
CONFIDENTIAL 0151 
interim analysis 
dose • 01 0 9 1 
09 
primary analy sis 21 Janua ry 2022 
Gates MRI-RSM01-101 Protocol v4.0 
16 
1.3. Schedule of Activitie s (SoA) 21 Janua ry 2022 
Gates MRI-RSM01-101 Protocol v4.0 
The SoA for the Dose Es calatio n Phase (Coho1 t s 1- 4) is presented in Table 2 and the SoA for the Expansion Ph ase (Coho1 t 5) is 
presented in Table 3. 
Table 2: Schedule of Activities for the Dose Es calation Phase (Cohort s 1-4) 
Visits 
Study Day and Visit window days ( d) 
Activities: 
Informed consent 
Check/veri fy eligibility c1iteria 
Confinement1 
Demogra phy, full medic al histor y, PE, heicll t, weicllt 
Focused PE 
Sennn premanc y test2 
HIV antib ody and Hepatitis B & C test 
Urine drng screen 
Urinalysis 
Safety laboratory assessment s3 
12-lead electroc ardioera m (ECG), tripl icate4 
Vital si2Us5 
Randomizat ion6 
Study intervent ion admini stration7 
Distribute/review diarv cards 
Collect diary ca rd 
Distribute memo1y aid 
Collect memor y aid 
Record solicited AEs (local for IM doses only, & 
systemic ) through Day 7 
Record unsolicited AEs, AESis, and SAEs 
Record concomi tant medications 
Bill & Melinda Gates Medi cal Resear ch Institute 
CONFIDENTIAL Screen 
D-30 to 
D-2d 
X 
X 
X 
X 
X X X 
X 
X X 
X Pre-Vl V2 V3 
Vl 
D-1 Dl D2 D3 
±O d ±Od ±O d ±O d 
X X 
X X X X 
X X X X 
X 
X 
X 
X 
X 
X X X 
X 
X 
X 
X 
X X X 
X X X X 
X X X X V4 vs V6 V7 V8 V9 V lO Vll Dis-
con 
D6 D8 D15 D29 D61 D91 D121 D151 Visit9 
±ld Day 8-10 ±3d Day 29-35 ±7d ±7d ±7d ±7d 
X X X X X X X X X 
X 
X X X X 
X X X X 
X 
X 
X X X X X X X 
X X X X X X X X X 
X 
X X X X X X X X X 
X X X X X X X X X 
17 
21 Janua ry 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Table 2 continued: Schedule of Activitie s for the Dose Escalation Phase (C ohort s 1-4) 
Visits Screen Pre-Vl V2 V3 V4 vs V6 V7 vs V9 V 10 vn 
Vl 
Study Dav and Visit window days ( d) -30 to D-1 DI D2 D3 D6 D8 D15 D29 D61 D91 D121 D151 
Activities: -2d ±0d ±0d ±Od ±Id Day8 -±3d Day29 -±7d ±7d ±7d ±7d 10 35 
Semm and V AMS sample for PK8 X X X X X X X X X X X 
Sennn and V AMS sample for ADA s8 X X X X X X X 
Sennn and V AMS sample for RSV nAb levels8 X X X 
V = Visit; D= Day; PE= physical examination ; HIV= Human immunodeficiency virus ; IM= intramu scular; AE=adverse event , SAE =serious adverse event; 
AESI =AE of special interest 
PK= phannacokine tics; ADA = anti-dtug antibodies ; V AMS = volumetric abso1p tive microsampling 
RSV mAb = Respira tory Syncytial Vims neutralizing antibody 
1 Confinement -pa1ticipant s will be confined to study site from Day -1 to after completion of Day 3 assessment (a total of3 nights). 
All Day 1 assessmen ts and sampl e collections are prior to study intervention . 
2 In addition to scheduled pregnancy tests in female pa1ticipan ts, if pregnancy is suspected during the study , a sernm test will be done . 
3 Safety laborato1y testing include s sernm chemi stty and hematology. Dis-
con 
Visit9 
X 
X 
X 
4 All 12-lead ECGs will be obtained after the pa1ticipant has rested in a supine position for at least 10 minutes . Triplicate ECGs will be taken approximately one minu te apart. 
Refer to Section 8.1.6 for details. The window for obtaining the initial ECG is± 15 minu tes. 
5 Day 1 vital signs will be taken pre-dose before blood sample collec tion, and 1 hour , 4 hour s and 8 hours after IM dose and at pre-dose, 15, 30 and 45 minu tes, 1 hour , 1.5 
hours , 2 hour s, 4 hours , and 8 hours after IV dose. The window for vital signs measuremen ts is± 3 minutes. Refer to Section 8.1.2. lfor details. 
On Day 2, vital signs will be taken at 24 hours post-dose . The window for these measuremen ts is± 0.5 hours . 
On Day 3, vital signs will be taken at 48 hours after dosing . The window for these measurements is± 1.0 hours. 
6 The first participan t in each coho1 t (Coho1ts 1-4) will recei ve RSM0l without being randomized . 
7 On any given day, participants should be dosed at least 2 hours apa1t, after the first sentinel paiticipant is dosed v.iith RSM0l , and 24 hours has passed. 
The :C::2-hour wait time between IV infusions is to begin at the end of the previous infusion. 
8 Blood samples for PK assessmen ts on Day 1 (Visit 1 ) will be drawn at pre-dosing 1 hour ( +/-30 minu tes) before adtninistt·ation of IM injection or beginning of infusion, at 
5 minu tes(± 1 minute ) after end of infusion for IV doses only, and at 8-hours (±0.5 how) and 24-hours (±1 how) after end of infusion for IV doses and at 8-hours (±0.5 how) 
and 24-hours (±1 how) after IM doses. 
ADA and RSV neutralizing antibody on Day 1 (Visi t 1 ) will be drawn pre-dose only 1 hour(+ /-30 minute s) before administration ofIM injec tion or beginning of infusion. 
9 Early Discon= A discontinuation visit will be scheduled for participan ts who discontinue or withdt·aw, whenever possible. 
Bill & Melinda Gates Medi cal Resear ch Institute 
CONFIDENTIAL 18 
21 Janua ry 2022 
Gates MRI-RSM 01-101 Protocol v4.0 
Table 3: Schedule of Activities for the Expan sion Phase (C ohort 5) 
Visits Screen Pre- Vl V l V2 V3 V 4 
Study Day and Visit window days (d) D-30 to Day-1 Dl D8 D29 D91 
Activitie s: D-l d ±0 Days Days ±7d 8-10 29-35 
Infonned consent X 
Check/ verifv eligibilitv criteria X X X 
Confinemen t1 X (X) 
Demograph y, full medical history, PE, height, weis4lt X 
Focused history!PE X X X X 
Senun pre211ancy test2 X X 
HIV antibody , Hepatitis B and C X 
Urine dmg screen X X 
Urinalysis X X X X 
Safety laboratory assessments3 X X X X 
12-lead ECG (performed in triplicate )4 X 
Vital si211s5 X X 
Randomization X 
Study intervention administration6 X 
Distribute/review diary cards X 
Collect diary cards X 
Distribute memory aid X X X X 
Collect memory aid X X X 
Record solicited AEs (loca l & systemic ) X 
Record unsolicited AEs, AESis and SAEs X X X X X X 
Record concomi tant medications X X X X X 
Senun and V AMS samp le for PK7 X X X X 
Senun and V AMS sample for ADA s7 X X X 
Senun and V AMS for RSV nAb levels 7 X X 
V = Visit; D= Day; PE= physical examina tion; HIV= Huma n immunodeficiency vims; IM= intramuscular ; 
AE=adverse event, SAE =seriou s adverse event; AESI =AE of special interest vs 
DlSl 
±7d 
X 
X 
X 
X 
X 
X 
X 
X 
X Discon 
visit8 
X X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1Confinemen t = participant should present to the clinic wit hin 24 hours of Day -1 visit and will stay at the clinic on the Pre-V l , 
Day - l (i.e., t he night before the Day 1 visit). 
(X)= A s econd overnight stay for the night of Day 1 is optional , based on investigator's decision. If pa1tic ipant is confined on the 
night of Day 1, vital signs will be taken 24 hours post-dose . 
PK= phannacokine tics; ADA = anti-dmg antibodies ; V AMS = volumetric absorptive 1nicrosampling ; 
RSV mAb = Respirato1y Syncytial Virus neutralizi ng antibody 
2 In addition to scheduled pregna ncy tests in fema le pa1tic ipants, if pregna ncy is suspected at any time during the study, a serum 
test will be done. 
3 Safety laboratory assessments includes serum che1ni stiy and hema tology. 
4 12-lead ECG s will be obtain ed after the paiticipant has rested in a supine position for at least 10 minutes . Tripl icate ECGs will 
be taken approximatel y one minu te apart. Refer to Section 8.1.6 for details. 
5 Day 1 vital signs will be taken before dose and again 4 hour s after dose. The window for vital signs measuremen ts is ± 3 
minutes . Refer to Section 8.1.2. lfor details. 
6 All Day 1 safety assessments and samp le collec tions will be done prior to study intervention. Symp tom assessments will be 
done after dosing. Follo wing dose administration, if the participant will not be confined overnight for the optional night of Day 
1, they will be observed fo r at least 4 how·s at the study site after recei ving the study intervention , for safety monitoring . 
7 Blood sainples for PK, ADA and RSV neutralizing antibody at Day 1 will be drawn at pre-dose only 1 hour ( +/-30 
minu tes) before administi·a tion ofIM injection. 
8 Early Discon = A discontin uation vis it will be schedule d for pa1ticipan ts who discontinue or withdraw, when possible. 
Bill & Melinda Gates Medi cal Resea rch Institute 
CONFIDENTIAL 19 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   20 
CONFIDENTIAL    2. Introduction  
2.1. RSV and Burden of Disease  
RSV is the most common pathogen identified in young children with acute LRTI. Most children 
acquire an RSV infection by the time they are 2 years old, causing a mild,  cold-like il lness within 
4 to 6 days after infection. However, in some children it leads to a more severe illness suc h as 
bronchiolitis and pneumonia and may also increase the risk of developing subsequent asthm a 
and/or recurrent wheezing episodes in earl y childhood. The highest childhood RSV ac ute LRTI 
burden occurs during the first year of life when children are most vulnerable.  
RSV is a global disease that also places high burdens on the economy and health care se rvices. 
Estimates show that approximatel y 33.1 million episodes occurred globally in 2015, r esulting in 
about 3.2 million hospital admissions in children younger than 5 years, and 1.4 million 
hospitalizations in children younger than 6 months. Healthy term infants 3 months of a ge and 
younger acc ount for more RSV -associated hospitalizations than any other age group. The  
hospital admission rate from RSV in LMICs is 15.9 per 1000 neonates per year with incide nce 
rates being 3 times greater in preterm than term infants [ Shi 2017].  
Globally, there are approximately 120,000 RSV -associated acute LRTI deaths among c hildren 
<5 years of age each year [ Obando -Pacheco  2018] which account for a third of all LRT Is, with 
most deaths occurring in LMICs [ Shi 2017]. Approximate ly 45% of in -hospital deaths du e to 
RSV-associated acute LRTI occur in children younger than 6 months (median age of RS V-
related deaths is 4 -7 months [ Shi 2017, Scheltema  2017]), indicating that these infants consti tute 
a critically important target group for prevention. However, the need for immediate prote ction 
and the difficulty of achi eving protective efficacy via active immunization of these infa nts have 
refocused research efforts toward maternal immunization and passive immune -prophy laxis as 
key priorities. Either of these strategies could be followed with active infant immuniza tion l ater 
in life as maternal/passive antibody titers wane [ Higgins  2016].  
The burden of RSV infection, especially among infants and young children, underscor es the need 
for safe and effective prevention against RSV disease that is affordable in LMICs.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   21 
CONFIDENTIAL    2.2. RSV Prevention - Monoclonal Antibodies  
There is an unmet medical need for an effective, durable, cost effective RSV prevention strategy 
for all infants and children . The World He alth Organization (WHO) Product Development for 
Vaccines Advisory Committee (PDVAC) indicates that RSV immunoprophylaxis with a 
monoclonal antibody (mAb) is a priority intervention. There is no approved vaccine against RSV 
currently - the majority of candid ates in clinical evaluation incorporate alternative antigens or 
constructs and target maternal or pediatric immunization strategies.  
Administration of a mAb directly to the infant at birth or at any time during the primary 
immunization series presents an a ttractive alternative to maternal immunization. The mAb would 
only need to be used in infants up to 6 months of age or those at risk of LRTIs during the local 
RSV season, which would reduce the overall programmatic cost of RSV disease prevention. 
Critical success factors intrinsic to a candidate mAb include high potency, product safety, high 
barrier to virus resistance, and stability / PK that gives adequate duration of protection.  
There is one approved RSV mAb, palivizumab, which is indicated for the preve ntion of serious 
LRTI caused by RSV and has been used in the past 2 decades. Palivizumab is an RSV fusion 
(F)-specific immunoglobulin G monoclonal antibody (Synagis®, Swedish Orphan Biovitrum)  
that requires monthly injections and is cost prohibitive for LM ICs. It is approved for use in high -
risk children, including 1) preterm infants born at ≤ 35 weeks gestational age and who are ≤ 6 
months old at the beginning of RSV season; 2) children with bronchopulmonary dysplasia that 
required medical treatment within  the previous 6 months and who are ≤ 24 months old at the 
beginning of RSV season; and 3) children with hemodynamically significant congenital heart 
disease and who are ≤ 24 months old at the beginning of RSV season. Among preterm infants, 
the American Aca demy of Pediatrics issued an updated guidance in 2014 to limit its 
recommendation for palivizumab to preterm infants born before 29 weeks gestational age and 
who are ≤ 12 months old, who would most likely benefit from this preventive agent [ Brady , 
2014].  
Motavizumab, a derivative of palivizumab with higher affinity for RSV, was not pursued by 
MedImmune for licensure after the Phase 3 trial failed to secure FDA approval for lack of clear 
superiority to palivizumab and a trend for a higher rate of skin rash [Feltes, 2011]. A mAb 
manufactured by Regeneron (REGN2222 or suptavumab) did not meet efficacy endpoints in 
Phase 3, and  clinical development was also discontinued. This was due to escape mutants in the 
predominantly circulating RSV B that affected the ove rall performance of REGN2222 [ Simões  
2020 ]. 
Two other RSV mAbs are in clinical development, with MEDI8897 (nirsevimab), being the most 
advanced. Nirsevimab binds to the s ame antigenic site Ø of RSV prefusion F but different 
epitope than RSM01. In a Phase 2b trial of 1453 premature infants 29 - to 34 -week gestational 
age who were ≤1 year old, nirsevimab administration reduced the incidence of RSV -associated 
medically -attende d LRTI by 70% and hospitalizations by 78% compared to Placebo [ Griffin  
2020]. The nirsevimab program has initiated enrollment of a Phase 2b/3 in preterm infants ≤35 
week s gestational age  with either chronic lung diseases or congenital heart disease or 
bronchopulmonary dysplasia  [Clinicaltrials .gov NCT No. 03959488], and a Phase 3 study in 
term and late preterm infants ≥35 weeks gestational age [ Clinicaltrials .gov NCT No. 03979313]. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   22 
CONFIDENTIAL    The primary endpoint of a statistically significant reduction in the incidence of medically -
attended RSV LRTIs was met in this trial [ AstraZeneca  2021].  
The other RSV mAb candidate, MK -1654, targets site IV of the RSV pre - and post -fusion F. A 
Phase 2 study of safety and PK study in infants is ongoing [Clinicaltrials.gov NCT No. 
03524118]. An RSV challenge study in healthy adults was completed in A ugust 2020 and no 
results are available to date [Clinicaltrials.gov NCT No. 04086472]. However, these mAb 
candidates in development are targeted primarily for high -income countries, with costs likely too 
high to allow affordable global access to the produc t. 
Evidence from the Novavax maternal RSV F nanoparticles vaccine trial suggests that prevention 
of RSV early in life can also result in 25% reduction in all -cause LRTI hospitalization up to one 
year of age [ Madhi  2020]. An efficacious RSV immunization product could have significant 
public health impact in preventing pneumonia deaths in young infants, with potential benefits 
that may extend longer.  
2.3. RSM01 mAb Candidate  
RSM01( also designated as ADI -15618 -IVNS YTE) is a fully human IgG1 neutralizing 
monoclonal antibody that targets site Ø (zero) of the prefusion conformation of the RSV F 
glycoprotein (pre -F), which has high neutralizing potency. RSM01 has a molecular weight of 
approximately 150 kilodaltons.  
RSM01 has the same half -life extension YTE mutation (M252Y/S254T/T256E, European Union 
numbering) in its crystallizable fragment (Fc) domain as 2 other next generation RSV mAb 
candidates, Merck’s MK -1654 and AstraZeneca’s nirs evimab, which are being evaluated in 
Phase 2 and 3 clinical trials, respectively. Both have a favorable safety profile in previous 
clinical trials [ Aliprantis  2020, Griffin  2017], and nirsevimab was shown to reduce the incidence 
of RSV -associated medically -attended LRTI and hospitalizations in a Phase 2b study [ Griffin  
2020].  
2.3.1.  Non-Clinical Development of RSM01  
The non -clinical development of RSM01 focused on non -clinical safety studies in rats and 
monkeys, in vitro potency against RSV A and B assessments and efficacy studies in a cotton rat 
RSV challenge model. These studies are considered sufficient to support entry into Phase 1 FiH 
study in adults, followed by age de -escalation into a Phase 1b/2a study in infants.  
The non -clinical pivotal safety package for RSM01 conducted to s upport FiH studies consists of 
a 4-week Good Laboratory Practice (GLP) study in monkeys and a cross -reactivity GLP study in 
human tissues.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   23 
CONFIDENTIAL    Overall, RSM01 was well -tolerated in non -GLP single dose studies in rats and monkeys, and in a 
4-week repeat -dose GLP  study in cynomolgus monkeys. In the 4 -week study, RSM01 was 
administered weekly plus one for a total of 5 doses at 30, 100, and 300 mg/kg, IV and at 100 mg 
total dose in 1mL, IM. There were no identified target organs of toxicity or test -article -related 
adverse local reactions; there were also no test -article -related effects on the cardiovascular, 
respiratory or the central nervous systems at all doses  The No -Observed -Adverse -Effect -Level 
(NOAEL) in the 4 -week study was 300  mg/kg/dose, IV (area under the c urve [AUC] 0-
168h :1,420,000 µg*h/mL; C 0: 11,900 µg/mL) and 100 mg/dose, IM (AUC 0-168h :264,000 µg 
*h/mL; maximum plasma concentration [C max]:1760 µg/mL). A tissue c ross-reactivity study with 
biotinylated RSM01 found no risk for off -target binding of RSM01 in human tissues. The non -
clinical safety profile of RSM01 supports dosing of humans in Phase  I clinical trials. No local 
toxicity was observed in monkeys following IM administration at the  same concentration of 
mAb (approximately 100 mg/mL) intended for u se in humans.  
The NOAEL of 300 mg/kg, IV supports a Maximum Recommended S tarting Dose (MRSD) of 
582 mg [ FDA  2005] with an applied safety factor of 10. T his suppor ts the proposed starting dose 
of 300 mg, IV, in adults.  
In vitro cell -based neutralization studies showed that RSM01 performe d as well or better than 
other RSV mAbs to neutralize both RSV A and RSV B clinical isolate s including important 
sequence  variants that are critical for epitope binding. RSM01 potenc y was comparable to that of 
nirsevimab and more potent than REGN2222 and palivizumab.  
In cotton rat challenge studies, RSM01 reduced lung and nasal viral t iters in a dose -dependent 
manner. Protec tion in the lower respiratory tract upon challenge with R SV A and B was greater 
with RSM01 compared to palivizumab.  
In summary, there were no test -article related target organ toxicities, no e ffects on vital systems, 
and no adverse local reactions reported  in non -clinical safety studies. R SM01 demonstrated a 
favorable efficacy and safety profile supporting its progression for cli nical development to 
prevent RSV disease.  
2.4. Study Rationale  
The burden of RSV infection, especially among infants and young children  underscores the need 
for safe and effective prevention against RSV disease that is affordable in LMICs. The goal of 
the clinical development program for RSM01 is to develop a safe, effective, affordable mAb to 
prevent severe RSV disease in infants in LMIC s. The clinical development approach for RSM01 
is to first study a wide dose range in healthy adults to assess safety and to cover target exposures 
in infants that will allow for pharmacokinetic (PK)/pharmacodynamic (PD) modeling to provide 
confidence in p redicting effic acious doses in infants.  
Refer to Section 2.5 for justific ation of dose levels.  
2.5. Justification for Dose  
2.5.1.  Doses for Escalation Phase Cohorts  
The selection of the dosing strategy for dose escalation is based on non -clinical safety data and in 
vivo pharmacological evaluation in the cotton rat RSV prophylactic model. This approach is 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   24 
CONFIDENTIAL    supported by assessments of the PK profile of other RSV mAbs with YT E mutations. The wide 
dose range, from 300mg to 3000mg, in healthy adults would cover target exposures in infants 
and support PK/PD modeling to predict infant dosing.  
RSM01 and nirsevimab were evaluated in the RSV cotton rat model. Collectively, the conclu sion 
from those experiments is that the EC90s for RSM01 is similar to nirsevimab in term of PK/lung 
RSV titers. In the literature, nirsevimab has been reported to have a EC90 of 6.8 µg/mL [ Zhu 
2017].  
The human PK exposure of RSM01 in healthy participants was projected based on extrapolation 
made from the non -human primate PK in the toxicology studies and published reports of the PK 
characteristics of competitor monoclonal antibod ies (nirsevimab and MK -1654) in healthy 
volunteers.  
These projections suggest that following RSM01 doses of ≥ 300 mg the RSM01 concentration is 
predicted to be above the target EC90 threshold at Day 151.  
RSM01 was well -tolerated in a definitive study in mo nkeys with a NOAEL of 300 mg/kg/dose 
or 100 mg/dose following IV or IM administration, respectively. The NOAEL at 300 mg/kg, IV, 
provided safety margins of approximately 10 -fold and 1.1 -fold to the starting dose of 300 mg IV 
and ending dose of 3000 mg IV, respectively, based on predicted human AUC. There were no 
test-article -related local reactions following administration of 100 mg/mL of RSM01 by IM 
injection in monkeys, which supports dosing of 600 mg, IM in humans at 100 mg/mL of RSM01.  
Safety and PK dat a from the FiH study in adults are required to support proceeding to the target 
population of infants. The wide fixed -dose ranges to be tested in healthy adults will cover the 
anticipated target exposures in infants. The 300 mg dose in adults is estimated to correspond to 
the target dose of 50 mg in infants. Importantly, the maximum dose for the escalation cohorts 
(3000 mg IV) and the maximum dose for the Expansion Phase cohort (600mg IM) will provide 
necessary safety information to inform selection of dose s in infants.  
2.5.2.  Dose for Expansion Phase Cohort  
Final selection of the dose to be administered to Cohort 5 will be made by the sponsor and 
informed by available RSM01 PK data, as well as relevant safety data, from the Dose Escalation 
Phase.  
Available interim PK data from the Dose Escalation Phase cohorts, combined with published 
data from previous studies of monoclonal antibodies, will be used to develop a population PK 
model to describe the individual concentration time profiles of RSM01. Su bsequently, the model 
will be used in a simulation mode to predict the proportion of participants that are expected to 
have RSM01 concentrations above the EC90 on Day 151.  
The tentatively determined dose to be tested in the Dose Expansion Phase cohort is ≥300 mg and 
≤600 mg IM, based on available pre -clinical and clinical PK data from nirsevimab and MK -1654 
(Griffin  2017, Aliprantis  2020). The 600mg IM dose in adults is expected to provide additional 
margin for meeting the EC90 threshold at Day 151, even in the case that the t1/2 of RSM01 is 
shorter  than those of nirsevimab and MK -1654. It will also provide additional information for 
infant dose selection for the planned Phase 1b/2a study.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   25 
CONFIDENTIAL    The 600 mg IM dose is anticipated to be equivalent to the maximum possible infant dose of 
100mg IM (based primar ily on the IM volume constraint of 1mL).  
2.6. Benefit/Risk Assessment  
The non -clinical safety of RSM01 has been evaluated in GLP -compliant studies in monkeys of 
up to 4 weeks in duration. RSM01 was well -tolerated at all doses tested; there were no test -
article related target organ toxicities, no effects on vital systems, and no adverse local reactions. 
Juvenile monkeys are commonly used in toxicology studies including studies conducted with 
RSM01. A tissue cross -reactivity study with biotinylated RSM01 found no risk for off -target 
binding of RSM01 in human tissues.  
Clinical risks and benefits have not been established for RSM01 when administered to humans. 
However, it is expected that RSM01 will have a similar benefit/risk profile to nirsevimab.  
There have not be en safety concerns identified to date from the 3 clinical trials of nirsevimab that 
had 102 adults and 1039 infants exposed to nirsevimab. No SAE related to the compound 
occurred during these studies. A Phase 1 FiH study in adults in the U.S. evaluated a single dose 
of nirsevimab or Placebo administered as an IV dose of 300mg, 1000mg, or 3000mg or as an IM 
dose of 100mg or 300mg [Griffin, 2017] and did not have any study discontinuations due to AEs 
or SAEs.  The most frequently reported nirsevimab -related A Es were headaches (all mild), 
occurring in 3 (2.9%) participants. The safety profile was similar to that of the Placebo.  
In the second clinical trial, a Phase 1b/2a study evaluated a single IM dose of 10mg, 25mg or 
50mg of nirsevimab or Placebo in infants in the U.S., South Africa, and Chile [Domachowske, 
2018]. Five infants (7.0%) who received nirsevimab experienced product -related AEs, which 
included nasal congestion, pyrexia, gastroenteritis, upper respiratory tract infection and wheezing 
(all Grade 1), and 5 experienced medically -attended LRTIs through Day 150; 1 tested positive 
for RSV (10mg group).  
In the third clinical trial, a Phase 2b study evaluated a single dose of 50mg IM of nirsevimab  vs. 
Placebo in 1453 healthy preterm infants (29 -34 weeks gest ational age, aged 0 -12 months). 
Through Day 150 of follow -up, AEs occurred at similar frequencies between the mAb (804/968, 
83%) vs. the Placebo (402/479, 83.9%) groups. SAEs were reported in 108/968 (11.1%) mAb vs. 
81/479 (16.9%) Placebo recipients, and n one were considered related to study drug. AESIs 
related to study drug were reported in 5/968 (0.5%) in nirsevimab vs. 3/484 (0.6%) in Placebo. 
There were no anaphylaxis or other notable hypersensitivity reactions. In the nirsevimab  group, 4 
infants experi enced rash. One infant experienced one day of petechiae occurring 4 months after 
nirsevimab , which was not assessed by a health care provider. All 3 AESI infants in the Placebo 
group had rash.  
AEs attributed to ADAs have not been observed in the nirsevimab  trials. In the Phase 1 adult 
trial, ADA occurred at a similar frequency in the mAb and Placebo groups. At the baseline visit, 
5/103 (4.9%) mAb vs. 3/34 (8.8%) Placebo recipients had ADA. During post -dose visits, 14/102 
(13.7%) mAb vs. 5/33 (15.2%) Placebo  recipients had ADA. In the nirsevimab  Phase 1b/2a 
infant trial none had ADA at baseline and only the mAb group had ADA at post baseline (20/71, 
28.2%) vs. 0/17 in the Placebo group. Aside from 2 infants with transient positive ADA at day 
50, all positive ADAs occurred after the intended coverage duration of 150 days. ADA did not 
impact safety but lowered the drug exposure between days 150 to 360 in some infants.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   26 
CONFIDENTIAL    The Phase 1 MK-1654 study randomized 152 healthy adults in a 3:1 ratio to MK -1654 (100mg 
IM, 30 0mg IM, 300mg IV, 1000mg IV and 3000mg IV) vs. Placebo. The overall safety profile 
of MK‐1654 was similar to that of Placebo.  No deaths, SAEs, discontinuations due to AEs, 
clinically significant laboratory AEs, or dose -dependent pattern of drug -related AEs  were 
reported [Aliprantis  2020].  
RSV Mutations  
RSV belongs to the class of ribonucleic acid (RNA) viruses and as such possesses an error -prone 
RNA polymerase. Th is raises potential concerns about the emergence of antibody resistant 
escape mutants. This is especially relevant for mAb that are considered for wide -spread use and 
target a single epitope on the viral surface. Zhu, et al published data on RSV escape var iants 
against nirsevimab, a highly potent, next generation anti -RSV -F antibody that also binds to 
antigenic site Ø that is currently under clinical investigation [ Zhu 2018].  
Escape mutant selection studies with RSM01 were performed by the former sponsor, Arsanis 
(Vienna, Austria). A total of 11 escape mutant selection studies were conducted by Arsanis 
during the selection phase of RSM01. Although previously identi fied antibody resistant mutants 
against palivizumab and nirsevimab were obtained, not a single resistance associated mutation 
was identified for RSM01, parental mAb 15618, or additional 15618 variants. The data suggest 
that the epitope of RSM01 is more sta ble and less prone to amino acid substitutions under 
selective pressure compared to nirsevimab. This is interesting since RSM01 and nirsevimab bind 
to the same antigenic site (epitopes differ) on the F protein and have largely comparable 
neutralization pot ency based on in vitro and in vivo virus neutralization assays. RSM01 
maintained anti -viral activity against a nirsevimab resistant strain, RSV -B9320 N208D [ Rouha  
2018].  
In vitro cell -based neutralization studies showed that RSM01 performed better than other RSV 
monoclonal antibodies palivizumab and REGN222 to neutralize both RSV A and RSV B strains 
inclu ding important sequence variants. RSM01 potency was comparable to that of nirsevimab.  
General Risks with MAb Infusion  
Administration of any mAb may carry a risk of immune reactions such as acute anaphylaxis, 
serum sickness and the generation of antibodies against the mAb. However, these reactions are 
rare and more often associated with mAbs targeted to human proteins or with the use of murine 
monoclonal antibodies, which would have a risk of human anti -mouse antibodies. In this regard, 
as RSM01 is targeted to a viral antigen, is a fully human mAb (IgG1), and is expected to have a 
low risk of such side effects.  
Typically, the side effects of mAbs are mild but may include fever, chills, rigors, nausea, 
vomiting, pain, headache, dizziness, shortness of breath, bronchospasm, hypotension, 
hypertension, pruritus, rash, urticaria, angioedema, diarrhea, tachycardia, or chest pain.  
Most infusion -related events occur within the first 24 hours after beginning administration. 
Severe reactions, such as anaphylaxis, angioe dema, bronchospasm, hypotension, and hypoxia, 
are infrequent and more often associated with mAbs targeted to human proteins and not 
pathogen -directed human mAbs like RSM01. Immediate infusion reaction is managed by 
temporarily stopping the infusion, admini stration of histamine blockers and restarting the 
infusion at a slower rate [ Vogel  2010]. Delayed allergic reactions to a mAb may include a serum 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   27 
CONFIDENTIAL    sickness type of reaction, which is characterized by urticaria, fever, lymph node enlargement, 
and joint pains. These symptoms may not appear until several days after the exposure to the mAb 
and are  noted to be more common with non -human/human chimeric types of mA bs [Hansel 
2010]. A ntibodies containing the YTE mutations in the Fc region have been safe  and well -
tolerated in humans [ Robbie  2013, Aliprantis  2020, Griffin  2020].  
No dire ct benefits are anticipated for the healthy adults enrolled in this Phase 1 st udy. RSM01is 
expected to have favorable safety profile based on experience with other fully human 
monoclonal antibodies targeting various viruses (e.g., anti -HIV, anti -influenza, a nd anti -RSV).  
3. Objectives and Endpoints  
Table 4: Objectives and Endp oints  
Objectives  Endpoints (Endpoints apply to all cohorts unless noted)  
Primary  
To characterize the safety and 
tolerability of a single dose of 
RSM01  • Unsolicited AEs through Day 151  
• All serious adverse events (SAEs) and AESIs through 
Day 151  
• Solicited systemic AEs for 7 days after dose 
administration  
• Solicited local AEs for injection site reactions for 7 
days after dose administration (only applies to IM 
doses)  
Secondary  
To characterize safety laboratory 
parameters following RSM01 
administration  • Safety laboratory parameters Grade 1 and above 
through Day 151  
To characterize the 
pharmacokinetics (PK) following 
RSM01 administration  PK parameters including:  
• Area under the capillary blood -concentration time 
curve from zero to infinity (AUC 0-∞) 
• Day 91 capillary blood -concentration and area under 
the capillary blood -concentration time curve (C D91 and 
AUC 0-D91) 
• Day 151 capillary blood -concentration and area under 
the capillary blood -concentration time curve  (CD151 and 
AUC 0-D151) 
• Cmax following IM a dministration and C 0 following IV 
administration), C min 
• Tmax and t1/2  
• CL 
• Vz of RSM01 through Day 151  
To characterize the formation of 
ADAs following RSM01 
administration  • Incidence  of ADAs to RSM01 through Day 151  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   28 
CONFIDENTIAL    Exploratory  
 To characterize RSV neutralizing 
antibody activity following 
RSM01 administration  • Capillary blood RSV neutralizing antibody levels 
through Day 151 
 
4. Study Design  
4.1. Design Overview  
Overall Design  
Disclosure statement:  This is a FiH trial of RSM01, administered to adults. It is a randomized, 
double -blind, placebo -controlled study of RSM01.  
Study Population and Number of Participants: Adult par ticipants between 18 and 49 years of 
age (inclusive) of both sexes who are cap able of and will ing to provide informed consent may be 
eligible for the study. The complete list of inclusion and e xclusion criteria can be found in 
Section 5.1and Section 5.2, respectively.  
Candidates will be screened to enroll 56 eligible participants.  
Assuming that all cohorts are allowed to undergo treatm ent, approximate ly 48 participants will 
receive RSM01 and approximately 8 will receive Placebo.  
Interventional model : The study will be conducted in 2 par ts: A Dose Escalation Phase (N=28) 
with 4 dosing cohorts, followed by an Expansion Phase (N =28) with a single cohort.  
Dose Escalation Phase:  
The first participant in each Dose Escalation Phase cohort w ill not be randomized and will 
receive the RSM01 dose level appropriate to assigned cohort to ser ve as a sentinel exposure 
(refer to Section 8.1.1 ). 
The remaining 6 participants in each of Cohorts 1, 2, 3, a nd 4 will be randomized 5:1 to receive 
either RSM01 or Placebo. The overall ratio of RSM01 t o Placebo will be 6:1 in  each cohort.  
The Dose Escalation Phase will  occur sequentially in 2 escalation steps.  
• Cohort 1:  7 participants will receive RSM01  300mg  IV (n=6 total including sentinel 
participant) or Placebo IV (n=1)  
First escalation step : from Cohort 1 to Cohorts 2 and  3, conducted in parallel  
• Cohort 2: 7 participants will receive RSM01 300m g IM (n=6 total including sentinel 
participant) or Placebo IM (n=1)  
• Cohort 3 : 7 participants to receive RSM01  1000mg IV (n=6 total including sentinel 
participant) or Placebo IV (n=1)  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   29 
CONFIDENTIAL    Second escalation step : from Cohorts 2 and 3 to Cohort 4  
• Cohort 4: 7 participants will receive RSM01 3000mg IV (n=6 total including sentinel 
participant) or Placebo IV (n=1).  
For the Dose Escalation Phase cohorts, all participants will be confined at the study site from 
Day -1 (i.e., the day before dosing) to after completion of the Day 3 assessments (a total of 3 
nights).  
Dose Escalation Phase, continued:  
After the sentinel pa rticipant in each cohort receives RSM01, the next participant can be dosed 
24 hours later, if there is no safety concern.  
After the 24 -hour post -dose period for the sentinel participant in each Dose Escalation Phase 
cohort, participants in the Dose Escalat ion Phase cohorts should be dosed at least 2 hours apart 
regardless of route of administration (IM or IV). The ≥2-hour interval between administering IV 
infusions is to begin at the end of the previous infusion.  
For participants receiving the IM dose of st udy drug in Cohort 2, the ≥2-hour interval between 
administering IM injections to successive participants is to begin at the time of the previous 
participant’s IM injection. If RSM01 is administered using 2 injections, the ≥2-hour interval 
begins at the ti me of the second injection.  
Each dose escalation step will proceed after all participants the prior cohort have completed Day 
15, and the SRT has reviewed the data and determined that a pausing rule has not been met. 
Refer to Section 8.2.6  for details regarding the SRT.  
Dose Expansion Phase : 
Enrollment in the Dose Expansion Phase (Cohort 5) will begin after Day 15 for participants in 
Cohort 4, and after  the SRT has reviewed the data and determined that a pausing rule has not 
been met. Cohort 5  will include  28 participants randomized 6:1.  
• Cohort 5: participants will receive RSM01 IM (n=24) or Placebo IM (n=4).  
For Cohort 5, participants will be asked to p resent to the clinic within 24 hours of the Day 1 visit 
for Day -1 (Pre -V1) confinement.  
On Day 1 after dosing, participants will be observed for at least 4 hours post -dose at the study 
site for safety monitoring. Based on investigator’s decision, a partic ipant may be asked to remain 
at the study site, for an additional overnight stay on the night of Day 1.  
Final selection of the dose of RSM01 to be administered to Cohort 5 will be made by the sponsor 
and informed by available RSM01 PK data from the Dose Es calation Phase.  
The tentatively determined dose to be evaluated in the Expansion Phase cohort is ≥300 mg to 
≤600 mg IM. This determination is based on predictions of RSM01 human PK exposures made 
using extrapolation from the RSM01 non -human primate PK and on published data from the 
other mAbs nirsevimab and MK -1654 administered to healthy adults [ Griffin  2017, Aliprantis  
2020]. The predictions suggest that the concentration of RSM01 will be above the efficacy 
threshold (EC90) on Day 151 following a RSM01dose of either 300 or 600 mg IM. Refer to 
Section 2.5.2  for dose justification.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   30 
CONFIDENTIAL    Pausing rules:  Refer to Section 7.1.1  
SRT and IDMC:  Refer to Sections 8.2.6  and 8.2.7  for information regarding the SR T and 
IDMC, respectively.  
Visits:  The study Schema is shown in Figure 1: Outline of Study Dosing Procedures  and the SoA 
is shown in Table 2 and Table 3, Dose Escalation Phase and Dose Expansion Phase, respectively.  
Blood Sampling: Refer to Sect ion 8.4. 
Masking : Refer to Section 6.5.2 . 
Analyses : An interim analysis wi ll occur after all participants in the Dose Escalation Phase 
cohorts 1 -4 have reached Day 91. The primary analysis will occur after all participants in all 5 
cohorts complete Day 151. Refer to Section 9. 
Total duration of study participation : The study duration for each participant is 151 days, in 
addition to a maximum 30 days for screening and Day -1. 
Study site/s : The study will be conducted in at least 1 site in th e U.S.  
4.2. End of Study Definition  
A participant is considered to have completed the study if he/she completes the final visit at Day 
151. 
The end of the study is defined as the date of the last visit of the last participant in the study or 
conduct of the last  scheduled procedure shown in the SoA for the last participant in the trial.  
5. Study Population  
A total of 56 eligible, healthy adult participants between 18 and 49 years of age (inclusive) of 
both sexes who are capable of and willing to provide informed con sent will be eligible for the 
study . See Section 5.1 and 5.2 for inclusion and exclusion criteria, respectively. Candidates will 
be screened for eligibility to enroll.  
Prospective approval of deviations to recruitment and protocol enrollment criteria, also known as 
protocol waivers or exemptions, will not be permitted.  
Recruitmen t 
All recruitment materials will be approved by the appropriate Institutional Review Board/s 
(IRBs) or Independent Ethics Committee/s (IECs). Interested participants will be invited to 
participate in the informed consent process.  
Various methods of recruit ment may be used, such as site databases, advertising, referrals, word -
of mouth, or other approved means.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   31 
CONFIDENTIAL    5.1. Inclusion Criteria  
Age 
1. Participant must be 18 to 49 years of age (inclusive) at the time of signing the informed 
consent  
Type of Participant and Disea se Characteristics  
2. Participants who are healthy as determined by medical evaluation including medical history, 
physical examination, and laboratory tests  
Weight  
3. Body mass index (BMI) 18 to 29.9 kg/m2 (inclusive)  
Sex 
4. Both males and females are eligible to participate.  
Male participants with partners of childbearing potential must agree to use condoms during 
their participation in the study and for 90 days after  the participant completes the study. 
Male participants must also agree to refrain from sperm donation for at least 90 days after 
they complete the study.  
Female participants of childbearing potential must not be pregnant, breastfeeding, or 
attempting to b ecome pregnant for 28 days before Screening and throughout the duration of 
their participation in the study. These participants must have a negative serum pregnancy 
test at Screening in order to be eligible for randomization and treatment with study 
interv ention. In addition, female participants must be willing to commit to using a consistent 
and acceptable method of contraception for the duration of their participation in the study 
and for 90 days after they complete the study if they engage in intercourse . Acceptable 
methods of contraception are:  
• Consistent use of systemic contraception, including birth control pills, transdermal 
patch, vaginal ring, implants, and injectables.  
• Consistent use of double barrier method, e.g., condoms, cervical cap, diaphragm,  
vaginal contraceptive film with spermicide.  
• Use of intrauterine device with a low failure rate (defined as < 1% risk of pregnancy 
per year)  
• Monogamous intercourse with a vasectomized man or has only same -sex partners.  
Female participants who are not sexua lly active but become so during the study must agree 
to follow the contraceptive requirements above.  
Female participants who are not of childbearing potential must meet at least one of the 
following criteria:  
• At least 1 year since the last menstrual period . 
• Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or 
hysterectomy)  
• Congenitally sterile  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   32 
CONFIDENTIAL    • Diagnosed as infertile and not undergoing treatment to reverse infertility.  
Refer to Appendix  10.3 for more information.  
Informed  Consent  
5. Capable of giving signed informed consent which includes complianc e with the requirements 
and restrictions listed in the informed consent form (ICF) and in this proto col 
Additional Requirements:  
6. Participants must agree to stay in contact with the study site for the du ration of the study, 
provide updated contact information as necessary, and have no curr ent plans to relocate from 
the study area for the duration of the s tudy.  
5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria  apply:  
Medical Conditions  
1. Acute illness and/or body temperature ≥37.5 °C or ≥99.5 °F on Stud y Day 1 (refer to Section 
5.4 for additional details). NOTE: This is a temporary exclusion fo r which the participant 
may be re -evaluated.  
2. Evidence and/or history of clinically significant medical condition(s)  as judg ed by the 
investigator, including malignancies, diabetes mellitus, and unstable or  uncontrolled 
hypertension  
3. History of any autoimmune disease or immune deficiency or other impa irment to the immune 
system, including but not limited to HIV, autoimmune condi tions, or imm unosuppressive 
therapy. Note: history of Hashimoto’s thyroiditis is not an exclusion c riterion.  
4. History of anaphylaxis  
5. Any current medical, psychiatric, occupational, or substance abuse problems that, in the 
opinion of the investigator, will make it unlikely that the participant will comply with the 
protocol  
Prior/Concomitant Therapy  
6. Receiving or plan to receive any medications or other therapies that may impact the immune 
system such as allergy injections, interferon, immunomodulators, cytoto xic drugs or other 
drugs known to be frequently associated with major organ toxicity within 90 days prior to 
Day 1.  
7. Having received any vaccination (including COVID -19 vaccine) within the 15 days before 
Day 1, or planning to receive a dose of any vaccine d uring the 15 -day period following Day 
1. 
8. Receiving or plan to receive immunosuppressive agents including systemic steroids within 
90 days prior to Day 1 (individuals using inhaled or topical corticosteroids, prednisone (or 
equivalent) dose of ≤ 20 mg/day f or ≤ 14 days, and intra -articular corticosteroids are 
permitted)  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   33 
CONFIDENTIAL    9. Receipt or donation of blood or blood products within 90 days prior to Day 1 or planned 
receipt or donation during the study period  
10. Receiving or plan to receive antibody or biologic therapy w ithin 180 days prior to Day 1 or 
any time during the study period, whether licensed or investigational (e.g., immunoglobulin 
products, monoclonal antibodies, or antibody fragments).  
Prior/Concurrent Clinical Study Experience  
11. Participation in an interventio nal clinical trial and/or receipt of any investigational drug 
within 30 days or 5 half -lives of the investigational drug before the first day of study drug 
dosing in this study, whichever is longer  
12. Concurrent enrollment in another interventional study  
13. Previously having participated and received study intervention in the current study.  
Diagnostic Assessments  
14. Female participants: positive serum pregnancy test  
15. Safety laboratory values outside of normal range, for age and sex that are suggestive of a 
disease state (Grade 1 ab normalities will not lead to exclusion if the investigator considers 
them not clinically significant.)  
16. Urinalysis abnormality greater than Grade 1 (with the exception of hematuria in a 
menstruating female), or  urinalysis abnormality judged  clinically significant by the 
investigator  
17. Clinically significant EC G abnormalities  
18. Reactive HIV antibody testing  
19. Current hepatitis B and/o r hepatitis C infection  
20. Positive urine drug scree n at screening or Day -1 (with the exception of prescribed drugs).  
Other Exclusions  
21. History of allergy or hyp ersensitivity to the study drug, excipients or related substances  
22. Female participants with any one of the following conditions: currently pregnant or 
lactating/nursing; having  positive serum pregnancy test during th e Screening Phase, planning 
a pregnancy within 1 yea r after first dose of study drug (Refer to Appendix 3, Section 10.3) 
23. Individuals who are acti ng as study person nel or immediate family members (brother, sister, 
child, parent) or the spou se/partner of study personnel.  
5.3. Lifestyle Considerations  
No restrictions are required.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   34 
CONFIDENTIAL    5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently entered into the study and do not receive study intervention. A minimal set of 
screen failure information is required to ensure transparent reporting of criteria for participants 
who are screen failures in order to m eet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria not met, and 
any SAE.  
Rescreening assessments as outlined below may be performed after obtaini ng informed consent, 
which must be completed prior to any rescreening procedure.  
Rescreening is only permitted under one or more of the following scenarios:  
• If a participant presents w ith an acute illness on the day of planned stud y intervention, e.g., 
elevated temperature, acute respiratory or gastrointestinal illness, or ur inary tract infection 
(UTI ), and meets all other eligibility criteria and can be rescreened withi n the originally  
defined screening window (SoA, Section 1.3). A new participant numbe r is not required. If 
the participant is rescreened during the original screening  window, obta ining a second 
infor med consent of the participant is not required.   
• If there are technical difficulties with phlebotomy at screening (e.g., labo ratory reports 
hemolyzed blood), technical error in running the laboratory tests or an abnormal urine 
analysis due to menstruation or UTI, and the participant can be rescree ned within the 
originally defined screening window (SoA, Section 1.3). A new participant  number is not 
required. If the participant is rescreened during the original screening windo w, obtaining a 
second informed consent of the participant is not required.   
• If a participant is undergoing screening and the study reaches a pausing  rule. The participant 
may be rescreen ed when and if the IDMC recommends, and the Sponsor determines, that the 
study may continue. A new participant number is not required. If the participant is 
rescreened during the original screening window, obtaining a second informed consent of 
the participant is not required.  
• If a participant fails to meet eligibility criteria upon initial screening, a one -time only 
rescreening for eligibility may be performed. In this case, the participant must be given a 
new particip ant number after signing a new informed consent.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   35 
CONFIDENTIAL    6. Study Intervention  
Study inte rvention is defined as any investigational intervention(s), marketed product(s), 
Placebo, or medical device(s) intended to be administered to a study participant according  to the  
study protocol.  
Two interventions will be used in this study: participants will receive either RSM01 or Pl acebo 
based on r andomization as described in Study Design, Section 4. 
Participants in the Dose Escalation Phase cohorts will receive a single dose of either 300 mg IV, 
1000mg I V, 3000mg IV or 300mg IM, of RSM01, or Placebo.  
The Expansion Phase cohort will receive a single dose of RSM01 IM or Placebo. The  RSM01 
dose will be selected based on review of available PK data from prior cohorts, as well  as relevant 
safety data.  
Table 5: Study Interventions  
 RSM01 Drug Product  Placebo (Control)  
Intervention  RSM01  (RSV F neutralizing 
monoclonal antibody)  Matching formulation buffer 
without API RSM01  
Unit -Dose Strength  100mg/mL  N/A  
 Dose Escalation Phase cohorts  
Dosage, Volume and 
Route of 
Administration  300mg (53mL) IV infusion  
1000mg (60mL) IV infusion  
3000mg  (130mL) IV infusion  
300mg (3 mL) IM injection (1 
injection in the anterolateral thigh 
muscle)  Same volume and number of 
infusions/injections as the 
RSM01 group.  
 Dose Expansion Phase Cohort  
Dosage, Volume and 
Route of 
Administration  Dose to be determined. Route of 
administration will be IM in the 
anterolateral thigh muscle.  Same volume and number of 
injections as the RSM01 
group.  
6.1. RSM01 Drug Product  
The RSM01 Drug Product (RSM01) used in this study is manufactured by Just -Evotec Biologics, 
Inc. RSM01 is supplied as a liquid in a single use, sterile filled glass vial at a product 
concentration of 100mg/mL, and 100mg/vial configuration. The volume injected or infused will 
vary depending on the cohort.  
Each vial contains an isotonic, sterile solutio n that is a colorless to yellow liquid, essentially free 
of visible particles; some opaque or translucent particles may be present. Refer to Pharmacy 
manual for details.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   36 
CONFIDENTIAL    6.2. Placebo Drug Product  
The RSM01 Placebo Drug Product (Placebo) control consists of all the excipients without the 
mAb, in the same type of vial/cap/seal fill as the RSM01 presentation. The volume injected or 
infused will depend on the randomized group and will be the same as the volume of the RSM01 
administered to participants within each re spective cohort.  
Each vial contains an isotonic, sterile solution that is a colorless to yellow liquid, essentially free 
of visible particles; some opaque or translucent particles may be present. Refer to Pharmacy 
manual for details.  
 
 
6.3. Study Intervention P reparation and Administration  
Refe r to Section 4.1 for dose administration within each cohort and Section 6.4 for handling, 
stora ge, and accountability.  
Unit-dose syringes will be provided for IM administration, and infusion bags for IV 
administration, all of which will be identified with the particip ant identification number, date and 
time of dose preparation, and the volume prepared. An investigator (i.e., physician) must be 
present in the clinic at the time of administration of the study interventions.  
Visually, RSM01 is transparent and the appearan ce is comparable to that of the Placebo.  
The Placebo control will be administered in the same manner as the RSM01, within each cohort.  
IM a dministration into the anterolateral thigh muscle will be performed using standard ’Z -track’ 
technique. Refer to Sect ion 6.3.1 . 
IV infusion will be administered over a duration of up to 2 hours using a volumetric pump. The 
infusion rate may vary based on the total volume needed to administer the full dose. The total 
time needed to administer the dose may be longer than 2 hours based on factors such as 
participant tolerance. Refer to Section 6.3.2 . 
For the Dose Escalation Phase, the first (sentinel) participant undergoing study intervention 
administration in each cohort will receive RSM01. The next participant in each cohort can be 
dosed at least 24 hours after the sentinel participant. After the 24 -hour post -dose period for the 
senti nel participant in each Dose Escalation Phase cohort, participants in the Dose Escalation 
Phase should be dosed at least 2 hours apart regardless of route of administration (IM or IV). The 
≥2-hour wait time between IV infusions is to begin at the end of the previous participant’s 
infusion. The ≥2-hour wait time between IM injections is to begin at the time of the previous 
participant’s IM injection.  
For the Dose Expansion Phase, participants will be observed either overnight or for at least 4 
hours at the study site after receiving the  study dose, depending on the investigator’s decision.  
6.3.1.  IM Injection  
Before administering the injection, the study intervention administrator must inspect the syringe 
and vial volume, checking that the syringe is identified with the correct participant iden tification 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   37 
CONFIDENTIAL    number and checking the date and time the dose was prepared. For IM dosing in the Dose 
Escalation Phase, participants in Cohort 2 will receive a total of 3mL administered in 1 injection 
into the anterolateral thigh muscle at the dosing visit, us ing the ‘Z -track’ technique. The ≥2-hour 
wait time between administration of IM injections to successive participants is to begin at the 
time of the previous participant’s injection.  
The Dose Expansion Phase cohort may receive RSM01 ( ≥300mg to ≤600mg) or P lacebo in the 
anterolateral thigh muscle. If more than 3 mL of study intervention is administered in a single 
dose, the volume and number of injections will be adapted, depending on the dose to be 
administered, and will be decided by the sponsor.  
6.3.2.  IV Infusi on 
The formulation for RSM01 is 100mg/mL, and the appropriate volume, based on group 
randomization, will be added to normal saline to achieve the desired volume for each of the IV - 
dosed  cohorts. The total IV infusion volume will be 53mL for Cohort 1, 60 m L for Cohort 3, and 
130mL for cohort 4. The IV infusion time will be approximately 2 hours or less depending on the 
cohort. The ≥2-hour wait time between administration of IV infusions to successive participants 
is to begin at the end of the previous parti cipant’s infusion.  
6.4. Handling/Storage/Accountability  
Further guidance and information for the preparation, handling, storage, and accountability are 
provided in the Pharmacy Manual.  
The study intervention (RSM01 and Placebo) must be stored at 2°C to 8°C in a  secure location 
with no access for unauthorized personnel.  
The study pharmacist (or designee) must confirm appropriate temperature conditions have been 
maintained during transit and during site storage for all study interventions received and any 
discrepa ncies are reported and resolved before use of the study intervention. Upon receipt of 
study supplies, the study pharmacist must immediately inspect all kits for damage. Any damage 
or discrepancies from the packing list must be documented and promptly discu ssed with the 
sponsor and the study monitor to determine the appropriate action.  
Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.  
The investigator is responsible for study intervention accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation, and final disposition records).  
Authorization for any unused study intervention and supplies to be destroyed is the responsibility 
of the sponsor. At the en d of the study, unused supplies will be destroyed according to the 
facility’s Standard Operational Procedures (SOPs) or per local regulations. Any disposal of study 
intervention conducted at the clinical site must be documented in the study file.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   38 
CONFIDENTIAL    6.5. Measures to Minimize Bias: Randomization and Blinding  
6.5.1.  Randomization  
The first participant in each Dose Escalation Phase cohort will not be randomized and will 
receive RS M01 dose level appropriate to the assigned cohort (refer to Section 8.1.1 ). 
The remaining 6 participants in each Dose Escalation Phase cohort (Cohorts 1, 2, 3 and 4) will 
be randomized 5:1 to receive either RSM01 or Placebo. The overall ratio of RSM01 to Placebo 
will be 6:1 in each cohort.  
The Expansion Phase (Cohort 5) will be  randomized 6:1 to receive either RSM01 IM (N=24) or 
Placebo (N =4). 
Randomization will be based on a randomly -generated sequence of participant identification 
(identifier) n umbers (randomization schedule) using a validated Interactive Voice/Web Response 
System (IXRS ). 
Before the study is initiated, the telephone number and call -in directions for the Interactive Voice 
response system and/or the log in information and instructi ons for the Interactive web response 
system will be provided to the study sites.  
The randomization schedule will be prepared by a statistician who will not be involved in the 
analysis of the study in order to maintain the blind of the study team.  
Randomiza tion for each participant will take place on Day 1.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   39 
CONFIDENTIAL    6.5.2.  Masking  
The study is double -blind: participants and all study personnel will be blinded to the 
randomization, with one exception: the first sentinel participant in each Dose Escalation Phase 
cohort will b e single -blinded (participant -blinded) and receive the respective dose of RSM01. 
Authorized study site personnel will administer doses.  
The unblinded investigational pharmacist will provide the prepared doses of RSM01 and Placebo 
to the clinic appropriatel y masked to the blinded treating nurse/physician.  
Only the following personnel will have access to the treatment allocation while the study remains 
blinded to other personnel:  
• Pharmacist preparing the RSM01 and Placebo doses  
• Biostatistician preparing the randomization list  
• Biostatistician preparing the IDMC data, as applicable, and for the interim analysis  
• Pharmacometrician preparing the PK data for IDMC (as applicable) and for the interim 
analysis  
• IDMC members, as applicable  
• Unblinded study Monitors.  
Addi tionally, the supplies manager/designate and quality assurance personnel of the sponsor, 
as well as  the IXRS system setup person and PK simulation and modeling vendor will have 
access to unblinding information.  
All unblinded persons must take care to not r eveal individual group assignments to any other 
member of the study team.  
Any study staff that become inadvertently unblinded must not participate in the evaluation of 
AEs. A delegation of authority log will be maintained by the site and will identify the 
individual(s) authorized to function as individuals with access to study blinding information.  
The interim analysis will be performed by an unblinded statistician. The investigator will be 
blinded during the entire study.  
Blinding will be maintained during  the aggregated PK data review to select the Dose Expansion 
Phase cohort dose and during interim analysis.  
The sponsor will review aggregated safety data by cohort only (data from both RSM01 and 
Placebo participants will be included) and will review aggreg ated PK data by treatment group 
(RSM01 vs. Placebo) within and across cohorts for the following purposes: 1) selecting dosing 
for the Dose Expansion Phase cohort, and 2) reviewing the interim analysis to inform a decision 
and plan for the infant study. Although the sponsor will be blinded throughout the study, such 
review of aggregated data could potentially lead to individual unblinding. An unblinding plan 
will be prepar ed to include unblinding details.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   40 
CONFIDENTIAL    6.5.3.  Blind Break  
The IXRS will be programmed with blind -breaking instructions. In addition, instructions on 
emergency unblinding in case of system outage will be provided. In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s treatment 
assignment is warranted. Participant safety must always be the first consideration in making such 
a determination. If the investigator decides that unblinding is warranted, the inves tigator should 
make every effort to contact the sponsor prior to unblinding a participant’s treatment assignment 
unless this could delay emergency treatment of the participant. If a participant’s treatment 
assignment is unblinded at any time during the stu dy, the sponsor must be notified within 24 
hours after breaking the blind. The date and reason that the blind was broken must be recorded in 
the source documentation and case report form (CRF), as applicable.  
6.6. Study Intervention Compliance  
Participant compl iance with study intervention will be recorded on his/her CRF.  
6.7. Concomitant Therapy  
Any prescription medication, anti -inflammatory drug, antipyretic drug, or vaccine that the 
participant receives from enrollment through study Day 151 must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and fr equency.  
The Medical Monitor should be contacted if th ere are any questions regarding concomitant or 
prior thera py. 
A COVID -19 vaccination ma y be received by a participant during the study but not within the 15 
days immediately following administration of the s tudy intervention.  
6.8. Dose Modification  
No unplanned dose modifications are allowed. This is a dose escalation and dose expansion 
study. Ref er to Section 3 for details regarding dose  escalation and dose expansion.  
7. Discontinuation of Study Interventio n and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention  
A participant withdrawn from the study intervention (i.e., any participant who does not receive 
the study intervention) will be withdrawn from the study.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   41 
CONFIDENTIAL    7.1.1.  Pausing Rules  
Pausi ng rules (reasons for pausing the study) are in effect during the active enrollment and 
dosing period. Any one of the following will prompt a study pause:  
• death in any participant in whom the event causing death is judged to be related to the study 
drug by  the investigator.  
• any occurrence in any participant of a SAE judged to be related by the investigator.  
• any occurrence in any participant of an AESI (anaphylaxis, hypersensitivity reaction, a nd/or 
infusion reaction resulting in permanent discontinuation of  study drug infusion during IV 
administration).  
• any occurrence of Grade 3 or higher toxicity assessed to be related to the study drug by  the 
investigator.  
• any occurrence of a clinically significant Grade 3 or higher laboratory abnormality assess ed 
to be related to the study drug by the investigator.  
If any of the pausing criteria are met, enrollment/patient accrual as well as dosing of enrolle d 
participants will be suspended pending IDMC’s review of all available safety data and the U .S. 
FDA will be notif ied in an expedited manner.  
Refer to Section 8.2.6  for the role of SRT and Section 8.2.7  for the role of the IDMC.  
If the investigator and/or the SRT observes that a pausing rule is met, the investigator will infor m 
the sponsor and/or the SRT as soon as possible and within 24 hours of the observation. The  SRT 
and/or sponsor will notify the investigator and the IDMC members of the pause in enrollment 
and participant dosing as soon as possible and within 24 hours of receiving notification of the 
pausing rule being met.  
When a pausing rule is met, the IDMC members will convene an urg ent ad hoc review mee ting, 
review all relevant unblinded safety data, and make a recommendation to the sponsor. The FDA 
will be advised of the IDMC actions and recommendations.  
The IDMC may recommend continuation of the study pause or resumption of enrollm ent and 
dosing with or without changes to the protocol. The final decision to pause or resume study  
activities will always be the responsibility of the sponsor. All IDMC recommendations will be 
stored according to the IDMC Charter.  
All sponsor decisions wi ll be documented in a memorandum to the study file. The sponsor or 
delegate is responsible for prompt communication to the study site of decisions related to 
pausing or resuming the study activities, including notification to the investigator, relevant 
IRBs/IECs and regulatory authorities.  
The clinical site will be allowed to resume activities only upon receipt of written notification 
from the sponsor.  
7.2. Participant Discontinuation or Withdrawal from the Study  
A participant may request withdrawal from the stu dy at any time. A participant may also be 
withdrawn from the study at any time for the following reasons:  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   42 
CONFIDENTIAL    a. at the request of the primary care provider if being in the study is no longer in the best 
interest of the participant  
b. participant is judged by the in vestigator to be at significant risk of failing to comply with 
the provisions of the protocol as to cause harm to self or seriously interfere with the validity 
of the study results  
c. at the discretion of the IRB/IEC or government agencies as part of their du ties, investigator, 
or sponsor.  
If possible, a discontinuation visit should be scheduled for any participant who wishes to 
discontinue or withdraw from the study. At this visit, topics around participant safety as well as 
the use of already collected biosp ecimens will be discussed, and the procedures and specimen 
collection indicated in the SoA ( Table 2 and Table 3) will be performed if possible and as 
needed.  
The time and reason for withdrawal should be noted in the space provided for this purpose in the 
CRF. Possible reasons responsible for withdrawal include:  
• no receipt of study intervention  
• SAE  
• non-serious AE  
• protocol violation (specify)  
• consent withdrawal not due to an AE*  
• move from study area  
• other (specify).  
*If a participant withdraws consent, the reason, if specified, will be documented in the CR F. 
Participants who are withdrawn because of occurrence of AE should be clearly distinguished 
from participants who are withdrawn for other reasons. Participants who are withdrawn because 
of an AE will be followed until the event resolves or stabilizes.  
Refer to Appendix 1, Section 10.1.4  regarding the informed consent process.  
All data collected until the date of withdrawal/last contact of the parti cipant will be used for the 
analysis, unless the participant requests destruction of any samples taken and not tested. The 
investigator must document this in the site study records and the CRF. If the participant 
withdraws consent for disclosure of future information the sponsor may retain and continue to 
use any data collected before such withdrawal of consent.  
If the participant leaves the study, the participant’s medical information will still be used or 
shared to the extent allowed by law. Any leftover samples will be destroyed after testing is 
completed unless the participant withdraws consent to sample use, in which case the samples 
will be destroyed at that time. Any test results from the samples collected before withdrawal 
can still be included in th e analyses.  
A participant who becomes pregnant during the study period will be asked to complete all visits 
and procedures through Day 151 as described in Table 2 or Table 3, as applicable. After she 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   43 
CONFIDENTIAL    comple tes Day 151, or in the event that she voluntarily withdraws from the study and agrees to 
provide  additional information regardin g the pregnancy, the investigator will utilize the 
‘Pregnancy Outcome Form’ during the remaining gestation period to collect information on the 
health of the participant, the outcome of the pregnancy, and the health of the neonate. Neonate 
follow -up will o ccur for 6 weeks beyond the estimated delivery date (refer to Section 10.3). 
7.3.  Lost to Follow -up 
A participant will be considered lost to follow -up if he or she repe atedly fails to return for 
scheduled visits (3 failed visits) and is unable to be contacted by the study site (3 failed attempts 
per fail ed visit).  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visi t: 
• The site must attempt to contact the participant and reschedule the missed visit as soon as 
possible and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or s hould continue in the 
study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact with the participant (where possible, telephone calls and, if 
necessary, a home visit by a member of the st udy team). These contact attempts should be 
documented in the participant’s medical record and the CRF.  
• Should the participant continue to be unreachable, he/she will be considered lost to follow -
up from the study.  
7.4. COVID -19 Contingency Plans  
In the e vent t hat SARS -CoV -2 coronavirus disease (COVID -19) affects the conduct of this trial, 
the sponsor will evaluate if in -person visits are necessary to fully ensure the safety of trial 
participants and whether alternative methods for safety assessments (e.g., phon e contact, virtual 
visit, alternative location for assessment such as local laboratories or home visits) could be 
implemented when necessary and feasible, and would be sufficient to ensure data integrity and 
safety of participants [ FDA , 2020].  
Any contingency plans must be sufficient to ensure the safety of trial participants. Changes in 
study visit schedules, missed visits, or withdrawal of the study intervention or participant  
discontinuations may lead to missing information (e.g., for protocol -specified procedures) must 
be captured in the CRF that explains the basis of the missing data (i.e., COVID -19). 
Approa ches to be used to protect trial participants and manage study condu ct during possible 
disruption of the study as a result of COVID -19 control measures at the study site must be 
documented. Depending upon the nature of the changes described above, a protocol amendment 
may be  required under the applicable regulations.  
Devia tions because of COVID -19 will be described in the clinical study report or in a separate 
study -specific document) including but not limited to the following:  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   44 
CONFIDENTIAL    • Contingency measures implemented to manage study conduct during disruption of the study 
as a result of COVID -19 control measures.  
• A listing of all participants affected by the COVID -19 related study disruption by unique 
participant number identifier and by investigational site, and a description of how the 
individual’s participation was altered.  
• Analyses and corresponding discussions that address the impact of implemented 
contingency measures (e.g., trial participant discontinuation from investigational product 
and/or study, alternative procedures used to collect critical safety and/or efficacy dat a) on 
the results reported for the study.  
8. Study Assessments and Procedures  
Study procedures and their timing are summarized in the SoA. Adherence to the study protocol, 
including those specified in the SoA, is essential and required for study conduct.  
Prior to any study procedure, all eligible participants will be assigned a unique participant 
identifier. This participant identifier will be used throughout the study for participant 
identification.  
Screening for eligibility assessment will occur after in formed consent is obtained. Eligibility for 
randomization will be based on the inclusion and exclusion criteria described in Section 5.1 and 
Section  5.2, respectively.  
Eligibility criteria will be checked during the screening process and prior to RSM01 or Placebo 
administration to ensure that all participants en rolled meet all of the inclusion criteria and none 
of the exclusion criteria. The investigator will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record the reasons for screening failure, as 
applicabl e. 
To evaluate eligibility criteria, a medical history and physical examination including vital signs 
will be performed.  
In addition, safety laboratory tests (hematology, chemistry, and urinalysis), HIV, hepatitis B and C 
screening, urine drug test, 12 -lead ECG, and serum pregnancy test (females only) will be performed.  
The investigator must document confirmation of eligibility prior to randomization.  
8.1. Safety Assessments  
The screening visit will take place between 30 days and 2 days before the planned Day 1 visit.  
All participants will also be required to attend the Day -1 (Pre -V1) visit within 24 hours before 
planned dosing to begin confinement.  
A negative serum pregnancy test (based on the serum sample collected on Day -1) must be 
confirmed prior to study i ntervention administration on Day 1.  
All Day 1 safety assessments and sample collections are prior to administration of study intervention.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   45 
CONFIDENTIAL    Prior to opening Cohorts 2 and 3 together, Cohort 4, and Cohort 5, respectively, to enrollment, 
the SRT will conduct  safety assessment of data for the previous cohort/s collected when all 
participants in the currently dosed cohort have completed Day 15.  
During each IV infusion, any infusion reactions will be recorded.  
Planned time points for all safety assessments are p rovided in the SoA.  
8.1.1.  Confinement Period and Sentinel Participants  
Details regarding confinement period are provided in the study manual.  
Dose Escalation Phase  
Participants in the Dose Escalation Phase will be confined at the study site from Day -1 to after 
completion of Day 3 assessment (a total of 3 nights).  
On Day -1, participants will undergo safety laboratory assessments and other screening 
procedures (refer  to the SoA, Table 2). 
The first participant in each of the Dose Escalation Phase cohorts will be a sentinel participant 
and will receive RSM01 at the respective dose of  RSM01 in a participant -blind fashion.  
The next participant in each cohort can be dosed at least 24 hours later, if there is no safety 
concern.  
Dose Expansion Phase  
For the Expansion Phase, participants will be asked to present to the clinic within 24 hour s of the  
Day 1 visit. On this Day -1 visit, participants will begin confinement, and undergo safety 
laboratory assessments and other screening procedures (refer to the SoA, Table 3). 
On Day 1 after dosing, participants will be observed for at least 4 hours post -dose at the study 
site for safety monitoring, and based on investigator’s decision, a participant may be asked to 
remain for an additional overnight stay on the ni ght of Day 1.  
8.1.2.  Full Physical Examination and Medical History  
A full physical examination and medical history will be conducted at screening to assess 
enrollment eligibility. Only participants that are considered as healthy by the investigator will be 
enroll ed. 
All conditions that exist prior to administration of study intervention will be recorded in the 
medical history. Day -to-day fluctuations in these conditions that do not represent a clinically 
significant change in the participant’s status will not nece ssarily be reported as AEs.  
Physical examination at screening will include, at a minimum, assessment of height and weight, 
body temperature, and resting vital signs (including percent oxygen saturation by pulse 
oximetry), in addition to assessments needed to determine eligibility. Assessments will include 
general appearance and specific organ systems (head, eyes, ears, nose, throat/mouth, neck 
(HEENT), respiratory, cardiovascular, gastrointestinal, and neurological systems, psychiatric, 
skin, and lymphatics ). 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   46 
CONFIDENTIAL    8.1.2.1.  Vital Signs  
Vital signs will be taken at screening and on Day 1, prior to RSM01/Placebo administration.  
Vital sign measurements will be recorded for pulse rate, systolic and diastolic blood pressure, 
respiratory rate, body temperature and percent oxygen saturation by fingertip pulse oximetry. 
Vital signs are to be taken after the participant is seated for at le ast 5 minutes in a quiet setting 
without distractions. Measurements are to be repeated if clinically significant changes are 
observed or a machine error occurs.  
Vital signs for the Dose Escalation Phase:  
• On Day 1 vital signs will be taken pre -dose, and 1 h our, 4 hours and 8 hours after the IM 
dose and at pre -dose, 15, 30 and 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, and 8 hour s 
after the IV dose. The window for these measurements is ± 3 minutes.  
• On Day 2, vital signs will be taken at 24 hours post -dose. The window for these 
measurements is ± 0.5 hours.  
• On Day 3 Visit vital signs will be taken at 48 hours after dosing. The window for these 
measurements is ± 1.0 hours.  
Vital signs for the Dose Expansion Phase:  
 
On Day 1, vital signs will be taken pre -dose and 4 hours post -dose. The window for these measur ements is 
± 3 minutes. If the participant stays overnight on Day 1, vital signs will be taken at 24 hours afte r dosing. 
The window for these measurements is ± 0.5 hours.  
8.1.3.  Focused Physical Examination and Medications/Vaccinations  
Focused physical examinations, will be performed on Day 1 and all subsequent visits, as 
indicated in the SoA ( Table 2 and Table 3). 
A focused physical examination will be performed if indicated by participant’s medical 
complaint and will include assessments of body systems involved in the complaint. Focused 
physical examinations will be symptom directed.  
Throughout the study, any concomitant medications taken, including antipyretics, anti -
inflammatories, and vaccinations will be recorded (refer to Section 6.7). 
8.1.4.  Pregnancy Status Assessment  
A blood sample will be collected from female participants at screening and at Day -1 for serum 
beta human chorionic gonadotropin (βHCG) testing.  
Serum βHCG testing of female participants should be performed during the study if a pregnanc y 
is suspected.  
Serum βHCG testing of female participants of childbearing potential should be performed at the  
discontinuation visit.  
During the study, participants will be asked about pregnancy during each  visit. If a pregnancy is 
reported, the investigator should inform the Medical Monitor within 24 hours of learning of the  
pregnancy and should follow the procedures outlined in Appendix 3, Section 10.3. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   47 
CONFIDENTIAL    A participant who becomes pregnant during the study period will be asked to complete all visits 
and procedures through Day 151 as described in Table 2 or Table 3, as applicable. After she 
completes Da y 151, or in the event that she voluntarily withdraws from the study and agrees to 
provide additional information regarding the pregnancy, the investigator will utilize the 
‘Pregnancy Outcome Form’ during the remaining gestation period to collect informati on on the 
health of the participant, the outcome of the pregnancy, and the health of the neonate. Neonate 
follow -up will occur for 6 weeks beyond the estimated delivery date (refer to Section 10.3). 
8.1.5.  HIV Antibody Assessment  
To be eligible for the study, participants must not have reactive anti -HIV antibody at screening. 
A blood sample will be collected to make this assessment.  
8.1.6.  Electrocardiogram, Hepatitis Screening an d Urine Drug Screening  
A 12 -lead ECG will be performed at screening using a machine that automatically calculates 
heart rate and determines intervals for PR, QRS, QT and QTc. Triplicate (unmarked) 12 -lead 
ECGs will be obtained. For the Dose Escalation Phas e, the ECGs will be taken at screening, and 
24 hours post -dose, on Day 2. For the Dose Expansion Phase, the ECGs will be taken at 
screening.  
All 12 -lead ECGs will be obtained after the participant has rested in a supine position for at least 
10 minutes. Al l Triplicate ECGs will be taken approximately one minute apart. Measurements 
that deviate substantially from previous readings will be repeated immediately.  
At the screening visit, a blood sample will be collected to test for the presence of hepatitis B 
surface antigen (HBsAg) and hepatitis C virus antibodies.  
A urine sample will be collected at screening and at Day -1 to screen for evidence of drugs of 
abuse.  
8.1.7.  Clinical Safety Laboratory Assessments  
Clinical safety laboratory assessments will be performed at  screening, on Day -1 (Pre -V1), and 
throughout the study at timepoints specified in the SoA (Section 1.3). 
Blood samples for laboratory assessments will be collected  at screening, and at study visits 
indicated in the SoA.  
Laboratory values from the most recent blood sample collected prior to randomization that are 
outside the normal range that are suggestive of a disease state (i.e., clinically significant Grade 1 
abnormalities or values greater than Grade 1 [refer to Section 10.4]) will lead to exclusion from 
study enrollment, with the exception of any grade hematuria in a menstruating female, or a 
urinalysis abnormality judged not clinically significant by the investi gator.  
Refer to Section 10.4 for toxicity table for grading for each clinical laboratory test.  
Clinical safety laboratory parameters that will be evaluated include:  
a. Hematology: Complete blood count (including hemoglobin, platelet count and white blood 
cell count) and absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   48 
CONFIDENTIAL    b. Serum chemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST ), 
alkaline phosphatase, total bilirubin, gamma glutamyl transferase (GGT), creatinine, blood 
urea nitrogen, lactate dehydrogenase (LDH), glucose, albumin, sodium, potassium, 
chloride, bicarbonate, and calcium.  
c. Urinalysis: Specific gravity, pH, glucose, pr otein, blood, ketones, bilirubin, urobilinogen, 
nitrite, leukocyte esterase by dipstick.  
Abnormal results and findings that make the participant ineligible for study participation will be 
discussed with the participant and the participant will be referred for follow -up care with their 
health care provider if necessary.  
All screening laboratory specimens will be processed according to laboratory SOPs available 
from the clinical laboratory(ies) designated for the study.  
All protocol -required safety laboratory  tests will be performed by the site local laboratory or at 
the point of care. Laboratory safety testing performed at point of care will be documented in 
participant source and captured in the electronic data capture (EDC) database.  
Information about the l aboratory(ies), including any instructions for performing and interpreting 
specific tests, will be maintained in the investigator’s study files.  
The investigator must review the laboratory report, document the review, and record any 
clinically relevant cha nges occurring during the study in the AE section of the CRF. The 
laboratory reports must be filed with the source documents.  
All protocol -required laboratory assessments must be conducted in accordance with the 
Laboratory Manual and the SoA.  
If laboratory values from non -protocol -specified laboratory assessments require a change in 
participant management or are considered clinically significant by the investigator (e.g., AE or 
SAE), then the results must be recorded in the CRF.  
Additional test s may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations.  
8.1.8.  Pre- and Post -Study Intervention Safety Monitoring  
Participants will remain under observation at the study site for 3 days in the Dose Escalation 
Phase cohorts (24 hours before dosing and 48 hours after dosing). Participants in the Dose 
Expansion Phase cohort will present to the study site before the planned Day 1 visit. After 
treatment on Day1, the participant will be observed for 4  hours at the study site and may remain 
overnight based on investigator’s decision.  
Allergic reactions to RSM01 are possible, therefore, appropriate drugs and medical equipment to 
treat acute anaphylactic reactions must be immediately available and a physi cian trained to 
recognize and treat anaphylaxis must be present in the clinic during study intervention 
administration and the post -dosing monitoring period.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   49 
CONFIDENTIAL    8.1.9.  Diary Card, Memory Aid and Daily Monitoring  
Diary card  
Before leaving the clinic after dosing and completion of the post -dosing on -site confinement, 
participants will be given a diary card and receive guidance on how to fill in the card. All 
participants will receive a digital thermometer to r ecord temperature. Participants who receive an 
IM dose will also receive a ruler to measure diame ter of redness and/or swelling at the injection 
site, if present.  
The diary card will be used by the study participants t o record the duration, and intensity (refer to 
Section 8.2.3.1 ) of solicited injection site AEs (for  participants who receive an IM dose) and 
solicited systemic AEs up to Day 7 following injec tion or infusion for all participants. This 
information should be recorded in the participant diary card at approximately the same time each 
evening, through Day 7 (refer to Section 8.2 for m ore information).  
The diary card will be collected and reviewed by t he investigator (or designee) on the Day 8 
Visit for both the Dose Escalation Phase and the Dose  Expansion Phase participants.  
No changes to the diary card will be permitted; ho wever, any verbally recalled information 
provided by the participant during review of the di ary card will be documented in the source 
document and reported as an AE as applicable.  
Memory aid  
A memory aid will be utilized by participants to collect unsolicited AEs beginning at discharge 
from the clinic, through Day 151 (end of study participation for an individual). Participant s will 
be instructed to record unsolicited AEs whenever they occur, recording such AEs on the memory 
aid. The memory aids will be collected and reviewed by site staff at each subsequent visit 
through the end of the study.  
8.1.10.  Participant Follow -Up 
Participants  will be instructed to contact a study team member to report new or worsening AEs, 
as well as new diagnoses, and to come to the study clinic if medical attention is needed.  
For emergencies and other unscheduled visits to a medical facility other than the s tudy clinic, 
medical records will, to the extent possible, be obtained by the investigator.  
Participants will be asked about the occurrence of AEs, SAEs, AESIs, receipt of concomitant 
prescription medications/vaccinations, and change in general health stat us and any other change 
in status that may affect the participant’s participation, as indicated in the SoA.  
Any deviation from protocol procedures, evaluations, and/or visits will be documented.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   50 
CONFIDENTIAL    8.2. Adverse Events and Serious Adverse Events  
Local injection sit e solicited AEs  will include pain, r edness and swelling, and  will be assessed 
after dosing at Visit 1 for 7 days (IM recipients only). If more than 1 injection is given, reactions 
will be assessed separately at each injection site.  
Systemic solicited AEs w ill be assessed in all participants after dosing at Visit 1 and recorded for 
7 days. These will include fever, headache, fatigue, muscle aches, nausea, vomiting, diarrhea, 
and joint pain.  
Site staff will document any AEs in the study source during the conf inement for all cohorts. The 
site staff will record solicited injection site AEs (IM doses only) and solicited systemic AEs (all 
participants), including duration and intensity, during confinement. Refer to Section 8.1.9  for 
solicited AEs to be recorded in the diary card by participants, through Day 7.  
Solicited AEs that continue beyond Day 7 will be captured in the unsolicited AEs memory aid 
and marked as continuatio n of solicited AE. Participants will be asked to record events at the 
same time each evening.  
Unsolicited AEs including AESIs, SAEs, and safety laboratory parameters Grade 1 and above 
will be collected from screening through Day 151 and recorded in the AE log by the study team.  
The definitions of AEs, SAEs, serious adverse drug reactions (ADRs) and AESIs can be found in 
Appendix 2, Section 10.2.1 , and 10.2.2 , 10.2.3 , 10.2.4 , respectively.  
Refer to Appendix 2, Section 10.2 for details regarding AEs, AESIs, and SAEs and Section 10.4 
(Table 9) for laboratory parameters.  
Immediate safety concerns should be discussed with the sponsor, and the SRT. The SRT will 
trigger an IDMC review if any pausing rule is met (see Section 8.2.7  for IDMC and Section 
10.2.5  for details regarding AE reporting and follow -up). 
AEs will be reported by the participant (or, as appropriate, the participant's legally authorized 
representative). Clinical chemistry and/or hematology results may also qualify as AEs (Section 
10.4, Appendix 4).  
Study nurses and physicians are responsible for collecting and documenting information and 
events that would potentially meet the definition of an AE. However only the investigator or sub -
investigator is responsible for assessment, including assignment of causality and, for unsolicited 
AEs, the inte nsity, and for reporting and management of all AEs. The investigator is responsible 
for following up all AEs regardless of their relatedness to study intervention or study procedures, 
or AEs that caused the participant to withdraw from the study (Section 7). 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   51 
CONFIDENTIAL    8.2.1.  Time Period and Frequency for Collecting AE and SAE Information  
Type of Event  Collection Time Period  
All solicited AEs  Day 1 through Day 7 (inc lusive)  
Unsolicited AEs, and SAEs including AESIs  Screening through end of study (Day 151)  
Distribution and collection days for diary cards and memory aids are shown in the SoA.  
Medical conditions that begin before the start of study intervention but af ter obtaining informed 
consent will be recorded on the Medical History/Current Medical Conditions section of the CR F, 
not in the AE section.  
All SAEs and AESIs will be reported to the sponsor or designee within 24 hours, as indicated in 
Appendix 2, Section  10.2.6 . The investigator will submit any updated SAE and AESI data to the 
sponsor or designees within 24  hours of it being available.  
Investigators are not obligated to actively seek AEs, SAEs or AESIs after a participant conclud es 
study participation. However, if the investigator learns of any SAE, including a death, at any  
time after a participant has been discharged from the study, an d he/she considers the event to be  
related to the study intervention or study participation, the investigator must notify the sponsor  or 
designee within 24 hours.  
8.2.2.  Method of Detecting AEs and SAEs  
The methods of recording and follow -up of AEs, SAEs and AESI s are provided in detail in 
Appendix 2, Section 10.2.5, which includes assessments of intensity, relationship to the stud y 
intervention, and outcome  of AEs, SAE and AESIs.  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading questions are the preferred method to inquire about AE  occurrences.  
8.2.3.  Follow -up of AEs  
After the initial SAE/AESI report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs/AESIs will be followed until resolution, 
stabilization, or the participant is withdrawn/withdraws, or is lost to follow -up or (as defined in 
Section 7.2 and Section 7.3, respectively). Refer to Appendix 2, Se ction 10.2.5.4 . 
8.2.3.1.  AE Intensity  
The intensity of AEs will be classified by the investigator based on the toxicity grading tables 
(Section 10.4 Appendix 4).  In the case of an AE or abnormal clinical laboratory result not 
included in Appendix 4, intensity will be assigned using the Grades described in the U.S. 
Departm ent of Health and Human Services, Common Terminology Criteria for Adverse Eve nts, 
Version 5.0 [ US HHS  2017]  (See Section 10.2.5.1 ). 
Local solicited AEs will be recorded on the diary card by the participant and graded and/or 
measured by the participant. An exception is that the study investigators will grade solicited AEs 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   52 
CONFIDENTIAL    during the confinement period. Any participant -reported Grade 3 or higher adverse event will be 
assessed by the investigator.  
8.2.3.2.  AE Causality/Relationship to Study Intervention  
All AEs will be evaluated  by the investigator or medically qualified designee (i.e., investigator, 
sub-investigator) to assess the relationship between study intervention and the AE (with the 
exception of local injection site reactions, which are assumed to be related to the injec tion).  
Careful medical judgment should be exercised to determine the level of causal relationship 
between an AE and the study intervention. The causality will be assessed as either related or not 
related.  
The sponsor or designee will have the opportunity t o confirm the seriousness and c ase causality 
based on the clinical judgment of the Medical Monitor or sponsor designee. If a serious adverse 
event is considered unrelated by the investigator but the sponsor believes th at there is a 
reasonable possibility t hat the event is related, the sponsor will upgrade the case to a ‘related’ 
status. The sponsor or designee will never downgrade a case from serious to non -serious or 
change the investigator assessment of causality from related to not related.  
Refer to Appe ndix 2, Section 10.2.5.2  for details.  
8.2.4.  Regulatory Reporting Requirements for SAEs  
Refer to Appendix 2, Section 10.2.6  for details regarding SAE reporting.  
The sponsor or delegate has a legal responsibility to notify both the local re gulatory authority 
and potentially other regulatory agencies abo ut the safety of the study interve ntion under clinical 
investigation. Therefore, prompt notification by the investigator to the sponsor of  a SAE is 
required.  
The sponsor will comply with country -specific regulatory requirements rela ting to safety 
reporting  to the regulatory authority, IRBs/IECs, and investigators.  
In the U.S., t he sponsor assumes responsibility for appropriate reporting of AEs to the regulatory 
authorities. The sponsor will also report to the investigator all SAEs includi ng SAEs associated 
with the use of the study intervention. The investigator must report these eve nts to the 
appropriate I RB that approved the protocol, unless otherwise required and doc umented by the 
IRB.  
AEs reportin g, including suspected unexpected serious adverse reaction s, will  be carried out in 
accordance with applicable local regulations.  
The sponsor will prepare, distribute, and submit Serious ADR reports accor ding to local 
regulatory re quirements of participating countries.  
Refer to Appendix 2, Section 10.2.6  for details regarding SAE reporting.  
8.2.5.  Death Events  
Any untoward medical occurrence (AE) resulting in death is reported as an SAE. The cause of 
death will be  appropriately documented in the SAE report form and supporti ng evidence will be 
provided.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   53 
CONFIDENTIAL    8.2.6.  Safety Review Team  
A SRT will be established as the team responsible for recommending dose escalation or dose 
expansion to the sponsor’s Chief Medical Officer. The S RT will operate according to the Safety 
Review Team Plan.  
Meetings of the SRT to provide a recommendation on dose escalation or dose expansion will 
occur during the Dose Escalation Phase when all participants in the current ly dosed cohort have 
completed Da y 15. The SRT will also meet approximately every 8 weeks during the Dose 
Expansion Phase. The SRT will review all available blinded safety data collected at the time of 
the review to determine whether or not any pausing event has occurred (See Section 7.1. 1.). If a 
pausing event does not occur, dose escalation or moving to the Dose Expansion Phase cohort 
will be recommended by the SRT.  
If a pausing rule is met, the SRT will ask the IDMC to conduct a review of unblinded safety data. 
The IDMC will make a reco mmendation to the sponsor regarding the further conduct of the 
study.  
8.2.7.  Independent Data Monitoring Committee  
The IDMC will operate according to a charter approved by the sponsor and all IDMC members. 
The IDMC structure, participants and other details will b e provided in the charter. The charter 
will be approved prior to enrollment of the first study participant.  
The role of the IDMC will be to (a) review unblinded safety data if a pausing rule is met  and (b) 
make recommendations to the sponsor on further conduct of the study if a pausing rule is met.  
The recommendations of the IDMC, along with the sponsor’s decision, will be communicated to 
the investigator, to the responsible IRBs/IECs and to the US FDA.  
8.3. Treatment of Overdose  
Overdose of any study interve ntion (including Placebo) is unlikely to occur since the injections 
and infusions are administered as a single dose by a trained study staff member. If an overdose 
were to occur, the overdose, including misuse or abuse of the product and medica tion errors,  
should be reported in in the clinician notes a nd the eCRF. If an overdose error occ urs, the 
participant will be monitored for symptoms and provided with necessary supporti ve care.  
8.4. Blood Sampling  
Refer to the SoA for blood sample collection at screening fo r eligibility and safety  laboratory 
assessments. Blood samples will be collected for pregnancy test, HIV, hepatitis B , hepatitis C 
and safety laboratory assessments as describ ed in Section 8.1.7 . 
Whole blood samples will be collected for measurement of PK, ADA, and RSV ne utralizing 
antibodies.  At Visit 1, all samples will be collected prior to dosing.  
A total of approximately 200mL of whole blood will be collected fro m each partic ipant during 
the entire study period assuming all planned samples are collected, according to t he SoA.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   54 
CONFIDENTIAL    8.5. Pharmacokinetics  
Dose Escalation Phase: At Visit 1, PK blood draw will occur at pre -dosing, 1 hour (+/- 30 
minutes) before administration of  IM injection or beginning of infusion,  for all participants in 
Cohorts 1 -4. For participants who receive IV study intervention, the timing of post -dose blood 
samples begins at the end of the IV infusion. Samples are obtained at 5 minutes (± 1 minute) at 
8-hours ( ± 0.5 hour) and at 24 -hours ( ± 1 hour) after the end of the infusion. For participants who 
receive IM study intervention, the timing of post -dose blood samples begins at the time of the IM 
injection and samples are obtained at 8 -hours ( ± 0.5 hour) and at 24 -hours ( ± 1 hour) after the IM 
injection.  
Dose Expansion Phase: At Visit 1, only a pre -dose sample, collected 1 hour (+/ - 30 minutes) 
before administration of IM injection is obtained at Day 1.  
Blood for PK samples at all visits after Day 1 will be obtained according to the SoA as shown in 
Table 2 and Table 3.  
 
For all samples, the actual date and time (24 -hour clock) of each sample will be recorded to 
calculate actual time elapsed since the prior dose administration.  
Whole blood samples in serum separator tubes and VAMS will be collected for measurement of 
RSM01 concentrations in serum and capillary blood, respectively, as specified in the SoA. The 
quantification of RSM01 in serum and capillary blood will be performed using a validated 
immunoassay  method. Concentrations will be used to evaluate the PK of RSM01. The PK 
parameters specified in the endpoints will be calculated.  
Remaining samples collected for analyses of RSM01 may also be used to evaluate 
immunogenicity and/or safety aspects related t o any concerns arising during or after the study. 
Details on processes for collection and shipment of these samples are in the Laboratory Manual. 
Retention time and possible analyses of samples after the end of the study are specified in the 
ICF. 
8.6. Pharmacod ynamics  
For this study, pharmacodynamics is being assessed as an exploratory endpoint. A surrogate 
pharmacodynamic marker will be used, measuring the ex vivo capability of RSM01 to neutralize 
RSV.  
Whole blood samples in serum separator tubes and VAMS devic es will be collected for detection 
of RSV neutralizing antibodies in serum and capillary blood respectively, as specified in the 
SoA. Samples on Day 1 will be collected prior to RSM01 administration.  
The quantification of RSV neutralizing antibodies in ser um and capillary blood will be 
performed using a validated viral neutralization method. This method will detect both RSM01 
and neutralizing anti -RSV antibodies from prior natural infection. Therefore, the Day 1 sample is 
needed to evaluate changes in neutr alization responses, post -treatment.  
Remaining samples collected for analyses of RSV neutralization may also be used to evaluate 
drug concentration, immunogenicity, and safety aspects related to concerns arising during or 
after the study. Details on proces ses for collection and shipment of these samples are in the 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   55 
CONFIDENTIAL    Laboratory Manual. Retention time and possible analyses of samples after the end of the study 
are specified in the ICF.  
8.7. Genetics  
No genetic testing will be performed for this trial.  
8.8. Biomarkers  
There are no prospective biomarker analyses planned.  
As dictated by clinical data and emerging science, the non -genetic biomarkers may be added 
during trial execution. These will be clearly documented in the clinical study report (CSR) and/or 
the trial master  file (TMF).  
Clinical safety laboratory assessments such as hematology may also be included as exploratory 
biomarkers in pre -specified analysis plans.  
8.9. Immunogenicity  
Whole blood samples in serum separator tubes and VAMS samples will be collected for 
detect ion of ADA against RSM01 in serum and capillary blood respectively, as specified in the 
SoA. Samples on Day 1 will be collected prior to RSM01 administration.  
The detection of ADA to RSM01 will be performed using a validated immunoassay method with 
tiered testing of screening, confirmatory, and titration. Confirmed positive ADAs may be further 
characterized.  
Remaining samples collected for analysis of anti -RSM01 antibodies may also be used to evaluate 
RSM01 concentration or exploratory biomarkers during or after the study. Details on processes 
for collection and shipment of these samples are in the Laboratory Manual. Retention time and 
possible analyses of samples after the end of the study are specified in the ICF.  
9. Statistical Considerations  
9.1. Sample Size Det ermination  
This trial is an exploratory trial to characterize safety, tolerability, and pharmacokinetics of 
single doses of RSM01 mAb. The trial is designed to be descriptive and is not based on formal 
testing of a null hypothesis. Therefore, this study is  not powered to detect any differences in 
potential safety data between treatment groups. Approximately 56 participants will be available 
for analysis: 28 participants in the Dose Escalation Phase and 28 participants in the Dose 
Expansion Phase.  
Assuming t hat all cohorts are allowed to undergo treatment, approximately 48 participants will 
be exposed to RSM01, and approximately 8 participants will receive Placebo.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   56 
CONFIDENTIAL    Safety  
With 6 participants (per RSM01 arm in each Dose Escalation Phase cohorts), there is 
approximately 80% (90%) power to observe at least one AE if the true AE rate is 23.53% 
(31.87%).  
With 24 participants (across all doses of RSM01 in the Dose Escalation Phase cohorts or the 
Dose Expansion Phase cohort), there is approximately 80% (90%) power to  observe at least one 
AE if the true AE rate is 6.49% (9.15%).  
Across all doses of RSM01 (48 participants), there is approximately 80% ( 90%) power to 
observe at least one AE if the true AE rate is 3.3% (4.68%).  
9.2. Populations for Analyses  
Analysis populations  are shown in Table 6. 
Table 6: Populations for Analyses  
Population  Description  
Intention to treat (ITT) PK 
population  All participants who received the study int ervention. Participants 
will be analyzed according to the interventi on actually received.  
Per protocol (PP) PK 
population  All participants who received RSM01 and did not  significantly 
deviate from study procedures, and who h ave at le ast one, non -
zero PK result available. Participants will be a nalyzed according 
to the intervention actually received.  
Safety  All participants who received the study int ervention. Participants 
will be analyzed according to the interventi on actually receive d. 
Immunogenicity 
population  All participants who received the study int ervention and have at 
least one valid ADA result. Participants wil l be analyzed 
according to the intervention actually rece ived.  
9.3. Statistical Analyses  
A detailed statistical analysis plan (SAP) centered on primary and seconda ry endpoints will be 
developed and finalized prior to unblinding the study and will further des cribe the participant 
populations to be included in each analysis, details of the stati stical methods , including 
procedures for accounting for missing, unused, and spurious data. Some e xploratory analyses, 
not associated with exploratory endpoint analyses, may be included in this S AP. Analyses are 
summarized in Table 7. 
Exploratory endpoint analyses, in particular, those centered on exploratory biomarker analyses, 
and details for PD and serum PK/ADA analyses, will be described in a separate  exploratory 
scientific and statistical analysis plan (exploratory SSAP). Specific objectives and hypotheses 
related to exploratory biomarker analyses will be documented in this exploratory SSAP prior to 
full data unblinding and analysis.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   57 
CONFIDENTIAL    Results from the exploratory analyses may be reported in a separate results memo and included 
as an addendum to the CSR.  
Table 7: Summary of Primary and Secondary Endpoints and Analyses  
Endpoint  Statistical Analysis  
Primary:  
Unsolicited AEs through  
Day 151  
All SAEs/AESIs through 
Day 151  
Solicited systemic AEs 
through Day 7  
Solicited local AEs for 
injection site reactions for 7 
days after dose 
administration (only applies 
to IM doses)  The incidence and Clopper -Pearson 95% CIs of AEs and 
SAEs/AESIs wi ll be summarized by treatment group, dose 
levels, routes of administration and overall, and by intensity. 
Duration, day of onset of local and systemic solicited AEs will 
be summarized by group. Relationship of unsolicited AEs and 
SAEs/AESIs to the study in tervention will be summarized by 
group.  
Any infusion reactions will be described.  
Secondary:  
Safety laboratory 
parameters Grade 1 and 
above through Day 151  The incidence of safety parameters outside of normal ranges 
(Grade 1 and above), change from basel ine, grades, grade shifts, 
as applicable, will be summarized by treatment group, dose 
levels, routes of administration and overall, and by intensity, 
and relationship to the study intervention.  
PK parameters  
AUC0 -∞, CD 91, AUC 0-D91, 
CD 151, AUC 0-D151 Cmax, 
Cmin, Tmax, t1/2, CL and 
Vz  RSM01 capillary blood concentrations and PK parameters will 
be summarized by treatment group using descriptive statistics, 
and the number of participants. Following summaries will be 
provided arithmetic mean, standard dev iation, arithmetic 
percent CV, median, minimum, maximum, geometric mean, 
and geometric percent CV.  
 The proportion of participants with observed or predicted 
CD 151 concentrations above the EC90 will be summarized by 
treatment group and country, as appropri ate. 
Incidence of ADAs to 
RSM01 through Day 151  ADA incidence will be summarized by treatment group. Exact 
analyses will be pre -specified in the SAP.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   58 
CONFIDENTIAL    9.3.1.  Safety Primary Endpoints  
The primary analysis will occur when all participants reach Day 151. All safety  summaries will 
be presented for all participants in the safety population.  
Solicited Local and Systemic AEs  
All solicited local AEs will be considered study intervention -related events and will be 
summarized for each injection site.  
All solicited AEs coll ected from Day 1 through Day 7 will be collected and summarized as 
described below.  
The number and percentage of participants who experience one or more solicited AE will be 
summarized for each solicited AE, by treatment group, and by intensity , by day aft er study 
intervention administration, and overall. The first onset of each AE, and the total number of days 
a participant experienced each AE will also be summarized. For participants with more than 1 
episode of the same event, the AE with maximum severity  will be used for tabulations.  
Exact 95% confidence intervals will be calculated on the percentages.  
Unsolicited Treatment Emergent AEs, SAEs and AESI  
All unsolicited AEs, serious adverse events (SAEs), and/or AESI will be recorded from 
screening through Day 151.  
Unsolicited AEs, S AEs, AESI  will be coded according to the Medical Dictionary for Reg ulatory 
Activities (MedDRA) and  summarized by System Organ Class (SOC), Preferred Term (P T) and 
greatest intensity.  Clopper -Pearson exact  95% CIs will be calculat ed on the percentages . AEs 
leading to withdrawal from the study will also be summarized.  
The number of eve nts reported, the number of participants and percentage of participants who 
experience one or more unsolicited AE through Day 151, one or more SAE, an d/or one or mor e 
AESI from screening through Day 151 will be summarized by treatment group, as approp riate, 
and across all RSM01 dose levels and routes of administration, combined. The intensity of each 
AE, and relationshi p between the AE and study interve ntion, will also be summarized.  
For participants with more than 1 episode of the same event, the AE with maximum intensit y 
will be used for tabulations. Participants reporting more than one occurrence for the PT t erm 
level being summarized will be counted only once.  
9.3.2.  Safety Secondary Laboratory Assessments  
Clinical safety laboratory evaluations are listed in Section 8.1.7 . All laboratory values coll ected 
at visits will be included in the summaries and listings. Descriptive summaries (n, mean, 
standard deviation, median, minimum, and maximum) of observed value and change from 
baseline (last result  available on or before Day 1) at each scheduled post baseline visit wil l be 
presented for each continuous variable test parameter.  
Summaries by toxicity grade and grading shifts in laboratory values from Day1 (baseline ) to Day 
8, Day 91, and Day  151 visits will be also presented.  
The frequency of safety laboratory parameters outs ide the normal range will be summariz ed by 
treatment group.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   59 
CONFIDENTIAL    9.3.3.  Other Safety Measures  
Vital signs, 12 -Lead ECG, medical history, and summary statistics will be tabulated by treatment 
group. Any other relevant information will be presented in participant data l istings. Further 
details will be provided in the SAP.  
9.3.4.  Pharmacokinetics  
All available PK data will be summarized at the time of dose selection for the Dose Expansion 
Phase, and for the interim and primary analyses when all participants reach Day 91 and Day 151, 
respectively.  
RSM01 capillary blood concentrations and the following PK parameters, AUC 0-∞, , AUC 0-t, Cmin, 
Cmax ,or C0, C D91, CD151, Tmax, t1/2, CL and Vz , will be summarized by treatment group. Each of 
the PK parameters will be summarized using desc riptive statistics (e.g., arithmetic mean, 
standard deviation, arithmetic percent CV, median, minimum, maximum, geometric mean, and 
geometric percent CV) , and the number of participants, as appropriate.  
The proportion of participants with observed C D151 concentrations above the estimated EC90 for 
RSM01 (based on available pre -clinical data)  will be summarized by treatment group. Exact 95% 
confidence interval will be calculated on the percentages.  
PK will be summarized in the PP PK population.  
In addition to  calculating the PK parameters using noncompartmental analysis (NCA) methods, 
RSM01 capillary blood and venous serum -concentration data obtained in this study will be used 
to develop a population PK model that will aid in the prediction of dose or doses to  be 
administered in infants and to assess potential covariates. The venous serum will be used for 
developing the model and not for the NCA analysis.  
This analysis will be described in an independent analysis plan and reported separately.  
9.4. Serum and Capillar y Blood Immunogenicity  
All available ADA results will be summarized for each treatment cohort at the time of the 
primary analyses, when all participants reach Day 151.  
Further details will be specified in the SAP for capillary blood analyses and in the exp loratory 
SSAP for serum.  
9.5. Serum and Capillary Blood RSV Neutralizing Antibody  
All available serum RSV neutralizing antibodies will be summarized for each treatment cohort at 
the time of the primary analysis, when all participants reach Day 151  
Analyses will  be specified in the exploratory SSAP.  
9.6. Demographic and Compliance Analyses  
Demographic parameters (age, sex, and race/ethnicity) and other baseline characteristics will be 
summarized descriptively by treatment group for all participants in the safety population.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   60 
CONFIDENTIAL    Listings of randomized participants with protocol deviations (to be defined in the SAP) will be 
presented by treatment group.  
9.7. Interim Analyses  
An interim analysis is planned for this study when all participants in each of the Dose Escalation 
Phase cohorts have completed Day 91. An Interim Report will be prepared when the results from 
Day 91 become available. Additional interim analyses may occur prior to the primary analysis to 
aid in the development of individual and population PK models to pre dict dose/s to be 
administered to infants and to assess covariates.  
The purpose of this interim analysis will be to inform on the broader program; no decision 
directly related to this study will be made from the results of this interim analysis. Agreement on 
the analysis plan, unblinding procedures, specific outputs, method of distribution, the level of 
data cleaning and details of to whom the results will be provided to will be outlined in a separate 
document (which will be finalized prior to the interim a nalysis).  
The interim analysis will be performed by an unblinded statistician. The investigator will be 
blinded. The sponsor and/or sponsor’s designee(s) will review aggregated safety data by cohort 
only (including data from both RSM01 and Placebo particip ants) and will review aggregated PK 
data by treatment group (RSM01 vs. Placebo) within and across cohorts. Although the sponsor 
will be blinded throughout the study, such review of aggregated data could potentially lead to 
unblinding of the treatment recei ved by individual participants.  
9.8. National Regulatory Authority  
The national regulatory authority will receive all expedited safety reports from the clinical trial 
and have the authority to terminate, suspend or require changes to a clinical trial.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   61 
CONFIDENTIAL    10. Supportin g Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
a. Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines  
b. Applicable International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use  (ICH) Good Clinical Practice (GCP) Guidelines  
c. Applicable laws and regulations  
d. The protocol, protocol amendments, ICF, and other relevant documents (e.g., diary cards) 
must be submitted to an IRB/IEC by the inv estigator and reviewed and approved by the 
IRB/IEC before the study is initiated  
e. Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
10.1.2.  Study Oversight  
The study sponsor, the institution through which the research is performed and all members of 
the investigator’s clinical team and the national regulatory authority share responsibility for 
ensuring the safety of participants in this trial.  
The investigator will be responsible for the following:  
a. Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently, in accordance with the requirements, policies, and procedures establis hed by the 
IRB/IEC  
b. Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC 
procedures  
c. Providing oversight of the conduct of the study at the site and adherence to requirements of 
ICH and GCP guidelines, national authority regulations, the IRB/IEC, and all other 
applicable country and local regulations  
d. Closely monitoring study participants and taking whatever measures necessary to ensure 
their safety. The investigator may delay an individual’s study intervention administrati on or 
pause study intervention administration altogether if the investigator is concerned that the 
study intervention might place a participant or participants at significant risk. Where 
specified, the responsibilities of the investigator may be delegated to a medically qualified 
team member (designee). The investigator determines intensity and causality with respect 
to the study intervention for each AE.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   62 
CONFIDENTIAL    The sponsor has an institutional responsibility to ensure participant safety and is ultimately 
accounta ble for safety oversight. Medical monitors and the IDMC play an important role in this 
regard and support the sponsor.  
The Medical Monitor is the sponsor’s representative and is a physician. The Medical Monitor:  
a. reviews the safety of the product for protocols in a specific region and, in consultation with 
the sponsor  
b. is responsible for safety oversight in -country and plays an important role in the reporting of 
Serious ADRs, SAEs, pregnancies, and other important safety information, as described in 
the protocol  
c. in consultation with the sponsor, may assess the intensity and causality for AEs and may 
upgrade the degree of intensity and causality that has been determined by the investigator 
or designee  
The Medical Monitor, like the investigator, will be bl inded until primary endpoint analyses are 
completed, unless emergency unblinding is required.  
The Institutional Review Board or Ethics Committee has institutional responsibility for the safety 
of research participants. The Institutional Review Board or Eth ics Committee has the authority to 
terminate, suspend or require changes to a clinical trial.  
10.1.3.  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year  after completion of the study.  
10.1.4.  Informed Consent Process  
The investigator or designee will explain the study to the participant and answer all questions 
regarding the study.  The investigator or designee will conduct the consent discussions on an 
individual  basis with each participant. Adequate time will be allowed for all questions to be 
addressed. Potential participants will be interviewed to ensure that they meet all entry criteria 
relating to history.  
Written informed consent will be obtained prior to co nducting any study -related procedures.  
Participants must be informed that their participation is voluntary. Participants will be required to 
sign a statement of informed consent that meets the requirements of FDA Code of Regulations 
(CFR) 21 CFR 50, local regulations, International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) guidelines, and the IRB/IEC or study 
center.  
Written informed consent must obtained before the participant is enrolled in the study, and the 
date the written consent was obtained must be documented. The authorized person obtaining the 
informed consent must also sign the ICF.  
A copy of the ICF must be provided to the participant.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   63 
CONFIDENTIAL    10.1.4.1.  Informed Consent Forms  
Participants will be required to sign a  statement of informed consent that meets the requirements 
of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability 
Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
Participants will be to ld that they are free to refuse to participate and may withdraw their consent 
at any time and for any reason during the study period. Any test results from the samples 
collected before withdrawing consent may still be used for the study.  
The informed conse nt form will be obtained by the use of a written ICF approved by the 
IRB/IEC and signed and dated by the participant.  
A copy of the signed consent form/s shall be given to the participant prior to conducting any 
study -related procedures.  
The medical record  must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
If there is a change to the ICF during the conduct of the study, participants must be re -consented 
using the most current version of the ICF.  
Any withdrawal of consent for sample testing will be documented in the CRF.  
If a participant cannot be randomized on the intende d day of dosing (e.g., due to elevated 
temperature) he/she is not required to sign another ICF, as long as re -screening and dosing occur 
within the protocol -defined window.  
10.1.5.  Data Protection  
Participants will be assigned a unique identifier by the sponsor. A ny participant record or dataset 
that is transferred to the sponsor will contain the identifier only; participant names or any 
information which would make the participant identifiable will not be transferred to the sponsor.  
The participant must be informe d that the participant’s study -related data will be used by the 
sponsor in accordance with local data protection law. The level of data disclosure must also be 
explained to the participant.  
The participant must be informed that the participant’s medical re cords may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
10.1.6.  Dissemination of Clinical Study Data  
Study information from this protocol will be posted on publicly available clinical trials registers 
(for example, clinicaltrials.gov) before enrollment of participants begins. Summaries of the 
results of the study will also be posted on the same website.  
The final CSR will include all available data through the final study visit. The database will be 
locked prior to preparation of the final CSR when all of the above data have been entered, 
reviewed, and all queries related to the data have been addressed.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   64 
CONFIDENTIAL    Modifications or additions to the analyses will be included in the relevant analysis plan. Any 
decisions to deviate from the planned analyses described in the protocol and in the SAP will be 
described in detail in the final CSR. The CSR will be reviewed an d approved by the sponsor 
signatory and the lead investigator.  
10.1.7.  Data Quality Assurance  
All participant data relating to the study will be recorded by an electronic CRF using an EDC 
system or transmitted to the sponsor or designee electronically (e.g., labor atory data). The 
investigator is responsible for verifying that data entries are accurate and correct by 
electronically signing the CRF.  
The investigator must maintain accurate documentation that supports the information entered in 
the eCRF.  
The study will  be monitored regularly by the sponsor or its designee throughout the study period. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.  
Monitor ing details describing strategy (e.g., risk -based initiatives in operations and quality such 
as Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities, and requirements, including handling of noncomplianc e issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in the Monitoring Plan.  
The sponsor or designee is responsible checking the accuracy and completeness of the data 
reported in the eCRFs and the consistency with the so urce documents. The sponsor assumes 
accountability for actions delegated to other individuals (e.g., contract research organizations 
[CROs]).  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authori zed site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.8.  Source Documents  
Source documentation consists of existing medical records and/or study records developed and 
maintained by the investigator. Source documents provide evidence for the existence  of the 
participant and substantiate the integrity of the data collected.  
Data recorded on source documents will be transcribed onto electronic case report forms 
(eCRFs) using an EDC system.  
Data entered in the eCRF that are transcribed from source documen ts must be consistent with the 
source documents or the discrepancies must be explained. The investigator may need to request 
previous medical records or transfer records, depending on the study.  
For the purpose of monitoring and auditing the study, source documentation will consist of 
existing medical records and/or study records developed and maintained by the investigator.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   65 
CONFIDENTIAL    10.1.9.  Record Retention  
Records and documents pertaining to the conduct of this study must be retained by the 
investigator for a minimum of 1 0 years after study completion unless local regulations or 
institutional policies require a longer retention period.  
No records may be destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to anoth er location or party without written notification 
to the sponsor.  
10.1.10.  Study and Site Closure  
The sponsor reserves the right to close the study site(s) or terminate the study at any time for any 
reason at their sole discretion. Study sites will be closed upon study completion. A study site is 
considered closed when all required documents and study supplies have been collected and a 
study site closure visit has been performed.  
The investigator may initiate study site closure at any time, provided there is reason able cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:  
d. Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor's procedures, or GCP guidelines  
e. Inadequate recruitment of participants by the investigator  
f. Discontinuation of further study intervention development.  
At the discretion of the sponsor, all  materials and supplies provided to the investigator will be 
returned or disposed of in compliance with local regulatory requirements upon authorization 
from the sponsor, upon study completion. The investigator or designated clinical site staff will 
notify  the IRB/IEC when the study has been completed.  
10.1.11.  Publication Policy  
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before sub mission. 
This allows the sponsor to protect proprietary information and to provide comments.  
The sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the sponsor will genera lly support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with Inte rnational Committee of 
Medical Journal Editors authorship requirements.  
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
10.2. Appendix 2: Adverse Events: Definitions and Procedures for 
Recording , Evaluating, Follow-up, and Reporting 
10.2.1. Definition of AE 
AE Definition 
An AE is any untoward medical occmTence in a patie nt or clinical study pa1ticipant , 
temporally assoc iated with the use of study intervention, whet her or n ot considered related to 
the study interventi on. 
NOTE : An AE can therefore be any unfavorable and unint ended sign (including an abno1ma l 
laborato 1 y finding ), sympto m, or disease (new or exacerbate d) tempora lly assoc iated with the 
use of study intervention. 
Events Meeting the AE Definition 
Any abno1ma l laborat ory test results (hemato logy, clinical chemistry , or minal ysis) or other 
safety assessme nts (e.g., ECG , radiological scans, vital signs measmements), including those 
that worsen from baseline, consi dered clinically significant in the medical and scientific 
judgment of the investigat or (i.e., not related to progressio n of underl ying disease) . 
Exace rbation of a chronic or inte1mittent pre-existing condition including eith er an increa se in 
frequenc y and/or intensity of the condition. 
New conditions detected or diagnosed after study interventi on admin isti·ation even though it 
may have been present before the start of the study. 
Signs, symptom s, or the clinical sequelae of a su spected drng-drng interactio n. 
Signs, symptom s, or the clinical sequelae of a suspected overdose of either s tudy intervention 
or a conc01nita nt medication. Overdose per se will not be repo1te d as an AE/SAE unless it is 
an intentional overdose taken with possib le suicidal/self -haimin g intent Such overdoses 
should be repo1ted regard less of sequelae . 
Events Meeting the AE Definition 
Any clinicall y significant abnonnal laborato1y findings or other abnonnal safety assess ments 
which are associated with the underlying disease , unless judged by the investigator to be more 
severe than expected for the paiticipant 's condition. 
The disease /disorder being studied or expected progression, signs, or symptom s of the 
disease /disorder being studied , unless more severe than expected for the pa1ti cipant's 
condition. 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 66 
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Medical or surgical proced ure ( e.g., endoscopy, appendectomy): the cond ition that leads to the 
proced ure is the AE. 
Situatio ns in which an untoward medi cal occurrence did not occur (social and/or convenience 
admissio n to a hospita l). 
Anticipated day-to-day fluctuations of pre-exi sting disease(s) or condition(s) present or 
detected at the strut of the study that do not worse n. 
10.2.2. Definition of SAE 
If an event is not an AE per definiti on above , then it cannot be an SAE even if serious conditi ons 
are m et (e.g., hospitaliz ation for signs/symptoms of the disease under study, death due to 
progress ion of disease) . 
A SAE is defined as any untoward medical occurrence that, at any dose: 
Results in death 
Is life-threatening 
The te1m 'life-threat ening' in the definition of 'serious' refers to an event in which the 
paiticipant was at risk of death at the time of the event. It does not refer to an event, w hich 
hypothetically might have caused death , if it were more severe. 
Requires inpatie nt hospitalizat ion or prolon gatio n of existing hospitalizat ion 
In general, hospitalizatio n signifie s that the paitic ipant has been detained (usually involving at 
least an overnigh t stay) at the hospital or emergency ward for observatio n and/or treatment that 
would not have been appropr iate in the physician 's office or outpatient setting. Compli catio ns 
that occur during hospitaliza tion are AEs. If a complication prolo ngs hospita lization or fulfill s 
any other serious c riteri a, the event is serious. Whe n in doubt as to whether "h ospitalizat ion" 
occuned or was necessa ry, the AE should be considered serious. 
Hospitalizatio n for elective treatme nt of a pre-exist ing conditi on that did not worsen from 
baseline is not conside red an AE. 
Results in persiste nt disability /incapacity 
The te1m disab ility means a substantial disrnpti on of a person 's ability to conduct nonnal life 
functions . 
This definition is not intended to inclu de expe riences of relatively minor medi cal significance 
such as uncomplicated headache, nausea, vomit ing, diaiThea, influen za, and accidental trauma 
(e.g., sprained ankle) which m ay interfere with or prevent eve1yday life functions but do not 
constitute a substantial disrnption. 
Is a congenital anomal y/biit h defect 
Other situations: 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 67 
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Medical or scientific judgment should be exercised in deciding whether SAE repo1iing is 
appropriate in other situation s such as impo1iant medi cal events that may not be immediately 
life-threatening or result in death or h ospitalization but m ay jeopardize the partic ipant or may 
require medi cal or s urgical inte1vention to prevent one of the other o utcomes listed in the 
above definition. These events should usually be considered serious. 
Example s of such events inclu de invasive or malignant cancers, inten sive treatmen t in an 
emergency room or at home for allergic broncho spasm , blood dyscrasias or convulsions that 
do not result in hospitalization , or deve lopment of drng dependency or drng abuse. 
10.2.3. Definition of Serious Adverse Drug Reaction (Serious ADR) 
When an AE is judged to be serious and related to an investigatio nal produ ct, it is a Serio us 
Adverse Drng Reaction and is subject to expedited repo1iing based on the parameters of this 
study. 
10.2.4. Definition of AESI 
AES is are AEs that the sponsor will carefully monitor. The following AEs will be collected and 
repo1ied as AES is: anaphylaxi s or hypersensitivity reactions, and/or infusion reactions resulting 
in pennan ent discontinu ation of study inte1vention infusion during IV admini stratio n. 
10.2.5. Recording and Follow-Up of AE, SAE, AESI 
Recording 
Care will be taken not to introdu ce bias when detecting AEs, SAEs and AESi s. Open-ended 
and non-leading verba l questioning of the pa1iicipant is the prefe1Ted meth od to inquire about 
AE occur rences. 
When an AE/SAE / AES! occurs, it is the responsibility of the investigator to review all 
available documentation ( e.g., hospital pro gress notes, laboratory repo1i s, and diagno stics 
repo1i s) related to the event. 
The investigator will record all relevant AE/SAE /AES I info1mat ion in the CRF . 
AEs will be repo1ied on the AE CRF using a recognized medi cal te1m or diagno sis that 
accurately reflect s the event. 
AE evaluations will be reviewed by the investigator or a medically qualified delegate. AE 
CRF page s are to be comp leted by member s of the study team who are designated to perfo1m 
this task by the investigator. The onset and resolution dates of an AE and action taken in 
response to the AE will be documen ted. 
After the initial AE/SAE / AES! report , the investigator is required to proactively follow each 
paiiicipant at subsequent visits/contacts. All SAEs , and non-serious AESi s will be followed 
until resolution, stabilization, the event is othe1 w ise explained, or the paiiicipant is lost to 
follow-up. 
It is not accep table for the investigator to send photocop ies of the paiticipant 's medical 
records to the spon sor in lieu of comp letion of the AEISAEI AES ! CRF page. 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 68 
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
There may be instances when copies of medical records for ce1iain cases are requested by the 
Medical Monitor, the SRT, the IDMC and/or the spon sor. In this case, all paiiicipant 
identifier s, with the exception of the paiiicipant number , will be redacted on the copies of the 
medical records before submi ssion. 
The investigator will attempt to estab lish a diagnos is of the event based on signs, symptom s, 
and/or other clinical info1mation . Whenever possible, the diagn osis (not the individual 
signs /symptoms) will be documented as the AE/SAE / AES!. 
AEs/SAEs / AES Is will be assessed for intensity and causal relation ship to the study 
interve ntion. Note that local AEs repo1ied within the first 7 days after IM dosing ai·e 
considered to be study intervention-relat ed. 
Follow-up and Resolution 
The investigator is obligated to perfo1m or aITange for the conduct of supplemen tal 
measurement s and/or evaluations as medically indicated to elucidate the nature and/or 
causa lity of the AE/SAE / AESI as fully as p ossib le. This may include addit ional laborato 1 y 
tests or investigatio ns, histopathological examinations, or consultation with other health care 
professio nals. 
If a pa1ii cipant dies during pa1iicipation in the study or during a recognized follow-up period, 
the investigator will prov ide the sponsor with a copy of any p ost-m01iem findings including 
histopa thology, if available. 
New or updated info1mation will be recorded in the originally completed CRF. 
The investigator will submi t any updat ed SAE / AESI data to the sponsor wit hin 24 hours of 
receipt of the info1mati on. 
The onset and resolution dates of the event and medical cai·e provided in response to the event 
will be documented . 
AEs will be considered resolved when the condition r eturns to n01m al or r eturns to the 
paiiicipant 's baseline sta.tus as established on Study Day 1, or when t he conditi on has 
stabilized with the expectation that it will remain chronic. 
If the event has not resolved by the final study visit, it will be docume nted as "ongoing" on the 
CRF, however , follow-up of the SAE /AESI must continue until resolved or the cond ition has 
stabilized. Info1m ation recorded on the CRF must be substantiated in the source documen ts. 
The resolution date to be recorded on the CRF is the last date on w hich the pa1iicipant 
experienced the AE. 
Bill & Melinda Gates Medical Research Institute 
CONFIDENTIAL 69 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   70 
CONFIDENTIAL    10.2.5.1.  Assessment of Intensity  
The investigator will assess the intensity of each AE reported during the study. In the case of 
local reactions, vital signs, systemic events, and laboratory abnormalities, the Grades 
delineated in Section 10.4, Appendix 4 will be employ ed. 
In the case of an AE or abnormal clinical laboratory re sult not included in Appendix 4, 
intensity will be assigned using the Grades described in the U.S. Department of Health and 
Human Services, Common Terminology Criteria for Adverse Events, Version 5.0 [ US HHS  
2017]  as follows:  
Grade 1 Mild ; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 Moderate;  minimal, local or noninvasive int ervention indicated; limiting age-
appropriate instrumental Activities of Daily Living (ADL)*  
Grade 3 Severe  or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care ADL**symptoms, 
causing inability to perform usual social and functional activities with intervention or 
hospitalization indicated  
Grade 4 Life -threatening consequences;  urgent intervention indicated  
Notes:  
A semi -colon indicates ‘or’ within the description of the grade.  
*Instrum ental ADL refers to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
**Self -care ADL refers to bathing, dressing, and undressing, feeding self, using the toilet, 
taking medications, and not bedridden.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   71 
CONFIDENTIAL     
10.2.5.2.  Assessme nt of Causality  
The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE/AESI. Only AEs that are local reactions to an IM injection are 
automatically assumed to be related to the study intervention, and therefore are not required to 
have causality assessed by the investigator.  
The investigator will assess whether the AE/SAE/AESI is either:  
Related: An AE/SAE/AESI is considered related to study intervention if there is a reasonable 
possib ility that the study intervention contributed to the AE.  
or 
Not related: There is no reasonable possibility that the AE/SAE/AESI is causally related to 
administration of the study intervention. There are other more likely causes for the AE.  
The investigato r will use clinical judgment to determine the relationship.  
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to study intervention administration will be 
consi dered and investigated.  
For each AE/SAE/AESI, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE/AESI and has provided an assessment of causality.  
There may be situations in which an SAE has occurred and the investigato r has minimal 
information to assess causality to include in the initial report. However, it is very important that 
the investigator always provide makes an assessment of causality with the initial submission 
of the SAE data.  
The investigator may change his /her assessment of causality when considering additional follow -
up information and submit an SAE follow -up report with the updated causality assessment.  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements  applicable to SAEs.  
10.2.5.3.  Assessment of Expectedness  
Not applicable  
10.2.5.4.  Assessment of Outcome  
The outcome of each SAE/AESI must be reported. For analysis purposes, the outcome for 
serious adverse events will be determined on the final study visit.  
Outcome of  all AEs will be classified as one of the following:  
•Resolved  
• Resolve d with sequelae 
•Ongoing 
•Dea th . 
10.2.6. SAEs, AESis, and Serious ADR Reporting 21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Reporting to Sponsor or Delegate Via the Electronic Data Collection Tool 
The primary mechanism for reporting an SAE or AES I by the investigator to the sponsor or 
delegate will be the electronic data collectio n tool. 
The site will enter the SAE or AESI data into the electro nic syste m as soon as it is identified . 
All SAEs (related and unrelated) and AES is are reported to the spon sor or delegate through out 
the study. 
Serious AD Rs are repo1ied to the spon sor or delegate during the entire study period . Serious 
AD Rs are to be repo1ied after completion of the study , if the investigator becomes aware of a 
serious A DR. 
The investigator must not wait to collec t additional infonnation to fully document the event 
before notifying the spon sor or delegate of a SAE or an AESI. The initial notification should 
include the following: 
• Protocol number and name and contact number of the investigator 
• Paiiicipant ID number (and initial s and date of birth, if available) 
• D ate paiiicipant received study interventio n 
• SAE / AES I te1m and date of event onset 
• CmTent status of SAE / AES I 
The investigator is responsible for expedited safety repo1i submi ssion to the sponsor delegate 
and the sponsor delegate repo1is to the national regulato1y authority(ies) within speci fic time 
periods of being notified of the event. Therefore, it is impo1iant that the investigato r subinit 
additional info1mation reque sted as soon as it becomes available. 
Original and follow- up repo1is must be subini tted according to the requirements of the 
regulato1y authorities. 
If the electronic syste m is unavailable, the site may use the paper SAE / AESI data collectio n 
tool (see next sectio n) instead of the EDC, in order to repo1i the event within 24 hours of 
beco ming aware. 
After the study is comple ted at a given site, the electronic data collection tool, if used, will be 
taken off-line to prevent the entry of new data or changes to existing data .. 
If a site receives a repo1i of a new SAE from a study pa1ii cipant or receives updated data on a 
previously repo1ied SAE after the electronic data. collectio n tool has been taken off-line, t hen 
the site can repo1i this info1mation on a paper SAE fonn (see next sectio n). 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 72 
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Contacts for SAE /AES! repo1i ing and for all safety perso nnel are containe d in the Team 
Contact List which will be stored on-site in the Site Regulato1y Binder and maintained by the 
study sponsor. 
Reporting via Paper CRF 
If the eCRF cannot be completed , the S uppl emental SAE / AES! Repo1i (paper fo1m) should be 
completed by the investigator or his/her designee , and scanned and emailed, or faxed to the 
sponsor or delegate. The investigator is responsible for ensuring an adequate transmission of 
the fax and will store the distributi on confnm ation in the study file. 
In rare circumstances and in the absence of facsi mile equipm ent, notification by telephone is 
acceptab le with a copy of the SAE / AES ! report form sent by overnight mail or courier service. 
Initial notification via telephone does not replace the need for the investigato r to complete and 
sign the SAE / AES! CRF pages within the designated reporting time frame s. 
10.3. Appendix 3: Contraceptive Guidance and Collection of 
Pregnancy Information 
Contraceptive Guidance: 
Male paiiicipants with pa1iners of childbearing potential must agree to use condoms durin g the 
study and for 90 days after the s tudy, and they must refrain from spe1m donation for at least 90 
days after the end of study . 
Fema le pa1iicipants of childbeai· ing potential must not be pregnant, breastfeeding , or attempting 
to become pregnant for 28 days before Scree ning and throughout the duration of the study. These 
paiiicipants must have a negative sernm pregnancy test at Screening in order to be eligible for 
randomizat ion and treatment with study intervention. In addit ion, th ese female paiiicipants must 
be willing to commit to using a consistent and acceptable method of contraceptio n for the 
duration of the study and for 90 days after study completion if they engage in intercourse. 
Acceptable method s of contraceptio n are: 
• Consistent use of syste mic contraception , including biith control pills, transde1mal 
patch, vagina l ring, implant s, and injectables. 
• Consistent use of doubl e banier method , e.g., condoms, cervica l cap, diaphragm , 
vaginal contraceptive film with spe1micide. 
• Use of intrauterine device with a low failure rate ( defined as < 1 % risk of pregnancy 
per yeai-) 
• Monogamo us interco urse with a vasectomized man or has only same-sex paiiners . 
Fema le pa1iicipants who ai·e not sexually active but become so dming the study must agree to 
follow the contraceptive requii·ements above. 
Female pa1iicipants who ai·e not of childbeai· ing potential must meet at least one of the 
following criteria: 
• At least 1 year since the last menstrual period. 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 73 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   74 
CONFIDENTIAL    • Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or 
hysterectomy)  
• Congenitally sterile  
• Diagnosed as infertile and not undergoing treatment to reverse infertility.  
Collection of Pregnancy Information:  
• A participant who becomes pregnant during the study period will be asked to complete all 
visits and procedures through Day 151 as described in Table 2 or Table 3, as applicable. 
After she completes Day 151, or in the event that sh e voluntarily withdraws from the 
study and agrees to provide additional information regarding the pregnancy, the 
investigator will utilize the ‘Pregnancy Outcome Form’ during the remaining gestation 
period to collect information on the health of the partic ipant, the outcome of the 
pregnancy, and the health of the neonate. Neonate follow -up will occur for 6 weeks 
beyond the estimated delivery date.  
• If a participant is determined to be pregnant during the study (after receiving a dose of the 
study interventio n), the investigator will report the pregnancy to the sponsor or delegate 
and collect follow -up information on the participant and the neonate. Generally, follow -
up will not be required for longer than 6 weeks beyond the estimated delivery date. Any 
termin ation of pregnancy will be reported, regardless of fetal status (presence or absence 
of anomalies) or indication for the procedure.  
• While pregnancy is not considered to be an AE or a SAE, any pregnancy complication or 
elective termination of a pregnancy wi ll be reported as an AE or a SAE. Any abnormal 
pregnancy outcome that comes to the attention of the investigator (e.g., spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) is considered to 
be a SAE.  
• Any pregna ncy-related SAE that occurs after study participation and is made known to 
the investigator and is assessed as related to the study intervention will be reported to the 
sponsor or the sponsor’s designee. The investigator is not obligated to actively seek s uch 
information in former study participants who become pregnant during the study. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   75 
CONFIDENTIAL    10.4. Appendix 4: Toxicity Tables  
The following toxicity tables are extracted from the FDA Guidance for Industry [ FDA  2007].  
Table 8: FDA Toxicity Grading Scale - Clinical Abnormalities  
 Local Reactions  
Local Reaction to  
Injectable Product  Mild  
(Grade 1)  
 Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Pain  Does not interfere  
with activity  Repeated use of 
non-narcotic pain 
reliever > 24 hours 
or interferes with 
activity  Any use of narcotic 
pain reliever or 
prevents daily  
activity  Emergency room  
(ER) visit or  
hospitalization  
Tenderness  Mild discomfort to 
touch  Discomfort with 
movement  Significant  
discomfort at rest  ER visit or  
hospitalization  
Erythema/Redness *  2.5 – 5 cm  5.1 – 10 cm  > 10 cm  Necrosis or  
exfoliative 
dermatitis  
Induration/Swelling 
**  2.5 – 5 cm and does 
not int erfere  
with activity  5.1 – 10 cm or  
interferes with  
activity  > 10 cm or  
prevents daily  
activity  Necrosis  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be  
recorded as a continuous variable.  
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement.  
Table 8:  FDA Toxicity Grading Scale - Clinical Abnormalities - 
Vital Signs  
Vital Signs *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Fever (°C) **  
(°F) **  38.0 – 38.4 
100.4 – 101.1  38.5 – 38.9 
101.2 – 102.0  39.0 – 40 
102.1 – 104  > 40 
> 104  
Tachycardia - beats 
per 
minute  101 – 115  116 – 130  > 130  ER visit or  
hospitalization for  
arrhythmia  
Bradycardia - beats 
per 
minute***  50 – 54  45 – 49  < 45  ER visit or  
hospitalization for  
arrhythmia  
Hypertension 
(systolic) - 
mm Hg  141 – 150  151 – 155  > 155  ER visit or  
hospitalization for  
malignant  
hypertension  
Hypertension 
(diastolic) - 
mm Hg  91 – 95  96 – 100  > 100  ER visit or  
hospitalization for  
malignant  
hypertension  
Hypotension 
(systolic) – 
mm Hg  85 – 89  80 – 84  < 80  ER visit or  
hospitalization for  
hypotensive shock  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   76 
CONFIDENTIAL    Respiratory Rate – 
breaths  
per minute  17 – 20  21 – 25  > 25  Intubation  
* Participant should be at rest for all vital sign measurements.  
** Oral temperature; no recent hot or cold beverages or smoking.  
*** When resting heart rate is between 60 – 100 beats per minute. Use clinical judgment when characterizing bradycardia 
among some healthy populations, for example, conditioned athletes.  
Table 8:  FDA Toxicity Grading Scale - Clinical Abnormalities, continued…  
Systemic Events  
Systemic  
 (General)  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3) Potentially Life  
Threatening  
(Grade 4)  
Nausea/vomiting  No interference  
with activity or 1 – 
2 
episodes/24 hours  Some interference  
with activity or > 2  
episodes/24 hours  Prevents daily  
activity, requires  
outpatient IV  
hydration  ER visit or  
hospitalization for  
hypotensive shock  
Diarrhea  2 – 3 loose stools 
or 
< 400 gms/24 hours  4 – 5 stools or  
400 – 800 gms/24  
hours  6 or more watery  
stools or  
> 800gms/24 hours  
or requires  
outpatient IV  
hydration  ER visit or  
hospitalization  
Headache  No interference 
with 
activity  Repeated use of 
non- 
narcotic pain  
reliever > 24 hours 
or 
some interference  
with activity  Significant; any  
use of narcotic  
pain reliever or  
prevents daily  
activity  ER visit or  
hospitalization  
Fatigue  No interference 
with 
activity  Some interference  
with activity  Significant;  
prevents daily  
activity  ER visit or  
hospitalization  
Myalgia  No interference 
with 
activity  Some interference  
with activity  Significant;  
prevents daily  
activity  ER visit or  
hospitalization  
Systemic Illness  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Illness or clinical 
adverse  
event (as defined  
according to applicable  
regulations)  No interference 
with 
activity  Some interference  
with activity not  
requiring medical  
intervention  Prevents daily  
activity and  
requires medical  
intervention  ER visit or  
hospitalization  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   77 
CONFIDENTIAL    Table 9: FDA Toxicity Grading Scale - Laboratory Abnormalities  
Serum *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening  
(Grade 4)**  
Sodium – Hyponatremia mEq/L  132 – 134  130 – 131  125 – 129  < 125  
Sodium – Hypernatremia mEq/L  144 – 145  146 – 147  148 – 150  > 150  
Potassium – Hyperkalemia mEq/L  5.1 – 5.2  5.3 – 5.4  5.5 – 5.6  > 5.6  
Potassium – Hypokalemia mEq/L  3.5 – 3.6  3.3 – 3.4  3.1 – 3.2  < 3.1  
Glucose – Hypoglycemia mg/dL  65 – 69  55 – 64  45 – 54  < 45  
Glucose – Hyperglycemia  
Fasting – mg/dL  
Random – mg/dL  100 – 110 
110 – 125  111 – 125 
126 – 200  >125  
>200  Insulin requirements 
or hyperos -molar 
coma  
Blood Urea Nitrogen  
BUN mg/dL  23 – 26  27 – 31  > 31  Requires dialysis  
Creatinine – mg/dL  1.5 – 1.7  1.8 – 2.0  2.1 – 2.5  > 2.5 or requires 
dialysis  
Calcium – hypocalcemia mg/dL  8.0 – 8.4  7.5 – 7.9  7.0 – 7.4  < 7.0  
Calcium – hypercalcemia mg/dL  10.5 – 11.0  11.1 – 11.5  11.6 – 12.0  > 12.0  
Magnesium – hypomagnesemia 
mg/dL  1.3 – 1.5  1.1 – 1.2  0.9 – 1.0  < 0.9  
Phosphorous – hypophosphatemia 
mg/dL  2.3 – 2.5  2.0 – 2.2  1.6 – 1.9  < 1.6  
CPK – mg/dL  1.25 – 1.5 x 
ULN***  1.6 – 3.0 x ULN  3.1 –10 x 
ULN  > 10 x ULN  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.1  2.5 – 2.7  < 2.5  --  
Total Protein – Hypoproteinemia 
g/dL  5.5 – 6.0  5.0 – 5.4  < 5.0  --  
Alkaline phosphate – 
increase by factor  1.1 – 2.0 x 
ULN  2.1 – 3.0 x ULN  
 3.1 – 10 x 
ULN  > 10 x ULN  
Liver Function Tests –ALT, AST  
increase by factor  1.1 – 2.5 x 
ULN  2.6 – 5.0 x ULN  5.1 – 10 x 
ULN  > 10 x ULN  
Bilirubin – when accompanied  
by any increase in Liver Function 
Test increase by factor  1.1 – 1.25 x 
ULN  1.26 – 1.5 x 
ULN  1.51 – 1.75 x 
ULN  > 1.75 x ULN  
Bilirubin – when Liver Function Test 
is normal; increase by factor  1.1 – 1.5 x 
ULN  1.6 – 2.0 x ULN  2.0 – 3.0 x 
ULN  > 3.0 x ULN  
Cholesterol  201 – 210  211 – 225  > 226  ---  
Pancreatic enzymes – amylase, lipase  1.1 – 1.5 x 
ULN  1.6 – 2.0 x ULN  2.1 – 5.0 x 
ULN  > 5.0 x ULN  
* The laboratory values provided in the tables serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference ranges should be provided to 
demonstrate that they are appropriate.  
** The clinical signs or symptoms associated with laboratory abnormalities might result in 
characterization of the laboratory  abnormalities as potentially life -threatening (Grade 4). For 
example. a low sodium value that falls within a Grade 3 parameter (125 -129 mE/L) should be 
recorded as a Grade 4 hyponatremia event if the participant had a new seizure associated with the 
low s odium value.  
***ULN is the upper limit of the normal range.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   78 
CONFIDENTIAL    Table 9: FDA Toxicity Grading Scale - Laboratory Abnormalities, continued…  
Hematology *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life  
Threatening (Grade 4)  
Hemoglobin (Female) - gm/dL  11.0 – 12.0  9.5 – 10.9  8.0 – 9.4  < 8.0  
Hemoglobin (Female)  
change from baseline value - 
gm/dL  Any decrease 
– 1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
Hemoglobin (Male) - gm/dL  12.5 – 13.5  10.5 – 12.4  8.5 – 10.4  < 8.5  
Hemoglobin (Male)  
change from baseline value – 
gm/dL  Any decrease 
– 1.5  1.6 – 2.0  2.1 – 5.0  > 5.0  
WBC Increase - cell/mm3 10,800 – 
15,000  15,001 – 
20,000  20,001 – 25, 
000  > 25,000  
WBC Decrease - cell/mm3 2,500 – 3,500  1,500 – 2,499  1,000 – 1,499  < 1,000  
Lymphocytes Decrease - 
cell/mm3 750 – 1,000  500 – 749  250 – 499  < 250  
Neutrophils Decrease - cell/mm3 1,500 – 2,000  1,000 – 1,499  500 – 999  < 500  
Eosinophils - cell/mm3 650 – 1500  1501 - 5000  > 5000  Hypereosinophilic  
Platelets Decreased - cell/mm3 125,000 – 
140,000  100,000 – 
124,000  25,000 – 
99,000  < 25,000  
PT – increase by factor  
(prothrombin time)  1.0 – 1.10 x 
ULN**  
1.11 – 1.20 
x ULN  1.21 – 1.25 x 
ULN  > 1.25 ULN  
PTT – increase by factor  
(partial thromboplastin time)  1.0 – 1.2 x 
ULN  1.21 – 1.4 x 
ULN  1.41 – 1.5 x 
ULN  > 1.5 x ULN  
Fibrinogen increase - mg/dL  400 – 500  501 – 600  > 600  --  
Fibrinogen decrease - mg/dL  150 – 200  125 – 149  100 – 124  < 100 or associated  
with gross bleeding or 
disseminated intravascular 
coagulation (DIC)  
WBC= white blood cell count  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institut ional normal reference rang es should be provided to demonstrate that the y are appropriate.  
** “ULN” is the up per limit of the normal range.  
GGT grading is not provided in the FDA toxicity grading scale tables. The following  grading 
scale is from the  U.S. Department of Health and Hum an Services, Common Te rminology 
Criteria for Adv erse Events, Version 5.0 [ US HHS  2017]:  
• Grade 1:  >ULN - 2.5 x ULN if baseline is normal; 2.0 - 2.5 x baseline if ba seline is 
abnormal  
• Grade 2: > 2.5 - 5.0 x ULN if baseline is normal; >2.5 - 5.0 x baseline if ba seline is abnormal  
• Grade 3: >5.0 - 20.0 x ULN if baseline is normal; >5.0 - 20.0 x baseline if ba seline is 
abnormal  
• Grade 4: >20.0 x ULN if baselin e is normal; >20.0 x baseline if baseline  is abnormal.  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   79 
CONFIDENTIAL    Table 10: FDA Toxicity Grading Scale - Urine  
Urine *  Mild (Grade 1)  Moderate  
(Grade 2)  Severe (Grade 3)  Potentially Life  
Threatening  
(Grade 4)  
Protein  Trace  1+  2+  Hospit alization or  
dialysis  
Glucose  Trace  1+  2+  Hospitalization 
for 
hyperglycemia  
Blood 
(microscopic)  
red blood cells per 
high power field 
(rbc/hpf)  1 - 10  11 – 50  > 50 and/or gross  
blood  Hospitalization or  
packed red blood  
cells (PRBC)  
transfusion  
* The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal 
parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   80 
CONFIDENTIAL    11. References  
AstraZeneca. Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower 
respiratory tract infections in healthy infants. 26 April 2021. 
https://www.astrazeneca.com/media -centre/press -releases/2021/nirsevimab -phase -iii-trial-met-
primary -endpoint.html  
Aliprantis A, Wolford D, Caro L, Maas BM, et al. A Phase 1 Randomized, Double -Blind, 
Placebo -Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a 
Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK -1654 in Healthy Adult s. 
Clin Pharmacol Drug Dev . 2020 Oct 30. doi: 10.1002/cpdd.883. Epub ahead of print. PMID: 
33125189.  
Brady M, Byington C, Davies H, et al. Updated Guidance for Palivizumab Prophylaxis Among 
Infants and Young Children at Increased Risk of Hospitalization fo r Respiratory Syncytial Virus 
Infection. Pediatrics . 2014; 134(2):415 -20. 
Clinicaltrials.gov NCT No. 03979313. A Study to Evaluate the Safety and Efficacy of 
MEDI8897 for The Prevention of Medically -Attended RSV LRTI in Healthy Late Preterm and 
Term Infants  (MELODY). June 2019.  
Clinicaltrials.gov NCT No. 03959488. A Study to Evaluate the Safety of MEDI8897 for The 
Prevention of Medically -Attended RSV Lower Respiratory Tract Infection (LRTI) in High -Risk 
Children. May 2019.  
Domachowske J, Khan AA, Esser M, et  al. Safety, Tolerability and Pharmacokinetics of 
MEDI8897, an Extended Half -life Single -dose Respiratory Syncytial Virus Prefusion F -targeting 
Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr Infect 
Dis J. 2018;37:886 –892. 
Food and Drug Administration (FDA) 2020. FDA Guidance on Conduct of Clinical Trials of 
Medical Products during COVID -19 Pandemic Guidance for Industry, Investigators, and 
Institutional Review Boards.  
FDA CDER (U.S. Department of Health and Human Servi ces Food and Drug Administration, 
Center for Drug Evaluation and Research). Guidance for Industry: Estimating the Maximum 
Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. July 
2005.  
FDA Guidance for In dustry: Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. September 2007  
Feltes T, Sondheimer H, Tulloh R, et al. A Randomized Controlled Trial of Motavizumab Versus 
Palivizumab for the Proph ylaxis of Serious Respiratory Syncytial Virus Disease in Children with 
Hemodynamically Significant Congenital Heart Disease. Pediatric Research.  2011:70(2):186 -91. 
Griffin MP, Khan AA, Esser M, et al. Safety, Tolerability, and Pharmacokinetics of MEDI8897,  
the Respiratory Syncytial Virus Prefusion F -Targeting Monoclonal Antibody with an Extended 
Half-Life, in Healthy Adults. Antimicrob Agents Chemother . 2017;61(3)e017:14 -16. 
Griffin P, Yuan Y, Takas T, Domachowske J, et al. Single -Dose Nirsevimab for Preven tion of 
RSV in Preterm Infants. NEJM . 2020;383(5):415 -25. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   81 
CONFIDENTIAL    Hansel T, Kropshofer H, Singer T, et al. The safety and Side Effects of Monoclonal Antibodies. 
Nat Rev Drug Discov . 2010; 9(4):325 -38. 
Higgins D, Trujillo C, Keech C. Advances in RSV Vaccine Research  and Development – A 
Global Agenda. Vaccine . 2016;34:2870 -75. 
Madhi S, Polack F, Piedra P, et al. Respiratory Syncytial Virus Vaccination during Pregnancy 
and Effects in Infants. N Engl J Med.  2020;383:426 -39. 
Obando -Pacheco P, Justicia -Grande A, Rivero -Calle I, et al. Respiratory Syncytial Virus 
Seasonality: A Global Overview. Clin Inf Dis.  2018:217:1356 -64. 
Robbie G, Criste R, Dall’Acqua W, et al. A Novel Investigational Fc -Modified Humanized 
Monoclonal Antibody, Motavizumab -YTE, Has an Extended Half -Life in Healthy Adults. 
Antimicrobial Agents and Chemotherapy.  2013;57(12):6147 –6153.  
Rouha H, Badarau A, Mirkina I, et al. Characterization of highly potent human monoclonal 
antibodies targeting different antigenic sites on the prefusion RSV -F protein. RSV 20 18. 11th 
International Respiratory Syncytial Virus Symposium; Ashville NC.  
Scheltema N, Gentile A, Lucion F, et al. Global Respiratory Syncytial Virus -Associated 
Mortality in Young Children (RSV GOLD): A Retrospective Case Series. Lancet Glob Health.  
2017; 5:e984 –91. 
Shi T, McAllister DA, O'Brien KL, et al. Global, Regional, and National Disease Burden 
Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young 
Children in 2015: A Systematic Review and Modelling Study. The Lan cet. 
2017;390(10098):P946 -958. 
Simões E, Forleo -Neto E, Geba G, et al. Suptavumab for the Prevention of Medically Attended 
Respiratory Syncytial Virus Infection in Preterm Infants. Clin Infect Dis. Published online 08 
Sept 2020.p1 -9. https://academic.oup.c om/cid/advance -article/doi/10.1093/cid/ciaa951/5902774.  
Vogel WH. Infusion Reactions: Diagnosis, Assessment, And Management. Clinical J Oncology 
Nursing.  2010 ;14(2): E10 -21. 
U.S. Department of Health and Human Services (US HHS), Common Terminology Criteria  for 
Adverse Events (CTCAE) Version 5.0. November 27, 2017.  
Zhu Q, McLellan J, Kallewaard N, Ulbrandt N, et al. A Highly Potent Extended Half -Life 
Antibody as a Potential RSV Vaccine Surrogate for All Infants. Sci Transl Med. 
2017;9(388):eaaj1928.  
Zhu Q, L u B, McTamney P, et al. Prevalence and Significance of Substitutions in The Fusion 
Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape from Antibody 
MEDI8897. J. Infect. Dis. 2018; 218:572 –80. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   82 
CONFIDENTIAL    12. Protocol Version History  
The Protocol Version updates and amendment summary of changes is provided below.  
• Version 1, dated 26 May 2021  
• Version 1.1, dated 09 June 2021  
• Version 2.0, dated 20 July 2021  
• Version 3.0, dated 10 December 2021  
• Version 4.0, dated 21 January 2022  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   83 
CONFIDENTIAL    Version 1.1, dated 09 June 2021  
Rationale for changes to  V1: The update from Version 1 to Version 1.1 was made prior to study start 
and prior to IRB approval, and was issued as a response to a preliminary review by the IRB, and internal 
reviews of supporting documents. For this reason, the update was not consid ered as a protocol 
amendment.  
• Section 5.1 Inclusion Criteria; recommendation: Since the apparent terminal half -life of the 
drug in monkeys is around 20 days, the Board recommends ensuring male contraception is 
used for duration of the study (5 months) to s urpass the 5x t1/2 time window.  
text added: For male participants who have a female partner of childbearing potential or a 
pregnant partner: condom use for the duration of the study period (approximately 5 months).  
• Section 5.4 Screen Failures; edited as fo llows:  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomized to entered into the study and do not receive  study 
intervention /entered in the study.  A minimal set of screen failure in formation is required to 
ensure transparent reporting of screen failure  criteria for participants who are screen failures in 
order  to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regul atory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria not met , and any SAE.  
Screening assessments can be done at any time during the screening interval, window (Day -30 to 
Day -2; SoA, Section 1.3),  except for the written informed consent, which must be completed 
prior to any screening procedure.  
Re-screening is only permitted under one or more of  the following conditions:  
• If a participant presents with an acute illness on the  day of first planned  study 
intervention, e.g., elevated temperature, acute respiratory or gastrointestinal illness, or 
urinary tract infection (UTI), and meets all other inclusion/exclusion  eligibility  criteria 
and can be rescreened within the originally defined screening window (SoA, Section 1.3).  
• When If there are technical difficulties with phlebotomy at screening (e.g., laboratory 
reports hemolyzed blood), technical error in running the laboratory tests or an abnormal 
urine analysis due to menstruation or UTI, and the participant can  be rescreened within 
the originally defined screening window (SoA, Section 1.3).  
• If a participant is undergoing  screening period and the study reaches a pausing rule. The 
participant may rescreen re-screen when and if the IDMC provides approval to restart 
recommends, and the Sponsor determines, that the  study may continue . 
Repeat screening procedures may be performed as long as they are completed within the 
screening window. Rescreened participants should be assigned the same participant number as 
for the i nitial screening.  
 
• Section 7.2 Participant discontinuation or withdrawal.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   84 
CONFIDENTIAL    Text added to be in line with changes made to ICF. If the participant leaves the study, the 
participant’s medical information will still be used or shared to the extent allowed by la w. Any 
leftover samples will be destroyed after testing is completed unless the participant withdraws 
consent to sample use, in which case the samples will be destroyed at that time. Any test results 
from the samples collected before withdrawal can  still b e included in the analyses.  
Text regarding diary cards and memory aids was clarified as requested by the IRB. Edits are 
shown below (new text= bold italics and old text= strike -through)  
• Section 8.1.9 Diary card and Memory aid, edited as follows:  
Diary Card  
Before leaving the clinic after dosing (Dose Escalation Phase, on Day 3 and Expansion Phase on 
Day 1 or Day 2 depending on whether completion of the participant is kept overnight), post-
dosing on -site confinement , participants will be given a diary card and receive guidance on how 
to fill in the card. All participants will receive a digital thermometer to record temperature . 
Participants who receive an IM dose  will also receive a digital thermometer, mirror, and a  ruler 
to measure diameter of redness and/or swelling at the injection site, if present.  
The diary card will be used by the study participants to record the duration, and intensity (refer to 
Section 8.2.3.1) of solicited local injection site  AEs (for parti cipants who receive an  IM doses 
only) dose) , and solicited systemic AEs up to Day 7 following injection / or infusion. Unsolicited 
AEs will also  for all participants. This information should  be recorded if any occur during up to 
in the participant diary car d at approximately the same time each evening, through  Day 7 , 
including any local reactions reported after Day 7. The site staff will record duration and 
intensity of solicited local AEs (IM doses only) and solicited AEs while the participant is under 
confinement. This documentation of this information should be collected at approximately the 
same time each evening up to Day 7.  
Memory aid  
A memory aid will be distributed to the participant on the Day 8 visit and at each subsequent 
visit through Day 121 for Dose Escalation Phase cohorts and through Day 91 for the Expansion 
Phase cohort. Participants will be instructed to record unsolicited AEs whenever they occur,  
using the aid. The memory aids will be collected and reviewed with site staff at each subsequent  
visit through the end of the study.  
• Section 8.2 Adverse Events and Serious Adverse Events  
Site staff will document the local in the study source during the confinement for all cohorts. 
The site staff will record solicited  injecti on site AEs (IM doses only) and solicited  systemic 
solicited AEs in the study source on Day  1AEs (all participants), including duration and 2 for 
Cohort 2 and the systemic solicited AEs in t he study source on Day 1 and 2 intensity, during 
confinemen t. Refer to Sect ion 8.1.9  for Cohorts 1, 3, and 4. Site staff will document the local 
injection site and systemic solicited AEs in the study source on Day 1 for Cohort 5 if the 
participant is confined from Day 1 to Da y 2. Participants will record their information on a to be 
recorded in the  diary card (starting on Day 3 for the Dose Escalation Phase and on Day 1 in the 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   85 
CONFIDENTIAL    Expansion Ph ase or Day 2 if the participant is confined overnight) and will return the diary card 
to the site on Day 8.  by participants, through Day 7.  
Unsolicited AEs including AESIs, SAEs, and safety laboratory parameters Grade 1 and above 
will be collected from scr eening through Day 151 and recorded in the AE log by the study team.  
• Section 8.2.6 Safety Review Team  
Edits made during review of the SRT plan. Members changed to 4 and added AESIs in text to be 
consistent with other text.  
An ad hoc SRT meeting will occur immediately if any Grade 3 or higher AE, or SAE, or AESI, 
is reported, regardless of relationship to the study intervention. If the event is determined to be 
study intervention -related, the IDMC review will be triggered, and pausing will occur with 
enrollm ent and further dosing, until after the IDMC review.  
The SRT will consist of a panel of at least 34 members, including the Gates MRI study physician  
clinical lead , a the Gates MRI pharmacovigilance physician  safety  lead, the study Medical 
Monitor , and the site principal investigator. The SRT members are part of the study team and 
will review blinded safety data.  
• Section 8.8 Biomarkers  
Text removed: Samples collected during this clinical study may be transferred to a biobank and 
used for exploratory research  outside the clinical protocol as described in the ICF. Transfer to the 
biobank will be documented and any testing of coded biobank samples will not be reported in the 
CSR.  
• Section 10.1.4 and 10.1.14.1  
 Informed Consent and Process, deleted text that no longer applies to the study  
Removed text that is no longer applicable:  The ICF will contain a separate section that addresses 
the use of remaining mandatory samples for optional exploratory research. The investigator or 
authorized designee will explain to each participant the objectives of the exploratory research. 
Participants will be told that they are free to refuse to participate and may withdraw their consent 
at any time and for any reason during the storage period. A separate signature will be required to 
document a participant's agreement to allow any remaining specimens to be used for exploratory 
research. Participants who decline to participate in this optional research will not provide this 
separa te signature. Refer to ( section deleted ) for sample retention.  
The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for research not described in the protocol, e.g., assay development and assay quality control. A 
separate signature will be required to document a participant's agreement to allow any remaining 
specimens to be used for research not described in the protocol.  
Samples collected for storage for exploratory endpoint testing are included in the protocol and 
are not optional. However, consent for storage and testing of samples for research not described 
in the protocol  is optional, and if not signed, would not exclude the participant from the study.  
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   86 
CONFIDENTIAL     
Version 2.0, dated 20 July 2021  
Rationale for c hanges to V1 : The update from Version 1.1 (v1.1) to Version 2 (v2), was 
prepared following FDA review and comments after IND submission. The major changes 
include the following:  
In response to FDA’s comment that all adverse events should be collected throu ghout the dosing 
and follow -up period irrespective of who is collecting and documenting the event (i.e., 
participant vs. study site staff) , the protocol was amended and text was aligned throughout.   All 
adverse events (both solicited and unsolicited) will be collected throughout the dosing and 
follow -up periods (up to Day 151 for all participants) irrespective of who is 
collecting/documenting the event.  
In response to the FDA’s comment to use the same standardized toxicity grading scale 
consistently throug hout entire protocol. The Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers enrolled in Preventive Vaccine Clinical Trials, September 2007 was 
referenced consistently throughout the protocol and added textual reference to CTCAE version 
5.0 for events not covered by the vaccine grading scales.  
The pausing rules and contraceptive requirements were modified as recommended by the FDA.  
Exclusion criteria were added for COVID -19 vaccine and for participants who previously 
received the study inte rvention in this study, based on Data Management and study team review 
regarding safety of the participant.  
Other changes were considered minor to improve readability and clarity.  
Complete List of Changes:  
Title page and footer and header : change v1.1 to v 2.0. 
Added a page for Document History (Page 2)  
Document History  
Document  Date  
Version 2.0  20 July 2021  
Original Protocol v1.1  09 June 2021  
 
Signature page:  added v2  
List of Abbreviations:  Added for RSMO1  to abbreviation for AUC, and of RSM01 to abbreviations for 
CD91, CD151, Cmax, Cmin and Tmax, deleted AKA for AUC, added NCT National (U.S.) Clinical Trial  
 
Synopsis:  
Dose Escalation Phase:  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   87 
CONFIDENTIAL    After the sentinel participant in each Dose Escalation Phase  cohort receives RSM01, the next 
participant can  be dosed 24 hours later, if there is no safety concern. After the 24 -hour post -dose 
period for the sentinel participant  in each cohort  On any given day, individual  participants in 
the Dose Escalation Phase cohorts should be dosed at least 2 hours apart re gardless of route 
mode of administration (IM or IV). The ≥2-hour interval between administering IV infusions is 
to begin at the end of the previous infusion. For participants receiving the IM dose of study drug 
in Cohort 2, the ≥2-hour interval between adm inistering IM injections to successive participants 
is to begin at the time of the previous participant’s IM injection. If RSM01 is administered using 
2 injections, the ≥2-hour interval begins at the time of the second injection.  
Each dose escalation step will proceed after all participants in  the prior cohort have s completed 
Day 15, and the Safety Review Team (SRT) has reviewed the data and determined that a 
pausing rule has not been met. there are no events  necessitating a pause.  
Dose Expansion Phase : 
Enrollment in the Dose Expansion Phase cohort (Cohort 5) will begin after Day 15 for all 
participants in Cohort 4, and after the SRT has reviewed the data and determined that a pausing 
rule has not been met.  no pausing event has occurred  Cohort 5  will include  28 participants 
randomized 6:1.  
Theose predictions suggest s that the concentration of RSM01 will be above the efficacy 
threshold (EC90) on Day 151 following a RSM01dose of 300 or 600 mg IM.  
Synopsis  
Pausing Rules : Pausing rules include:  
Pausing rules ( reasons for pausing the study) are in effect during the active enrollment and 
dosing period. Any one of the following will prompt a study pause:  
• death in any participant in whom the event causing death is judged to be related to the 
study drug by the inves tigator.  
• any occurrence in any participant of a SAE judged to be related by the investigator.  
• any occurrence in any participant of an AESI (anaphylaxis, hypersensitivity reaction, 
and/or infusion reaction resulting in permanent discontinuation of study dru g infusion 
during IV administration).  
• any occurrence of Grade 3 or higher toxicity assessed to be related to the study drug by 
the investigator.  
• any occurrence of a clinically significant Grade 3 or higher laboratory abnormality 
assessed to be related to t he study drug by the investigator.  
If any of the pausing criteria are met, enrollment/patient accrual as well as dosing of enrolled 
participants will be suspended pending IDMC’s review of all available safety data and the U.S. 
Food and Drug administration (FDA) will be notified in an expedited manner.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   88 
CONFIDENTIAL    • at least 1 participant with a Grade 3 or higher AE (other than solicited AEs), considered 
related to the study intervention,  
• at least 1 participant with a SAE that is considered related to the study intervent ion 
• at least 1 participant with an AESI (AESIs include anaphylaxis, hypersensitivity reaction, 
and infusion reactions resulting in permanent discontinuation of the study intervention 
infusion during IV administration).  
If a pausing rule is met, this will t rigger a pause in enrollment and any dosing of participants, and 
an IDMC review of safety data will be conducted  
IDMC:  added: See Section 8.2.7.  
Safety Review Team: Meetings to decide on proceeding to each subsequent Dose Escalation  
Phase  cohort will occur  when all participants in  the current cohort complete s Day 15. The SRT 
will also meet approximately every 8 weeks during the Dose Expansion Phase (See Section 
8.2.6).  The SRT will also receive an alert for any Grade 3 or higher AE or SAE and will 
determine  if the AE/SAE is related to study intervention in order to trigger an IDMC review.  
Visits:  The participants in the Dose Expansion Phase cohort will remain at the clinic for at least 
4 hours after dosing on Day 1, and possibly for the night of Day 1 , based  on investigator 
decision.  
Blood Sampling : Dose Escalation Phase cohorts: On Day 1, PK blood draw will occur pre -
dosing 1 hour  (+/- 30 minutes before administration of IM injection or beginning of infusion),  
at within  5 minutes (± 1 minute) after en d of infusion for IV dosing only, and at 8 -hours (±0.5 
hour) and 24 -hours (±1 hour) after end of infusion for IV doses and at 8 -hours (±0.5 hour) and 
24-hours (±1 hour) after IM dose  and at 8 hours post dose for both the IV and IM dosing  ADA 
and RSV neutra lizing antibody activity samples will be obtained  pre-dose only (+/- 30 minutes) 
before administration of IM injection or beginning of infusion  
Dose Expansion Phase cohort: On Day 1, the blood collection for PK, ADA and RSV 
neutralizing antibody activity w ill occur pre -dosing only 1 hour  (+/- 30 minutes)  before 
administration of IM injection.  
Masking: Participants and all study personnel will be blinded to the randomization, with one 
exception: the first sentinel participant in each Dose Escalation Phase co hort will be single -
blinded (participant -blinded) and will receive the respective dose of RSM01. Authorized study 
site personnel will administer doses  
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Figure 1 :Removed tag for Day 15 Coho1i 5 visit then and moved a1Tow for interim analy sis to 
appear below Coho1i 4 instead of below Coho1 i 5. Removed ve1iical line at Day 91 for interim 
analysis and adde d a diago nal line and removed ve1iical line from Day 151 and added a diagonal 
old version 
lllifft- '•0 ----• • ".,._...,.. •m 
Sllfre-.iew 
ow 
HiiU.¥41 -· -
new vers10 n 
i 
01 
""""'' 8,rt-.vN"r .l001"'1£ and 60C r-,g "I 1 6 .I 
primary analysis 
Schedule of Activitie s (SoA) 
Table 2: Schedule of Activities for the Dose Escalation Phase (Cohorts 1-4) 
Added distribut e mem o1 y a id to V3 and V 4 and collect mem o1 y a id to V 4 and VS for Table 2 
and distribute to Vl and collect to V8 for Table 3 
Table 2: Schedule of Activities for the Dose Escalatio n Phase (Coho1is 1-4) 
Visits Sere 
en 
Distribute mem o1y aid 
Collect mem ory a id 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL Pre V1 
Vl V2 V3 V4 vs 
X X X 
X X 
89 
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Table 3: Schedule of Activities for the Expansion Phase (Cohort 5) 
Visits Screen Pre-Vt Vl V2 
Distribute memo1 y aid X X 
Collect memory aid X 
Adde d an X for pregnan cy test and vital signs, for discontinuati on vis it for both Table 2 and 
Table 3 
Visits Discon 
Studv Dav and Visit window davs ( d) Visit 
Activities: 
Sennn pregna ncy test2 X 
Vital siims X 
Table 2 F ootnote 8: Blood samples for PK assess ments on Day 1 (Visi t 1) will be drawn at pre-
dosing J hour( +/-30 minute s) before admini stration of IM injection or beginning of infusion, 
after end of infusion for IV doses and at 8-hour s (±0.5 hour) and 24-hour s (±1 hour) after IM 
doses past dase fer eatli IV aad IM dases 
ADA and RSV neutralizing antib ody on D ay 1 (Visit 1) w ill be draw n pre-dose only 1 hour (+l-30 
minute s) before admini stration of IM 
Table 3 F ootnote 7: Blood samples for PK, ADA and RSV neutralizin g antibody at Day 1 will be 
drawn at pre- dose only 1 hour (+/-30 minute s) before admini stration of IM 
Section 2.1 RSV and Burden of Disease 
RSV is the m ost common pa thogen identified in young children with acu te LRTI. Most childr en 
acquire~ an R SV infection by the time they are 2 years old, causing a mild, cold-like illness 
within 4 to 6 days after infection. Howeve r, in some c hildren it l eads to a more severe illness 
such as bronchiolitis and,lpneumonia and may also increase theif risk of deve loping subsequent 
asthma and/or recunent wh eezing episodes in early childh ood. 
Section 2.3 RSM01 mAb Candidate 
RSM0l(also designated as alffi.ADI-1 5618-IVNS YTE ) 
Section 2.3.1 Non-Clinical Development of RSM01 
In summ ary, there were no test-aiiicle related target org an,s....ef toxicities~, no effects on vi tal 
systems, 
Section 2.5.1 Edited text: 
The.e se projections sugges t that following aa RSM0l doses ~300 mg is predieted the R SM0 l 
concentration is predicted to be ab ove the tai·get EC90 threshold at Day 151. 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 90 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   91 
CONFIDENTIAL    Section 2.5.2: Edited text:  
Final selection of the dose to be administered to Cohort 5 will be made by the sponsor and 
informed by available RSM01 PK data, as well as r elevant safety data, from the Dose Escalation 
Phase.  
Available interim Any available PK data from  the Dose Escalation Phase cohorts  from earlier 
s, combined with published data from previous studies of monoclonal antibodies, will be used 
to develop a popul ation PK model to describe the individual concentration  time profiles  of 
RSM01. Subsequently, the model will be used in a simulation mode to predict the proportion of 
participants that are expected to  have RSM01 concentrations be above the EC90 on Day 151 . 
The tentatively determined dose to be tested in the Dose  Expansion Phase cohort is between 
≥300 mg and ≤600 mg IM , based on…  
Section 2.6 Benefit/Risk Assessment  
However, it is we expect ed that RSM01 will have a similar benefit/risk profile to nirsevimab.  
A Phase 1 FiH study in adults in the U.S. evaluated a single dose of nirsevimab or Placebo 
administered as an IV dose of 300mg, 1000mg, or 3000mg or as an IM dose of 100mg or 300mg 
[Griffin, 2017] and did not have any study discontinuations due to AEs or S AEs.  The most 
frequently reported nirsevimab -related AEs were headaches (all mild), occurring in 3 (2.9%) 
participants.  
There were no anaphylaxis or other notable hypersensitivity reactions. In the nirsevimab  group, 4 
infants experienced  cases  reported  rash. One infant experienced  case reported  one day of 
petechiae occurring 4 months after nirsevimab , which was not assessed by a health care provider. 
All 3 AESI infants  cases in the Placebo group had rash.  
In the nirsevimab  Phase 1b/2a infant trial : none  no one  had ADA at baseline and only the mAb 
group…  
The Phase 1 MK-1654 study randomized 152 healthy adults in a at 3:1 ratio  
RSV Mutations  
Escape mutant selection studies with RSM01  were performed…  
… have largely comparable neutralization potency based on  in vitro and in vivo virus 
neutralization assays…  
In vitro cell -based neutralization studies showed that RSM01 performed better than other RSV 
monoclonal antibodies  palivizumab  
General Risks with MAb Infusion  
Administration of any mAb may carry a risk of immune reactions such as acute anaphylaxis, 
serum sickness and the generation of antibodies against the mAb .; hHowever, these reactions are 
…. In this regard, as RSM01 is targeted to a viral antigen, and is a fully human mAb (IgG1), and 
it is expected to h ave …  
Section 4.1 Study Design Overview  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   92 
CONFIDENTIAL    Dose Escalation Phase, continued:  
After the 24 -hour post -dose period for the sentinel participant in each Dose Escalation Phase  
cohort,  On any given day, each  participant s in the Dose Escalation Phase cohorts should be 
dosed at least 2 hours apart regardless of route mode  of… 
Each dose escalation step will proceed after all participants  in the prior cohort ha ves completed 
Day 15, and the SRT has reviewed the data and determ ined that a pausing rule has not been met 
that no pausing event has occurred  that no pausing event has occurred.  
Dose Expansion Phase : 
Enrollment in the Dose Expansion Phase (Cohort 5) will begin after Day 15 for participants in 
Cohort 4, and after the SRT  has reviewed the data and determined that a pausing rule has not 
been met.  
Those predictions …  
Section 5.1 Inclusion Criteria: (inclusive ) 
Sex 
4. Both males and females are eligible to participate.  
Male participants with partners of childbearing potential  must agree to use condoms 
during their participation in the study and for 90 days after the participant completes the 
study. Male participants must also agree to refrain from sperm donation for at least 90 
days after they complete the study.  
Female partic ipants of childbearing potential must not be pregnant, breastfeeding, or 
attempting to become pregnant for 28 days before Screening and throughout the duration 
of their participation in the study. These participants must have a negative serum 
pregnancy tes t at Screening in order to be eligible for randomization and treatment with 
study intervention. In addition, female participants must be willing to commit to using a 
consistent and acceptable method of contraception for the duration of their participation 
in the study and for 90 days after they complete the study if they engage in intercourse. 
Acceptable methods of contraception are:  
• Consistent use of systemic contraception, including birth control pills, transdermal 
patch, vaginal ring, implants, and injec tables.  
• Consistent use of double barrier method, e.g., condoms, cervical cap, diaphragm, 
vaginal contraceptive film with spermicide.  
• Use of intrauterine device with a low failure rate (defined as < 1% risk of pregnancy 
per year)  
• Monogamous intercourse with  a vasectomized man or has only same -sex partners.  
Female participants who are not sexually active but become so during the study must 
agree to follow the contraceptive requirements above.  
Female participants who are not of childbearing potential must meet  at least one of the 
following criteria:  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   93 
CONFIDENTIAL    • At least 1 year since the last menstrual period.  
• Surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, or 
hysterectomy)  
• Congenitally sterile  
• Diagnosed as infertile and not undergoing treatment to reverse infertility.  
For female participants: not pregnant and agree to avoid pregnancy throughout the study. For 
male participants who have a female partner of childbearing potential or a pregnant partner: 
condom use for the duration of the study perio d (approximately 5 months).  
Women physically capable of pregnancy must agree to use an acceptable method of avoiding 
pregnancy during the study. Acceptable methods of avoiding pregnancy include sexual 
abstinence (not engaging in sexual intercourse), a conf irmed sterile partner, or at least 2 
contraception methods from the following list: male or female condom, diaphragm, 
intrauterine devices (IUDs), hormonal contraceptive (oral, injection, transdermal patch, or 
implant). Adequate contraception does not appl y to participants of childbearing potential 
with same sex partners, when this is their preferred and usual lifestyle.  
Additional Requirements: Participants must who …  
Section 4.2 End of Study Definition  
The end of the study is defined as the date of the la st visit of the last participant in the study or 
conduct of the  last scheduled procedure shown in the SoA for the last participant in the trial.  
Section 5.2 Exclusion Criteria: restarted numbering at 1 (previously started at 7) and 
renumbered after adding new criteria.  
Prior Concomitant Therapy: added the following criterion  
Added 7. Having received any vaccination (including COVID -19 vaccine) within the 15 days 
before Day 1, or planning to receive a dose of any vaccine during the 15 -day period following 
Day 1.  
Prior/Concurrent Clinical Study Experience  
Added:  13. Previously having participated and received study intervention in the current study.  
 
 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   94 
CONFIDENTIAL    Section 6. Study Intervention  
Table 5  
Dosage, Volume  and 
Route of 
Administration  300mg (53mL ) (50mL) per IV 
infusion  
1000mg (60mL)  (50mL) per IV 
infusion  
3000mg (130mL)  (100mL) per  IV 
infusion  
300mg (3mL)  IM injection (1 
injection of 3mL  in the anterolateral 
thigh muscle)  Same volume and number of 
infusions/injections as the 
RSM01 group.  
 Dose  Expansion Phase Cohort  
 
Section 6.1 RSM01 Drug Product  
Deleted Vials with visible particles at the end of the thaw procedure should not be used.  Refer to 
Pharmacy manual for details.  
Section 6.2 Placebo Drug Product  
Each vial contains an isotonic, sterile solution that is a colorless to yellow liquid, essentially 
free of visible particles; some opaque or translucent particles may be present. Refer to 
Pharmacy manual for details.  
Section 6.3 Study Intervention Preparation and Administration  
For the Dose Escalation Phase, the first (sentinel) participant undergoing study intervention 
administration in each cohort will receive  be in the  RSM01 arm. The next participant in each 
cohort can be dosed at least 24 hours after the sentinel participant.  After the 24 -hour post -dose 
period for the sentinel participant in each Dose Escalation Phase cohort On any given day,  
participants in the Dose Escalation Phase only should be dosed at least 2 hours apart regardless 
of route mode of administration (IM or IV). The ≥2-hour wait time between IV infusions is to 
begin at the end of the previous participant’s  infusion. The ≥2-hour wait time between IM 
injections is to begin at the time of the previous participant’s IM injection.  
Section 6.3.1 IM Injection  
For IM  dosing in the Dose Escalation Phase, participants in Cohort 2  the 300mg Cohort  will…  
The Dose Expansion Phase cohort may receive RSM01 ( ≥300mg to ≤ 600mg)  or Placebo  up to 
600mg IM of RSM01 in the anterolateral thigh muscle. If more than 3 mL of study intervention  
300mg is administered in a single dose, the volume and number of injections will be adapted…  
Section 6.3.2 IV Infusion  
The total IV infusion volume will be 53mL for Cohort 1, 60 mL for Cohort 3, and 130mL for 
Cohort 4. 50mL for the 300mg cohor t and the 1,000mg cohort, and 100mL for the 3,000mg 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   95 
CONFIDENTIAL    cohort  The IV infusion time will be approximately 2 hours or less depending on the cohort. The 
≥2-hour wait time between administration of IV infusions to successive participants is to begin at 
the end of  the previous participant’s  infusion.  
Section 6.4. Handling/Storage/Accountability  
The study intervention (RSM01 and and Placebo) must be stored at 2°C to 8°C in a secure d 
location with no access for unauthorized personnel.  
At the end of the study,  u Unused supplies will be destroyed…  
Section 6.5.1.  Randomization  
The remaining 6 participants in each Dose Escalation  Phase cohort (Cohorts 1, 2, 3 and 4) will 
be…  
Section 6.5.2 Masking  
Deleted duplicate text  The first sentinel participant in each of the Dose Es calation Phase cohorts 
will each receive the respective dose of RSM01 in a single blind fashion: participants will be 
observer blind (the study personnel will know their study assignment).  
Section 6.7 Concomitant Therapy  
anti-inflammatory drug s and , antipyretic drug, or…  
A COVID -19 vaccination may be received by a participant during the study but not within the 
15 days immediately following administration of the study intervention.  Note that any planned 
COVID 19 vaccination may be given, but it is re commended to defer vaccination until at least 7 
days following study intervention administration  
Section 6.8 Dose Modification  
This is a dose escalation and dose expansion study. Refer to Section 3 for details regarding dose 
escalation and dose expansion  
Section 7.1.1. Pausing Rules  
Pausing rules (reasons for pausing the study) are in effect during the active enrollment and 
dosing period. Any one of the following will prompt a study pause:  
• death in any participant in whom the event causing death is judged to be related to the 
study drug by the investigator.  
• any occurrence in any participant of a SAE judged to be related by the investigator.  
• any occurrence in any partici pant of an AESI (anaphylaxis, hypersensitivity reaction, 
and/or infusion reaction resulting in permanent discontinuation of study drug infusion 
during IV administration).  
• any occurrence of Grade 3 or higher toxicity assessed to be related to the study drug  by 
the investigator.  
• any occurrence of a clinically significant Grade 3 or higher laboratory abnormality 
assessed to be related to the study drug by the investigator.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   96 
CONFIDENTIAL    If any of the pausing criteria are met, enrollment/patient accrual as well as dosing of enrolled 
participants will be suspended pending IDMC’s review of all available safety data and the U.S. 
FDA will be notified in an expedited manner.  
Refer to Section 8.2.6 for the role of SRT and Section 8.2.7 for the role of the IDMC.  
If the investigator and/or the SRT observes that a pausing rule is met, the investigator will 
inform the sponsor and/or the SRT as soon as possible and within 24 hours of the observation. 
The SRT and/or sponsor will notify the investigator and the IDMC mem bers of the pause in 
enrollment and participant dosing as soon as possible and within 24 hours of receiving 
notification of the pausing rule being met.  
When a pausing rule is met, the IDMC members will convene an urgent ad hoc review 
meeting, review all re levant unblinded safety data, and make a recommendation to the 
sponsor. The FDA will be advised of the IDMC actions and recommendations.  
The IDMC may recommend continuation of the study pause or resumption of enrollment and 
dosing with or without changes t o the protocol. The final decision to pause or resume study 
activities will always be the responsibility of the sponsor. All IDMC recommendations will be 
stored according to the IDMC Charter.  
All sponsor decisions will be documented in a memorandum to the study file. The sponsor or 
delegate is responsible for prompt communication to the study site of decisions related to 
pausing or resuming the study activities, including notification to the investigator, relevant 
IRBs/IECs and regulatory authorities.  
The c linical site will be allowed to resume activities only upon receipt of written notification 
from the sponsor.  
If an investigator observes that a pausing rule is met , the investigator will inform the sponsor or 
delegate as soon as possible and within 24 hou rs of the observation. The sponsor or delegate will 
notify the investigator and the IDMC members of the pause in enrollment and participant dosing 
as soon as possible and within 24 hours of receiving notification of the condition being met.  
The IDMC member s will review all relevant safety data, convene an urgent ad hoc review 
meeting and make a recommendation to the sponsor with regards to maintaining the pause or 
resuming enrollment/participant dosing.  
If the SRT observes that a pausing rule is met , the SRT will inform the sponsor and the IDMC 
as soon as possible and within 24 hours of the identification of the condition being met.  
The SRT will notify the study investigator of the pause in enrollment and dosing as soon as 
possible and within 24 hours of t he observation.  
If the sponsor or delegate observes that a pausing rule is met , the sponsor will notify the study 
investigator and the IDMC of the pause in enrollment and dosing as soon as possible and within 
24 hours. The IDMC will review all relevant saf ety data, convene an urgent ad hoc review 
meeting and make a recommendation to the sponsor with regards to lifting or maintaining the 
pause in enrollment/participant dosing.  
The IDMC may recommend resumption of enrollment and dosing with or without changes  to the 
protocol. The final decision to pause or resume study activities will always be the responsibility 
of the sponsor. All IDMC recommendations will be stored according to the IDMC Charter.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   97 
CONFIDENTIAL    All sponsor decisions will be documented in a memorandum to th e study file. The sponsor or 
delegate is responsible for prompt communication to all relevant study sites of decisions related 
to pausing or resuming the study activities, including notification to the investigator, relevant 
IRBs/IECs and regulatory author ities.  
The clinical sites will be allowed to resume activities only upon receipt of written notification 
from the sponsor.  
 Section 7.2 Participant Discontinuation or Withdrawal from the Study  
At this visit, topics around participant safety as well as the use of already collected biospecimens 
will be discussed, and the procedures and specimen collection  indicated in the SoA…  
A participant who becomes pregnant during the study period will be asked to complete all 
visits and procedures through Day 151 as desc ribed in Table 2 or Table 3, as applicable. After 
she completes Day 151, or in the event that she voluntarily withdraws from the study and 
agrees to provide additional information regarding the pregnancy, the investigator will utilize 
the ‘Pregnancy Outcom e Form’ during the remaining gestation period to collect information 
on the health of the participant, the outcome of the pregnancy, and the health of the neonate. 
Neonate follow -up will occur for 6 weeks beyond the estimated delivery date (refer to Sectio n 
10.3).  
Neonate follow -up will occur for 6 weeks beyond the estimated delivery date (refer to 
Section10.3).  
A participant who becomes pregnant will be followed for safety as described in the protocol, 
without any of the protocol required blood draws. She will be followed up during the gestation 
period and after the delivery to collect information on the health of the participant and the 
newborn. The results of the outcome of pregnancy will be captured in a ‘Pregnancy Outcome 
Form’ and the sponsor will be n otified.  
 
Section 7.4 COVID -19 Contingency Plans  
Assure changed to ensure 3 times  
At the study sites  study site  
Section 8. Study Assessments and Procedures  
described in Section s 5.1 and Section  5.2, respectively . 
Section 8.1 Safety Assessments  
All Day 1 safety assessments and sample collections are prior to administration of  study 
intervention.  
Prior to opening each of Cohorts 2, 3, and 4 to enrollment, the SRT will conduct safety 
assessment of data for the previous cohort collected for all part icipants  through Day 15,  
Section 8.1.1 Confinement Period and Sentinel Participants  
Participants in the Dose Escalation Phase will be confined at the study site after informed 
consent is signed,…  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   98 
CONFIDENTIAL    On Day -1, participants will undergo a serum pregnancy test,  safety laboratory assessments and 
other screening procedures  
The first participant in each of the Dose Escalation Phase cohorts will be a sentinel participant 
and will receive RSM01 at the respective dose of RSM01 in a participant -blind  an observer
blind fashion.  
The next participant in each cohort can be dosed at least 24 hours later ., if there is no safety 
concern.  
Dose Expansion Phase  
On this Day -1 visit,… participants will begin confinement, and undergo a serum pregnancy test,  
safety laboratory assessments and…  
Section 8.1.2  
Physical examination at screening will include, at a minimum, assessment of height and weight, 
body temperature, and resting vital signs (including percent oxygen saturation by pulse 
oximetry) ,… 
Section 8.1 .2.1 Vital Signs  
Vital sign measurements will be recorded for pulse rate, systolic and diastolic blood pressure, 
respiratory rate, and body temperature and percent oxygen saturation by fingertip pulse 
oximetry . 
Section 8.1.3 Focused Physical Examination an d Medications/Vaccinations  
A fFocused physical examinations, will be performed on Day 1 and all subsequent visits, as 
indicated in the SoA  if indicated by participant’s medical complaint and will include 
assessments of body systems involved in the complain t. Focused physical examinations will be 
symptom directed.  
Throughout the study, any concomitant medications taken, including antipyretics, and anti -
inflammatories, and vaccinations  will be recorded  
Section 8.1.4 Pregnancy Status Assessment  
A blood sample will be collected from female participants  at screening and at Day -1 for serum 
beta human chorionic gonadotropin (βHCG) testing.  
Serum βHCG testing of female participants  should be performed during the study if a pregnancy 
is suspected.  
Serum βHCG testing of female participants of childbearing potential should be performed at 
the discontinuation visit.  
A participant who becomes pregnant during the study period will be asked to complete all 
visits and procedures through Day 151 as described i n Table 2 or Table 3, as applicable. After 
she completes Day 151, or in the event that she voluntarily withdraws from the study and 
agrees to provide additional information regarding the pregnancy, the investigator will utilize 
the ‘Pregnancy Outcome Form’  during the remaining gestation period to collect information 
on the health of the participant, the outcome of the pregnancy, and the health of the neonate. 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   99 
CONFIDENTIAL    Neonate follow -up will occur for 6 weeks beyond the estimated delivery date (refer to Section 
10.3) . 
If a participant becomes pregnant during the study, she will be withdrawn from all study 
procedures going forward, i.e., blood draws and laboratory evaluations described in the SoA will 
not be performed once a participant is known to be pregnant.  However , she will be encouraged to 
continue in the study for safety follow up. 
Section 8.1.6  Electrocardiogram, Hepatitis Screening and Urine Drug Screening  
Triplicate (unmarked) 12 -lead ECGs will be obtained and averaged . For the Dose Escalation 
Phase, the ECGs will be taken at screening, and 24 hours post -dose, on Day 2. For the Dose  
Expansion Phase, the ECG s will be taken at screening.  
Section 8.1.7.  Clinical Safety Laboratory Assessments  
Clinical safety laboratory parameters that will be evaluated include:  
g. Hem atology: Complete blood count (hemoglobin, hematocrit, red blood cell count , 
platelet s count  and white blood cell s count ) and absolute counts for neutrophils, 
lymphocytes, eosinophils  and monocytes  
h. Serum chemistry: alanine aminotransferase (ALT), aspartate  aminotransferase (AST), 
alkaline phosphatase, total bilirubin, gamma glutamyl transferase (GGT), creatinine, blood 
urea nitrogen, lactate dehydrogenase (LDH),  and glucose, albumin, sodium, potassium, 
chloride, bicarbonate, and calcium  
The investigator mus t review the laboratory report, document th ise review  
Section 8.1.9  
Diary Card  
The diary card will be collected and reviewed by the investigator (or designee) on the Day 8 
Visit  
Memory Aid  
A memory aid will be utilized by participants to collect unsolicited AEs beginning at discharge 
from the clinic, through Day 151 (end of study participation). Participants will be instructed to 
record unsolicited AEs whenever they occur, recording such AEs on the memory aid.  
A memory aid will be distributed to t he participant on the Day 8 visit and at each subsequent 
visit through Day 121 for Dose Escalation Phase cohorts and through Day 91 for the Expansion 
Phase cohort. Participants will be instructed to record unsolicited AEs whenever they occur, 
using the aid . 
Section 8.2 Adverse Events and Serious Adverse Events  
Site staff will document any AEs  in the study  
Solicited AEs that continue beyond Day 7 will be captured in the unsolicited AEs memory…  
Immediate safety concerns should be discussed with the sponsor, and the SRT. The SRT will 
trigger an IDMC review if any pausing rule is met  event occurs  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   100 
CONFIDENTIAL    Clinical  Biochemistry and/or hematology results  findings  may also qualify as AEs (Section 
10.4, Appendi x 4). if the investigator considers them as such.  
However only the investigator or sub -investigator  study physician  is responsible for assessment, 
including assignment of causality and, for unsolicited AEs, the intensity, and for reporting and 
management o f all AEs. The investigator is responsible for following up all AEs regardless of 
their relatedness to study intervention or study procedures, or AEs that caused the participant to 
withdraw from  discontinue the study…  
Medical History/Current Medical Condit ions section of the CRF, not  in the AE section.  
Investigators are not obligated to actively seek AEs, SAEs or AESIs after a participant 
concludes  conclusion of  study participation. However, if the investigator learns of any SAE, 
including a death, at any t ime after a participant has been discharged from the study, and he/she 
considers the event to be related to the study intervention or study participation, the investigator 
must notify the sponsor or designee within the same  24 hours. timeline.  
Section 8.2. 3.1 AE Intensity  
The intensity of AEs will be class ified by the investigator based on the toxicity grading tables 
(Section 10.4 10.4 Appendix 4).  In the case of an AE or abnormal clinical laboratory result 
not included in Appendix 4, in tensity will be assigned using the Grades described in the U.S. 
Department of Health and Human Services, Common Terminology Criteria for Adverse 
Events, Version 5.0 [US HSS 2017]  (See Section 10.2.5.1.)  
Local solicited AEs will be rec orded on the diary card by the participant and graded and/or 
measured by the participant. An exception is that the study investigators will grade solicited 
AEs during the confinement period. Any participant -reported Grade 3 or higher adverse event 
will be assessed by the investigator.  
Unsolicited AEs will be classified by the investigator as mild (Grade 1, not inte rfering with 
normal daily activities), moderate (Grade 2, interfering with normal daily activities), severe 
(Grade 3, preventing normal daily activities) or potentially life threatening (Grade 4). Refer to 
Appendix 2, Section 10.2.5.1 and Section 10.4 for toxicity grading tables. Local solicited AEs 
will be recorded on the diary card by the participant and either graded and/or measured by the 
participant. An exception is that the study investigators will grade solicited AEs during the 
confinement period for  the Dose Escalation Phase.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   101 
CONFIDENTIAL    Section 8.2.3.2 AE Causality/Relationship to Study Intervention  
All AEs will be evaluated by the investigator or medically qualified designee (i.e., investigator, 
sub-investigator  study physician ) to assess characterize  the relationship between study 
intervention and  the AE…  
The causality will be assessed as either related…  
the Medical Monitor or and sponsor designee  
The sponsor or designee will never downgrade a case from serious to non -serious  or change the 
investigato r assessment of causality from related to not related.  
Any participant -reported Grade 3 or higher adverse event will be assessed by the investigator.  
Section 8.2.6 Safety Review Team  
Meetings of the SRT to decide on proceeding to each subsequent cohort wil l occur when all 
participants in the current cohort have completed Day 15. The SRT will also meet 
approximately every 8 weeks during the Dose Expansion Phase. The SRT will review all 
available blinded safety data collected at the time of the review to dete rmine whether or not 
any pausing event has occurred (See Section 7.1.1.). If a pausing event does not occur, dose 
escalation or moving to the Dose Expansion Phase cohort can occur.  
If a pausing rule is met, the SRT will ask the IDMC to conduct a review of unblinded safety 
data. The IDMC will make a recommendation to the sponsor regarding the further conduct of 
the study.  
Meetings to decide on proceeding to each subsequent cohort will occur when the current cohort 
completes Day 15. The SRT will review all av ailable safety data collected at the time of the 
review to determine whether or not any pausing event occurs that would trigger an IDMC 
review. If a pausing event does not occur, dose escalation or moving to the Dose Expansion 
Phase cohort can occur.  
An ad  hoc SRT meeting will occur immediately if any Grade 3 or higher AE, or SAE, or AESI, 
is reported, regardless of relationship to the study intervention. If the event is determined to be 
study intervention related, the IDMC review will be triggered, and pau sing will occur with 
enrollment and further dosing, until after the IDMC review.  
Section 8.2.7 Independent Data Monitoring Committee  
The IDMC will operate according to a charter approved by the sponsor and all IDMC members . 
The IDMC structure, participants, and other details will be provided in the charter. The charter 
will be approved  prior to enrollment of the first study participant . 
The role of the IDMC will be to (a) monitor the progress of the study, (b) review  blinded safety 
data provided by the SRT, (c) review unblinded safety data if a pausing rule is met, and (d) 
make recommendations to the sponsor on further conduct of the study if a pausing rule is met. 
review unblinded safety data and make recommendations  if events necessitating a pause in 
enrollment and in participant dosing occur. Refer to Section 7.1.1 for pausing rules.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   102 
CONFIDENTIAL    If a pausing rule is met, the IDMC may request additional information.  
The IDMC will make a formal recommendation to the sponsor on th e continued enrollment into 
the trial if a pausing rule was met. Immediate safety concerns should be discussed among 
sponsor representatives and the SRT, and if needed the IDMC.  
If RSM01administration is paused by the Medical Monitor or the investigator, t he IDMC will 
convene on an ad hoc basis.  
The recommendations of the IDMC, along with the sponsor’s decision, will be communicated to 
the investigator, to the responsible IRBs/IECs and to the US FDA . the investigators and the 
IRBs/IECs and the national regu latory authorities as required. The sponsor or its designee agrees 
to abide by any directives issued by the national regulatory authority or the IRB/IEC.  
Section 8.3. Treatment of Overdose  
If an overdose  it were to occur, the overdose, including misuse or abuse of the product and 
medication errors, …  
Section 8.4 Blood Sampling  
Whole blood samples will be collected for measurement of PK, ADA,  and RSV  
8.,5 Pharmacokinetics  
Dose Escalation Phase: At Visit 1, PK blood draw will occur pre -dosing , 1 hour (+/- 30 
minutes) before administration of IM injection or beginning of infusion,  for all participants in 
Cohorts 1 -4. For participants who receive IV study intervention, the timing of post -dose blood 
samples begins at the end of the IV infusion. Samples are obtain ed at 5 minutes (± 1 minute) 
at 8-hours ( ± 0.5 hour) and at 24 -hours ( ± 1 hour) after the end of the infusion. For 
participants who receive IM study intervention, the timing of post -dose blood samples begins 
at the time of the IM injection and samples are obtained at 8 -hours ( ± 0.5 hour) and at 24 -
hours ( ± 1 hour) after the IM injection.  
Dose Expansion Phase: At Visit 1, only a pre -dose sample collected 1 hour (+/ - 30 minutes) 
before administration of IM injection  is obtained at Day 1.  
is obtained at Day 1.  
Blood for PK samples at all visits after Day 1 will be obtained according to the SoA as shown 
in Table 2 and Table 3.  
Dose Escalation Phase: At Visit 1, PK blood draw will occur predosing,  within 5 minutes (± 1 
minute) after end of infusion for IV dosing  only, and at 8 hours ( ± 0.5 hours) and 24 hours ( ± 1 
hours) post dose for both IV and IM doses.  
Dose Expansion Phase: Blood samples at Day 1  will be drawn at pre -dose only.  
Remaining samples collected for analyses of RSM01 may also be used to evaluate 
immunogenicity and /or safety aspects or efficacy aspects  related to  any concerns arising during 
or after the study.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   103 
CONFIDENTIAL    Section 8.6 Pharmacodynamics  
Whole blood samples in serum separator tubes and VAMS devices  will be  
Remaining samples collected for analyses of RSV neutralization may also be used to evaluate 
drug concentration, immunogenicity, and safety or efficacy  aspects  
Section 9.1 Sample Size Determination  
 
This trial is an exploratory trial to characterize safety, tolerability , and pharmacokinetics of 
single dose s of RSM01 mAb.  
Section 9.2 Populations for Analyses  
Table 6  
Modified  Intention to treat ( mITT) PK population  
Participants will be analyzed according to the intervention they actually received.  
Section 9.3 Statistical Analyses  
A detailed statistical analysis plan (SAP) centered on primary and secondary endpoints will be 
developed and finalized prior to unblinding the study  and will further  
Section 9.3.1 Safety Primary Endpoints  
All solicited  systemic  AEs collected from Day 1 thr ough Day 7 will be collected and 
summarized as described below.  
For participants with more than 1 episode of the same event, the AE with  maximum severity will 
be used for tabulations.  
All unsolicited AEs, serious adverse events (SAEs), and/or AESI will be recorded from 
screening through Day 151.  
…Preferred Term (PT) and  greatest highest intensity.  
The number of events reported, the number of participants and percentage of participants who 
experience one or more unsolicited AE through Day 151,  and one or mor e SAE, and/or  one or 
more AESI from screening through Day 151 will be summarized  
For participants with more than 1 episode of the same event, the AE with  maximum intensity 
will be used for tabulations.  
Section 9.7 Interim Analysis  
Although the sponsor will  be blinded throughout the study, such review of aggregated data could 
potentially lead to unblinding of the treatment received by  individual s participants . 
Section 10.1.4.1 Informed Consent Forms  
If a participant cannot be randomized on the intended day o f dosing (e.g., due to  if elevated 
temperature)  
Section 10.2.4 Definition of AESI  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   104 
CONFIDENTIAL    The following AEs will be collected and reported as AESIs: anaphylaxis or hypersensitivity 
reactions, and /or infusion reactions resulting in permanent discontinuation of study intervention 
infusion during IV administration. of a participant who receives an IV dose of the study 
intervention  
Section 10.2.5 Recording and Follow -Up of AE, SAE, AESI  
There may be instances when copies of medical records for certain cases are requ ested by the 
Medical Monitor, the SRT , the IDMC and/or the sponsor.  
The investigator will then record all relevant AE/SAE /AESI  information in the CRF.  
There may be instances when copies of medical records for certain cases are requested by the 
Medical Moni tor, the SRT,  the IDMC and/or the sponsor.  
Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the 
AE/SAE /AESI . 
Note that local AEs reported within the first 7 days after IM dosing are considered to be study 
intervent ion-related.  
Follow -up and Resolution  
The onset and resolution dates of the event and medical care provided taken  in response to the 
event will be documented.  
Section 10.2.5.1 Assessment of Intensity  
The investigator will assess the intensity of each AE re ported during the study. In the case of 
local reactions, vital signs, systemic events, and laboratory abnormalities, the Grades 
delineated in Section 10.4, Appendix 4 will be employed.  
In the case of an AE or abnormal clinical laboratory result  not included in Appendix 4, 
intensity will be assigned using the Grades described in the U.S. Department of Health and 
Human Services, Common Terminology Criteria for Adverse Events, Version 5.0 [USHSS 
HSS 2017]  as follows:  
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL*  
Grade 3 Severe or medically significant but not immediat ely life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care ADL**symptoms, 
causing inability to perform usual social and functional activities with intervention or 
hospitalization indicated  
Grade 4 Life -threatening consequences; urgent intervention indicated  
A semi -colon indicates ‘or’ within the description of the grade.  
Notes:  
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   105 
CONFIDENTIAL    **Sel f-care ADL refers to bathing, dressing, and undressing, feeding self, using the toilet, 
taking medications, and not bedridden.  
The investigator will make an assessment of intensity for each AE reported during the study and 
assign it to 1 of 4 categories, a s defined in Appendix 4, Section 10.4  
Grade 1 Mild  symptoms, causing no or minimal interference with usual social and functional 
activities with intervention not indicated  
Grade 2 Moderate  symptoms, causing greater than minimal interference with usual soci al and 
functional activities with intervention indicated  
Grade 3 Severe  symptoms, causing inability to perform usual social and functional activities 
with intervention or hospitalization indicated  
Grade 4 Potentially life threatening  symptoms, causing inab ility to perform basic self care 
functions with intervention indicated to prevent permanent impairment, persistent disability, or 
death  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described 
in the definition of a n SAE, NOT when it is rated as severe.  
Section 10.2.5.2 Assessment of Causality  
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements applicable to SAEs . 
Section 10.2.5.4. Assessment of Outcome  
The outcome of each SAE/AESI must be reported to the sponsor . 
Section 10.2.6 SAEs, AESIs, and Serious ADR Reporting  
Reporting to Sponsor ’s or Delegate ’s (CRO Safety Team)  Via the Electronic Data 
Collection Tool  
Serious ADRs are reported to the sponsor or delegate during  and to the CRO Safety Team for 
the entire study period. Serious ADRs are to be  reported after completion of the study, if the 
investigator becomes aware of a serious ADR . even after the trial is over, if the sponsor, 
Medical Monitor or investigator become aware of them  
The investigator must not wait to collect additional information to fully document the event 
before notifying the CRO Safety Team of an  the sponsor or delegate of a  SAE or an AESI.  
• SAE /AESI  term and date of event onset  
Contacts for SAE /AESI  reporting and for all safety personnel  
Reporting via Paper CRF  
If the eCRF cannot be completed, the Supplemental SAE/AESI Report (paper form) should be 
completed by the investigator or his/her designee, and scanned and emailed, or faxed to the 
sponso r or delegate. CRO Safety Team.  
Other Events Requiring Immediate Reporting  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   106 
CONFIDENTIAL    The investigator must report the following events by scanning and emailing, or faxing the 
appropriate form to the sponsor or delegate  CRO Safety Team  within 24 hours of becoming 
aware of the event:  
Section 10.3 Appendix 3 Contraceptive Guidance and Collection of Pregnancy Information  
Contraceptive Guidance:  
Male participants with partners of childbearing potential must agree to use condoms during 
the s tudy and for 90 days after the study, and they must refrain from sperm donation for at 
least 90 days after the end of study.  
Female participants of childbearing potential must not be pregnant, breastfeeding, or 
attempting to become pregnant for 28 days bef ore Screening and throughout the duration of 
the study. These participants must have a negative serum pregnancy test at Screening in order 
to be eligible for randomization and treatment with study intervention. In addition, these 
female participants must b e willing to commit to using a consistent and acceptable method of 
contraception for the duration of the study and for 90 days after study completion if they 
engage in intercourse. Acceptable methods of contraception are : 
• Consistent  use of systemic contraception, including birth control pills, transdermal 
patch, vaginal ring, implants, and injectables.  
• Consistent use of double barrier method, e.g., condoms, cervical cap, diaphragm, 
vaginal contraceptive film with spermicide.  
• Use of i ntrauterine device with a low failure rate (defined as < 1% risk of 
pregnancy per year)  
• Monogamous intercourse with a vasectomized man or has only same -sex partners.  
Female participants who are not sexually active but become so during the study must 
agree to follow the contraceptive requirements above.  
Female participants who are not of childbearing potential must meet at least one of the 
following criteria:  
• At least 1 year since the last menstrual period.  
• Surgically sterile (tubal ligation, bilateral oopho rectomy, salpingectomy, or 
hysterectomy)  
• Congenitally sterile  
• Diagnosed as infertile and not undergoing treatment to reverse infertility.  
Collection of Pregnancy Information:  
• If a participant is determined to be pregnant during the study (after receiving a  dose of 
the study intervention), the investigator will report the pregnancy to the sponsor or 
delegate and collect follow -up information on the participant and the neonate. 
Generally, follow -up will not be required for longer than 6 weeks beyond the estim ated 
delivery date. Any termination of pregnancy will be reported, regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   107 
CONFIDENTIAL    • While pregnancy is not considered to be an AE or a SAE, any pregnancy complication 
or elective  termination of a pregnancy will be reported as an AE or a SAE. Any 
abnormal pregnancy outcome that comes to the attention of the investigator (e.g., 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) 
is considered to b e a SAE.  
• Any pregnancy -related SAE that occurs after study participation and is made known to 
the investigator and is assessed as related to the study intervention will be reported to 
the sponsor or the sponsor’s designee. The investigator is not obligated  to actively seek 
such information in former study participants who become pregnant during the study.  
Contraception Guidance:  
Women physically capable of pregnancy must agree to use an acceptable method of avoiding 
pregnancy for one year after study interv ention.  
Acceptable methods of avoiding pregnancy include at least one of the following:  
• sexual abstinence (not engaging in sexual intercourse)  
• a confirmed sterile partner  
• use of at least 2 of the contraceptive methods shown below:  
o hormonal contraceptives (oral, injection, transdermal patch, or implant)  
o IUD 
o male or female condom  
o diaphragm.  
Adequate contraception does not apply to participants of childbearing potential with same sex 
partners, when this is their preferred and usual lifestyle.  
i. The investigator  will collect follow up information on the participant and the neonate and 
the information will be forwarded to the sponsor. Generally, follow up will not be required 
for longer than 6 weeks beyond the estimated delivery date. Any termination of pregnancy 
will be reported, regardless of fetal status (presence or absence of anomalies) or indication 
for the procedure.  
j. While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy will be reported  as an AE or SAE. Abnormal 
pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, 
ectopic pregnancy) are considered SAEs.  
• Any pregnancy related SAE that occurs after study participation and is made known to 
the investigator and is assessed as related to the study intervention will be reported to the 
sponsor or the sponsor’s designee. The investigator is not obligated to actively seek this 
information in former study participants.
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   108 
CONFIDENTIAL    Section 10.4 Appendix 4: Toxi city Tables  
The following toxicity tables are extracted from the FDA Guidance for to the  Industry  
Notes to Table 9:  
** “ULN ” is the upper limit of the normal range.  
GGT grading is not provided in the FDA toxicity grading scale tables. The following grading  
scale is from the U.S. Department of Health and Human Services, Common Terminology 
Criteria for Adverse Events, Version 5.0  [US HSS 2017]:  
Other:  
eg changed to e.g.  
ie changed to i.e.  
added missing comma’s where applicable  
corrected minor spelling errors  
updated table of content  
updated first use of abbreviation as appropriate  
changed subject to participant throughout  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   109 
CONFIDENTIAL    Version 3.0, dated 10 December 2021  
Rationale for v3.0 (changes to v2, 20 July 2021) : The update from v2 to v3, was prepared to 
define the responsibilities of the Safety Review Team, the sponsor Chief Medical Officer, and 
the Independent Data Monitoring Committee.  
Other minor changes were made for correction or clarification. All changes are provided below. 
New text is shown in bo ld italics and old text is shown with strikethroughs.  
Synopsis  
Safety Review Team: A SRT will be established as the team responsible for recommending 
dose escalation or dose expansion to the sponsor’s Chief Medical Officer dose escalation 
decisions and proceeding to dose expansion .  
Meetings of the SRT to provide a recommendation on dose escalation or dose expansion  will 
occur  during the Dose Escalation Phase when all participants in the currently dosed cohort 
have completed Day 15 to decide on proceeding  to each subsequent dose escalation cohort will 
occur when all participants in the current  cohort complete Day 15.  
Schedule of Activities, Table 2 continued.  
A correction was made to the visit window for Day 3 Visit 3 in the table header on the second 
page of the table to align with the table header on the first page of the table. The window was 
corrected to ±0 days.  
V3 
D3 
±01d 
Section 8.1 Safety Assessments  
Prior to opening each of  Cohorts 2, 3 and 4  2 and 3 together , Cohort  4, and Cohort 5, 
respectivel y, to enrollment , the SRT will conduct a safety assessment of data for the previous 
cohort /s collected for when all participants in the currently dosed cohort  have completed  Day 
15., following the study intervention . 
Section 8.2.6 Safety Review Team  
A SRT will be established as the team responsible for recommending  dose escalation or 
decisions and decision on proceeding to dose expansion to the sponsor’s Chief Medical Officer.  
The SRT will operate according to the Safety Review Team Plan.  
Meetings of the SRT to provide a recommendation on dose escalation or dose expansion  decide 
on proceeding to each subsequent cohort  will occur during the Dose Escalation Phase when all 
participants in the current ly dosed cohort have completed Day 15.  
If a pausing eve nt does not occur, dose escalation or moving to the Dose Expansion Phase cohort 
will be recommended by the SRT  can occur . 
 
If a pausing rule is met, the SRT will ask the IDMC to conduct a review of unblinded safety data. 
The IDMC will make a recommendation  to the sponsor regarding the further conduct of the 
study (See Section 8.2.7.) .  
21 January 2022 
Gates MRI-RSM01-101 Protocol v4.0 
Tao SRT will eeastst ef a paael ef at least 4 IBembers , melHEhag the Gates ·MRI ehateel leae, the 
Gates MRI safety leae, the stHey Meeteal Meatter , aae the stte prtaetpal tft•resttgater . The SRT 
IBembers ftfO pati ef the stHEl-y teaIB ftfte Vltll r01rt01JI bltaeee safety eata. 
Section 8.2.7 Independent Data Monitoring Committee 
The role of the IDMC will be to (a)-review unblinded safety data if a pausing rule is met 
IBeatter the prngrnss ef the stHEl-y , (a) revte•N bltaeee safety Elate. pt'0'rteee by the SRT , (e) fOYtO'.V 
HB0lraeee safety eata tf a. paasmg mle ts IBet, and (he) make recommendati ons to t he spon sor on 
further conduct of the study if a pausing mle is met. 
Section 10.2. 6 SAE s, AESis, a nd Serious ADR Repo1ting 
Other E•.•eets R:etteirieg lmmetliete R:epertiBg 
Tao tftlresttgater must repe1i the fellewtag e•reats by seaftfttftg aae eIBatltag , er fffirmg the 
a.ppreprtate fetm te the speaser er eelega .te vrtthm 24 heHrs efbeeemtag awafe ef the 01,'eat: 
\\TtthernNral ef eeaseat eHrtag the stHey fer meeteal reaseas (Immeetately Repetiable B1,'0ftt 
Bmergeae=y HB0ltnemg (ItH:tBeetately Repe1iable BYeftt Fetm) 
Prnteeel Ytelatteft affeettag the safety ef a pa1itetpaftt er tBYel•rtftg the stHEl-y tate1veatteft 
aemtfttsfratteft prneess (Ifflffteetately Repetiable B•reftt Fetm) 
,'\By e•reat that, tft the epmteft efthe tw,'esttga .ter, prnelHees :faHtihet· aeffiiBtstt ·atteft ef the stHey 
tfttet"refttteft (ImIBeEltately Repe1iable Bireftt Fetm , \iflfess meets SAE et·ttet·ta) 
Pregaaaey (hmneeta .tely Repe1iable B1,'0ftt Fetm , aae Pregaaaey Netiaea.ttea Fetm) 
Bill & Melinda Gates Medical Resea rch Institute 
CONFIDENTIAL 110 
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   111 
CONFIDENTIAL    Version 4.0, dated 21 January 2022  
Rationale for v4.0 (changes to v3, 10 December 2021) : After the study site provided 
information that a large proportion of screening failures has been due to inability to meet the 
body mass index (BMI) requirement, the sponsor agreed to raise the BMI eligibility inclusion 
criterion to reflect real world con ditions, without affecting the safety of potential participants. 
The CDC criterion for obesity is a BMI>30; therefore, the updated inclusion criterion kept the 
BMI below this value. In addition, text was clarified for the exclusion criterion regarding timi ng 
of screening relative to a previous investigational drug.  
The text regarding screening failures was modified after approximately 30% of screen failures in 
Cohort 1 did not meet the BMI eligibility requirement. Therefore, participants previously 
exclude d due to BMI ≥25 kg/m2 may be rescreened once, under this amendment. Participants 
who also initially failed screening for other reasons may also be rescreened once.  
All changes are provided below. New text is shown in bold italics and old text is shown with 
strikethroughs.  
Section 5.1 Inclusion Criteria  
Weight  
3. Body mass index (BMI) 18 to 24.9 29.9 kg/m2 (inclusive)  
Section 5.2  Inclusion Criteria  
Prior/Concurrent Clinical Study Experience  
11. Participation in an interventional clinical trial and/or rec eipt of any investigational drug 
within 30 90 days or 5 half -lives of the investigational drug before the first day of study drug 
dosing in this study, whichever is longer  prior to administration of study drug on Day 1.  
Section 5.4 Screen Failures  
ResScreening assessments as ou tlined below may be performed afte r obtaining informed 
consent  can be done at any time during the screening window (Da y 30 to Day 2; SoA, Section 
1.3), except for written informed consent , which must be comple ted prior to any rescreening 
procedure.  
Rescreening is only permitted under one or more of the following  scenarios  conditions : 
• If a participant presents with an acute illness on the day of pla nned study intervention , e.g., 
elevated temperature, acute respiratory or gastrointestinal ill ness, or urinary tract infection 
(UTI), and meets all other eligibility criteria and can be resc reened within the originally 
defined screening window ( SoA, Section 1.3). A new participan t number is not required. If 
the participant is rescreene d during the original screening w indow, obtaining a second 
informed consent of the particip ant is not required.  
21 January 2022  
    Gates MRI -RSM01 -101 Protocol v4.0  
 
Bill & Melinda Gates Medical Research Institute   112 
CONFIDENTIAL    • If there are technical difficulties with phlebotomy at screening (e.g., laboratory reports 
hemolyzed blood), technical error in running the laboratory tests or an abnormal urine 
analysis due to menstruat ion or UTI, and the participant can be rescreened within the 
originally defined screeni ng window (SoA, Section 1.3). A new participan t number is not 
required. If the participant is rescreened during the original screening wi ndow, obtaining 
a second informed conse nt of the participant is not required.  
• If a participant is undergoing screening and the study reaches a pausing rule . The participant 
may be rescreen ed when and if the IDMC r ecommends, and the Sponsor de termines, that the 
study may continue.  A new participant number is not required. If the participant is 
rescreened during the original screening window, obtaining a second informed consent of 
the participant is not required.  
• If a participant fails to meet eligibility criteria upon initial screening, a one -time only 
rescreening for eligibility may be performed. In this case, the participant must receive a 
new participant number after signing a new informed consent.  
Repeat screenin g procedures may be performed as long as they are completed within the 
screening window.   
Minor change: On title page version is represented by v instead of V for consistency with version 
history page and header.  
Signature Page for Gates MRI-RSM01-101 Protocol Version 4.0 (21 Jan 2022) v7.0
Document Number: RSM01-CLIN-000009 v7.0e-Sig Approval
Clinical Development
25-Jan-2022 19:39:18 GMT+0000
